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Abstract 
 
Human norovirus (HuNoV) is the leading cause of gastroenteritis worldwide. Despite 
the significant disease and economic burden, currently there are no licensed vaccines 
or antivirals. The understanding of norovirus biology has been hampered by the 
inability to cultivate HuNoV in cell culture. To establish a tissue culture system, 
infectious HuNoVs were purified from clinical stool samples. HuNoV replication was 
tested in different cell types. The B-cell and intestinal organoids culture systems were 
validated. In addition, using organoids culture a DNA-based reverse genetic system 
was shown to recover infectious HuNoV. 
Due to the challenges associated with cultivating HuNoV, murine norovirus (MNV) was 
used as a surrogate system to understand the role of eIF4E phosphorylation in 
norovirus pathogenesis, and VP1-RdRp interaction in regulating viral genome 
replication. 
MNV infection results in the phosphorylation of the translation initiation factor eIF4E, 
re-programming host-cell translation during infection. Inhibiting eIF4E phosphorylation 
reduces MNV replication in cell culture suggesting a role in viral replication. A mouse 
model with eIF4E S209A, a phosphor-ablative mutation, was established to 
understand the role of eIF4E phosphorylation in MNV pathogenesis. In vitro and in vivo 
characterisations demonstrated that eIF4E phosphorylation may have multiple roles in 
norovirus-host interactions, but overall has little impact on MNV pathogenesis. 
The shell domain (SD) of norovirus major capsid protein VP1 interacts with viral RNA-
dependent RNA polymerase (RdRp) in a genogroup-specific manner to enhance de 
novo initiation of RdRp, and to promote negative-strand RNA synthesis. To understand 
how VP1 regulates norovirus genome replication, chimeric MNVs with genogroup-
specific residues mutagenised were characterised in vitro and in vivo. A single amino 
acid mutation was shown to destabilise viral capsid. SDs with reduced VP1-RdRp 
interaction showed less capacity to stimulate RdRp, resulting in delayed virus 
replication. In vivo, the replication of an MNV-3 with homologous mutations was 
abolished, highlighting the crucial role of this interaction. 
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1.1 Classification of the family Caliciviridae 
The family Caliciviridae is named after the latin calyx for cup, with reference to the 
common cup-like virion morphology observed by electron microscopy. Caliciviruses 
are a group of human and animal pathogens, which are small, non-enveloped, positive-
sense, single-strand RNA viruses. Caliciviruses are known for causing gastroenteritis 
as food-borne pathogens, other diseases also include respiratory infection and 
systemic haemorrhagic disease. 
Since the first norovirus sequence became available, a new system has been used for 
classifying caliciviruses (Xi et al., 1990, Green et al., 2000). Based on the major capsid 
protein VP1 sequence, there are 5 genera in the family Caliciviridae, including 
Lagovirus, Nebovirus, Norovirus, Sapovirus and Vesivirus. The genus Lagovirus 
includes rabbit haemorrhagic disease virus (RHDV), which causes necrotic hepatitis 
and haemorrhage in lagomorphs (Parra and Prieto, 1990, Ohlinger et al., 1990). The 
genus Nebovirus is newly classified into the family, causing haemorrhages in calves 
(Bridger et al., 1984). The prototypic norovirus, Norwalk virus, was named after the city 
of Norwalk, Ohio where an acute gastroenteritis outbreak in a school occurred 
(Kapikian et al., 1972). The genus Sapovirus, together with the genus Norovirus, are 
common causative agents of gastroenteritis in humans (Madeley and Cosgrove, 1976). 
The prototype sapovirus is Saporovirus, which was isolated from an infant during a 
family outbreak of acute gastroenteritis (Chiba et al., 1979, Matson et al., 1995, 
Numata et al., 1997, Nakanishi et al., 2011). The genus Vesivirus includes feline 
calicivirus (FCV), which causes respiratory infection in cats (Kreutz et al., 1994). 
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There are 6 more genera of the family Caliciviridae tentatively named Bavovirus, 
Nacovirus, Recovirus, Salovirus, and Valovirus (International Committee on Taxonomy 
of Viruses. et al., 2012). Bavovirus and Nacovirus both infect poultry (Wolf et al., 2012, 
Wolf et al., 2011). The genus Recovirus includes Tulane virus, which was originally 
isolated from rhesus macaques (Farkas et al., 2008). The genus Salovirus is the latest 
genus proposed, including the Atlantic salmon calicivirus (Mikalsen et al., 2014). St-
Valérien-like virus belongs to the genus Valovirus (L'Homme et al., 2009). 
The genus Norovirus can be further divided into 7 genogroups, named GI to GVII (Vinje, 
2015). The prototypic Norwalk virus belongs to GI and was isolated in 1968 (Kapikian 
et al., 1972). Human noroviruses cluster in GI, GII and GIV (Thorne and Goodfellow, 
2014). Porcine noroviruses also belong to GII (Sugieda et al., 1998), whilst bovine and 
ovine noroviruses cluster in GIII (Oliver et al., 2003, Bridger et al., 1984). Canine 
noroviruses belong to GIV, GVI and GVII noroviruses (Roerink et al., 1999, San Gabriel 
et al., 1997, Caddy et al., 2014). Hosts of GV noroviruses are limited to rodents 
(Thackray et al., 2007, Smith et al., 2012, Tse et al., 2012). 
Each genogroup can be further divided into genotypes, as summarised in Figure 1.1C. 
There are currently 9 genotypes in GI and 22 in GII (Kroneman et al., 2013). Of all the 
genotypes, GII.4 HuNoVs dominate the pandemics in the past two decades (Mikalsen 
et al., 2014). 
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Figure 1.1 Morphology and classification of Caliciviridae. A) Norwalk virus particles under electron 
microscopy. Picture adapted from (Kapikian et al., 1972). B) Crystal structure of Norwalk virus particle 
(PDB ID: 1IHM). Different colours indicate quasi-equivalent subunits. Image adapted from (Prasad et 
al., 1999). C) Classification of Caliciviridae. Under each genus the prototype virus is listed. In the genus 
Norovirus, under each genogroup the host species and genotypes were listed. 
1.2 Genome organisation 
The genomes of all known caliciviruses are about 7.4 kb in length (Xi et al., 1990, 
Thorne and Goodfellow, 2014). A subgenomic RNA (about 2.6 kb) encoding the 
structural genes is also found in infected cells and in purified viral particles (Neill, 2002, 
Herbert et al., 1997, Herbert et al., 1996, Meyers et al., 1991a). Both genomic and 
 6 
subgenomic RNA are linked to the viral protein VPg at the 5’ end and polyadenylated 
at the 3’ end (Schaffer et al., 1980, Burroughs and Brown, 1978). The 5’ and 3’ 
extremities of calicivirus RNA contain highly conserved RNA secondary structures, 
from the short untranslated regions (UTRs) extending into the coding region and are 
present throughout the genome (Lopez-Manriquez et al., 2013, Sandoval-Jaime and 
Gutierrez-Escolano, 2009, Gutierrez-Escolano et al., 2003, Gutierrez-Escolano et al., 
2000, Vashist et al., 2012a). These structures are involved in binding viral and host 
factors to regulate translation, replication and pathogenesis (McFadden et al., 2013, 
Bailey et al., 2010b, Simmonds et al., 2008). 
The calicivirus genome comprises 3-4 open reading frames (ORFs) (Figure 1.2). For 
genera Norovirus (HuNoV and MNV), Vesivirus (FCV) and Recovirus (TV, not shown 
in Figure 1.2), ORF1 encodes 6-7 non-structural proteins, whereas ORF2 and ORF3 
encode the major (VP1) and the minor (VP2) capsid proteins, respectively (Sosnovtsev 
et al., 2006, Belliot et al., 2003, Liu et al., 1996, Glass et al., 2000, Sosnovtsev et al., 
2002, Farkas et al., 2008). In genera Lagovirus (RHDV), Sapovirus (SaV), Nebovirus, 
and many of the recently proposed genera (Bavovirus, Nacovirus, Salovirus, Valovirus), 
the major structural protein is translated and processed as part of the ORF1 polyprotein 
(Meyers et al., 2000, Liu et al., 1995, Smiley et al., 2002, L'Homme et al., 2009, Wolf 
et al., 2011, Wolf et al., 2012, Mikalsen et al., 2014). In addition, they can also be 
synthesised via translation of the subgenomic RNA (Meyers et al., 1991b). In MNV, an 
ORF4 was identified with coding region overlapping ORF2, which encodes virulence 
factor 1 (VF1) (McFadden et al., 2011). Sapovirus is the only other member of the 
family Caliciviridae known to possess an equivalent ORF (Liu et al., 1995). ORF1 
encodes non-structural proteins including those important for replication complex 
formation (NS1/2, NS3, NS4), genome linkage (VPg), polyprotein processing (NS6), 
and genome replication (RdRp). Norovirus p48 or NS1/2 has no known homologue 
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from other viruses. The according picornavirus homologues of other non-structural 
proteins of norovirus ORF1 are 2C (NS3), 3A (NS4), 3B (VPg), 3C (NS6) and 3D 
(RdRp). FCV VP1 is translated as a precursor and proteolytically processed by the 
viral protease to generate mature VP1 and a small leader of capsid (LC) protein, which 
was shown to induce cytopathic effect in cells and promotes Norwalk virus replicon 
replication in trans (Abente et al., 2013, Chang et al., 2008). 
A unified nomenclature for norovirus proteins is yet to be defined (Figure 1.2). 
Throughout this thesis the names related to MNV will be used primarily, unless they 
are virus specific or for comparison purposes. The functions of norovirus proteins will 
be discussed in the context of the virus life cycle in more details below. 
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Figure 1.2 Genome organisation of caliciviruses. Open reading frames (ORFs) were coloured as 
indicated. The relevant genetic localisations of genes and their names were listed accordingly. 
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1.3 Epidemiology and transmission 
Norovirus is the most common causative agent of acute gastroenteritis worldwide (Tam 
et al., 2012). Globally, HuNoV is estimated to cause 669 million illnesses, 219,000 
deaths per year, in addition to $4.2 billion heath care cost and $60.3 billion societal 
cost (Bartsch et al., 2016). In the UK, it is estimated that the population burden of 
HuNoV infections is 59/1000 person year, equivalent to 3.7 million cases per year 
(Harris et al., 2017). The economic burden of HuNoV infections in the UK is estimated 
to be £81 million per year, which is more than the cost of Campylobacter and rotavirus 
infections combined (Tam and O'Brien, 2016). In the United States, the annual 
estimated HuNoV infections are 19-21 million illnesses per year, with 570-800 deaths 
(Hall et al., 2013), in addition to the associated cost of health care and loss of 
productivity of $2 billion (Bartsch et al., 2012). 
The majority (55-85%) of HuNoV outbreaks are caused by the GII.4 variants. These 
are in conjunction with higher possibility of severe outcomes and deaths (Desai et al., 
2012). The GII.4 variants are fast evolving, every two to three year a new circulating 
strain replaces the previous one due to the lack of cross protection. In the past two 
decades, at least seven GII.4 HuNoV variants caused pandemics: the US 1995/1996 
variant in 1996, the Farmington Hills variant in 2002, the Hunter variant in 2004, the 
2006a, 2006b variants in 2007-2008, the New Orleans variant from 2009 to 2012 and 
Sydney 2012 in late 2012 (Ramani et al., 2014, Lopman et al., 2004, Bull et al., 2006, 
Tu et al., 2008, Siebenga et al., 2009, van Beek et al., 2013). The latest dominant 
circulating strain is a GII.17 Kawasaki variant, however, which outcompeted the 
Sydney 2012 variant (Mori et al., 2017, Lu et al., 2016, Zhang et al., 2015, Chan et al., 
2015). It is proposed that the GII.17 pandemic was caused by the lack of cross 
protection and the broad binding spectrum of the GII.17 capsid (Chan et al., 2015). In 
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terms of seasonality, HuNoV incidents peak during the winter seasons, which is why 
the media has named norovirus “the winter vomiting disease” (Lopman et al., 2009). 
The detailed mechanism of this seasonality is not fully understood, but it has been 
associated with the change of societal behaviour, more hospitalisations due to other 
infectious diseases, and yearly fading herd immunity (Lopman et al., 2009, Debbink et 
al., 2013). 
Epidemiological studies of HuNoV infections mainly focus on the four categories: food-
borne and water-borne gastroenteritis outbreaks, infections in the elderly or 
immunocompromised patients, sporadic acute gastroenteritis in young children under 
age of 5, and sporadic acute gastroenteritis in adults (Hoa Tran et al., 2013, Ramani 
et al., 2014).  
There are many factors contributing to the large and fast outbreaks of HuNoV. First of 
all, HuNoV is resistant to environmental changes and survives through multiple 
inactivation procedures (Bohnker and Thornton, 2003, Vipond et al., 2002, Kuusi et al., 
2002, Wu et al., 2005, Cheesbrough et al., 2000, Escudero-Abarca et al., 2014, Lou et 
al., 2012, Feng et al., 2011, Park et al., 2007, Hudson et al., 2007). Also, HuNoV can 
be bioconcentrated by animals (e.g. oysters) or biocontaminates vegetables (e.g. 
lettuce), posing challenges to traditional cleaning procedures in the food industry (Le 
Guyader et al., 2006, Gandhi et al., 2010, Urbanucci et al., 2009). 
Secondly, HuNoV is highly infectious and can be transmitted by multiple routes. The 
50% human infectious dose is estimated to be between 1320 and 2800 genome 
equivalent (Atmar et al., 2014). In comparison, peak faecal shedding of HuNoV is 
estimated to be about 1010 genome copies per gram faeces (Atmar et al., 2008). 
Vomiting has been shown to be not only a symptom but also a transmission risk of 
HuNoV (Kirby et al., 2016, Makison Booth, 2014). HuNoV can be transmitted by 
person-to-person contact or faecal-oral route (Verhoef et al., 2015). Together with its 
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environmental persistence, outbreaks of HuNoV infections usually happen in close-
living environment, including hospitals, schools, care homes, and military bases 
(Sandmann et al., 2017, Godoy et al., 2016, Rajagopalan and Yoshikawa, 2016, 
Delacour et al., 2010). Repeated HuNoV outbreaks have also been reported in cruise 
ships (Vivancos et al., 2010). 
The fast evolution of HuNoV also contributes to its constant presence (Zakikhany et 
al., 2012, Boon et al., 2011, Nilsson et al., 2003). In particular, the emergence of 
antigenically distinct GII.4 variants gave rise to pandemics due to the lack of cross 
protection from the previous circulating strains (de Graaf et al., 2016, White, 2014, 
Eden et al., 2014, Bull et al., 2010). Recombination at the ORF1/ORF2 junction also 
contributes to the failure of herd immunity against emerging variants (Lommer and 
Verstraete, 2003, Martella et al., 2013, Eden et al., 2013, Waters et al., 2007, Rohayem 
et al., 2005, Bull et al., 2005). In addition, zoonotic transmissions have been proposed 
to aid HuNoV evolution (Bank-Wolf et al., 2010) because GII noroviruses can infect 
both human, pigs and calves (Souza et al., 2008, Cheetham et al., 2006). 
Seroprevalence of HuNoV in pet dogs was also reported, yet currently there is no 
evidence of productive HuNoV replication in dogs (Di Martino et al., 2017, Caddy et al., 
2015, Caddy et al., 2013, Summa et al., 2012). 
1.4 Symptoms and diseases 
The two major symptoms of HuNoV infections are watery diarrhoea and projectile 
vomiting, giving norovirus the name “the two-buckets disease”. Other symptoms 
include fever, stomach cramps, bloating and aching limbs. More severe symptoms 
have also been reported, in particular necrotising enterocolitis in neonates (Stuart et 
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al., 2010, Turcios-Ruiz et al., 2008), seizures in children (Hu et al., 2017, Ueda et al., 
2015, Bartolini et al., 2011, Chen et al., 2009), and acute liver dysfunction in adults 
(Nakajima et al., 2012). 
HuNoV infections have short incubation period of 12-48 hours. The onset of symptoms 
is fast and self-limiting, usually resolved in a few days. However, prolonged infections 
occur in the elderly (Harris et al., 2008) and in immunocompromised patients (van Beek 
et al., 2017, Jurgens et al., 2017, Westhoff et al., 2009, Lee et al., 2008, Gallimore et 
al., 2004). In particular, infections with HuNoV leads to complication of treatment 
(Engelen et al., 2011), rejection of transplant (Saif et al., 2011) or in severe cases the 
death of patients (Schwartz et al., 2011). Patients with persistent HuNoV infections 
were also thought as one of the reservoirs of HuNoV (Doerflinger et al., 2017, Schorn 
et al., 2010) but a recent analysis argued against it (Eden et al., 2017).  
Although nosocomial transmissions are mainly caused by symptomatic infections 
(Sukhrie et al., 2012), there is no difference in shedding between symptomatic and 
asymptomatic infections (Newman et al., 2016, Teunis et al., 2015, Phillips et al., 2010, 
Okabayashi et al., 2008). This leads to a possible role of asymptomatic food handlers 
in causing food-borne norovirus outbreaks (Franck et al., 2015). 
Not much is known about how norovirus infections cause vomiting and diarrhoea. A 
study characterising norovirus-infected duodenal biopsies showed disrupted epithelial 
barrier functions, reduced tight junctional sealing proteins and increased epithelial 
apoptosis, paralleled with increased intraepithelial cytotoxic lymphocytes and 
stimulated anion secretion. These are likely the cause of diarrhoea during norovirus 
infection (Troeger et al., 2009). 
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1.5 Challenges of cultivating HuNoV in vitro 
1.5.1 Norovirus tropism  
Despite its prevalence and impact, the understanding of noroivrus biology has lagged 
behind many RNA viruses, mainly because of the inability to propagate HuNoV in cell 
culture. There could be many factors contributing to this, one of which is the unknown 
tropism of HuNoV. It is unclear which cell type(s) HuNoV infects. However, because 
HuNoV is an enteric pathogen, the vast majority of reported attempts (and likely more 
unreported) at cultivating HuNoV have been focusing on human gastrointestinal tract 
epithelial cells, together with some common human and animal cell lines. Other 
possible factors such as virus strains, cellular differentiation status and cell culture 
additives have also been tested. These comprehensive efforts have led to no 
successful outcome as yet (Duizer et al., 2004). However, it was shown that 
transfection of VPg-linked Norwalk virus RNA into intestinal epithelial Caco-2 cells 
resulted in a single round of virus replication (Guix et al., 2007). This observation 
suggests that the restriction of HuNoV infection in epithelial cells is possibly viral entry. 
Since the discovery of MNV and its cell culture system, it has been long suspected 
HuNoV may share similar a haematopoietic tropism. MNV infects macrophages and 
dendritic cells, and virus replication is restricted by STAT1-dependent type I IFN 
responses (Wobus et al., 2004). However, infection of primary macrophages and 
dendritic cells isolated from peripheral blood showed no evidence of HuNoV replication, 
nor did the inhibition of innate immune responses with IFN cocktails promoted 
replication (Lay et al., 2010). The development of B cell culture system in 2014 by 
Jones et al. showed that both HuNoV and MNV infect B cells, and an enteric bacterium 
Enterobacter cloacae (E. cloacae) potentially bridges HuNoV to B cells ((Jones et al., 
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2015, Jones et al., 2014) will be discussed in Chapter 3). However, HuNoV replication 
in B cells is very limited, highlighting the need to identify host proviral and antiviral 
factors in this system. 
Besides cell types, it is also possible that established cell lines do not phenotypically 
represent fully differentiated cells as found in vivo, for example the polarised intestinal 
epithelial cells. In agreement with this, an ex vivo cell culture system reported HuNoV 
replication in duodenal biopsies (Leung et al., 2010). HuNoV replication was observed 
in glandular epithelial cells by evidence of increased viral RNA, the expression of viral 
structural and non-structural genes, and the presence of negative-sense replication 
intermediate. However, due to the limited supply and the inherent variations of ex vivo 
biopsies its application is limited. Attempts were also made to differentiate enteric 
epithelial cell lines to mimic primary intestinal epithelial cells. A three-dimensional 
culture system was first developed using rotating wall vessels (RWV) to maintain and 
differentiate INT-407 or Caco-2 cells, and the initial attempts showed increase of 
HuNoV viral RNA in infected cells (Straub et al., 2007, Straub et al., 2011). However, 
the extensive following attempts to repeat these results failed to reproduce the initial 
observations (Herbst-Kralovetz et al., 2013, Takanashi et al., 2014, Papafragkou et al., 
2014). In 2016, Ettayebi et al. established a primary intestinal organoids (or enteroids) 
culture system for HuNoV, which demonstrated an enterocytic tropism of HuNoV and 
virus strain-dependent requirement of bile for infection ((Ettayebi et al., 2016) will be 
discussed in Chapter 3). 
Without an in vitro infection system, the details of HuNoV life cycle are either inferred 
by surrogate viruses (will be discussed in later sections) or by studying certain stages 
of infection outside the context of infection. A Norwalk virus RNA replicon system was 
developed to study norovirus genome replication, showing antiviral effects of type I IFN 
responses and ribavirin (Chang et al., 2006). This system has been mainly used for 
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screening potential antiviral compounds (Bok et al., 2008, Chang, 2009, Chang and 
George, 2007). The RNA replicon system is complemented with recombinant virus-like 
particle (VLP) system. The major capsid proteins VP1 is the only protein on the outside 
of norovirus virion, and using various expression systems recombinant VP1 can self-
assemble into VLPs morphologically and antigenically indifferent to native HuNoV 
virions (Huang et al., 2005, Baric et al., 2002, Green et al., 1997, Jiang et al., 1992, 
Taube et al., 2005). Therefore, they are useful tools to study virion physical properties, 
antibody responses, and interactions with attachment factors (Tresset et al., 2013a, da 
Silva et al., 2011, Hutson et al., 2003, Harrington et al., 2002). 
1.5.2 In vivo model systems for HuNoV 
Volunteer challenge was the main method to understand HuNoV pathogenesis and 
immunity. Typically, volunteers are challenged with stool filtrates from infected 
individuals and the disease outcome, duration of infection, immunogenicity (also 
compared with individuals challenged with VLPs), and protective immune response 
from previous exposures were monitored (Lindesmith et al., 2015, Ramirez et al., 2012, 
Tacket et al., 2003, Harrington et al., 2002, Gray et al., 1994, Gary et al., 1987, Thornhill 
et al., 1975, Lindesmith et al., 2005, Bernstein et al., 2015, Johnson et al., 1990). The 
duration and magnitude of shedding were also investigated, including the median 
duration of illness (1-2 days), median duration of faecal shedding (28 days), and 
median peak amount of faecal shedding (9.5 × 1010 genomic copies per gram of 
stool), which are useful for disease control during outbreaks (Atmar et al., 2008). This 
in vivo model of HuNoV in its natural host also revealed a genetic factor (FUT2) that 
confer susceptibility to HuNoV infection (Hutson et al., 2005, Hutson et al., 2002, Chan 
et al., 2008, Marionneau et al., 2005, Lindesmith et al., 2003). However, the 
interpretation of results from the early volunteer studies are complicated by the limited 
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sample size, the variations in individual susceptibility to infection, and the lack of 
previous history of exposure. The use of faecal filtrates as a source of infectious 
HuNoV also poses safety concern of the potential inclusion of other pathogens. 
Because of the difficulties of volunteer studies, a robust animal model of HuNoV is long 
needed. Various non-human primates have been tested due to the genetic similarities. 
First of all, the presence of calicivirus in non-human primates was observed (Jiang et 
al., 2004, Smith et al., 1985). The infection of rhesus macaques with Norwalk virus was 
subclinical, but faecal shedding was detected, together with the induction of adaptive 
immune response (Rockx et al., 2005). Inoculation of a GII Toronto P2-A virus to new 
born pigtail macaques resulted in transmittable sporadic clinical symptoms (Subekti et 
al., 2002). Moreover, chimpanzees were demonstrated to be susceptible to 
asymptomatic Norwalk virus infection, and recently evaluated as a model system for 
vaccine development (Bok et al., 2011, Wyatt et al., 1978). Immunohistochemistry 
analysis of duodenal biopsies showed capsid expression in cells of the lamina propria 
positive for DC-SIGN (dendritic cells) or CD20 (B cells), supporting the proposed 
haematopoietic tropism of HuNoV (Bok et al., 2011). Although Norwalk virus does not 
replicate in PBDC, it is still possible that tissue-specific lineages of DCs and B cells are 
permissive for HuNoV infection (Lay et al., 2010). 
Gnotobiotic pigs are more widely used as a model system for HuNoV (Lei et al., 2016b, 
Lei et al., 2016a, Lou et al., 2015, Kocher et al., 2014, Bui et al., 2013, Jung et al., 
2012, Souza et al., 2008, Souza et al., 2007a, Cheetham et al., 2007, Cheetham et al., 
2006). This is supported by the presence of HBGA-like receptors in buccal and 
intestinal tissues enabling norovirus VLP binding, and that GII noroviruses have been 
isolated from healthy pigs (Cheetham et al., 2007, Sugieda and Nakajima, 2002, 
Sugieda et al., 1998). Infection of gnotobiotic pigs by a GII HuNoV caused mild 
diarrhoea, paralleled with faecal shedding of viral genomic RNA, expression of viral 
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structural and non-structural genes in intestinal enterocytes, and virus-specific innate 
and mucosal immunity (Souza et al., 2007a, Cheetham et al., 2006). Follow-up studies 
revealed the proviral effect of the cholesterol management drug simvastatin, and that 
pre-treatment of IFN-α prior to infection is inhibitory to virus replication (Bui et al., 
2013, Jung et al., 2012). In a severe combined immunodeficiency (SCID) phenotype 
gnotobiotic pig model where RAC/IL2R deficiency was generated by CRISPR knock 
out, increased HuNoV replication, dissemination and prolonged infections were 
observed (Lei et al., 2016a). This agrees with the observation of chronic HuNoV 
infections in immunocompromised patients (Echenique et al., 2016, Lemes et al., 2014, 
Saif et al., 2011, Siebenga et al., 2008, Woodward et al., 2017, Avery et al., 2017, 
Lambregts et al., 2010, Westhoff et al., 2009). However, in this model the enteric 
bacterium E. cloacae was found to inhibit HuNoV infection, where in the B cell culture 
model E. cloacae promotes infection (Lei et al., 2016b, Jones et al., 2014). Due to the 
large animal size gnotobiotic calves are not widely used, although calves are naturally 
susceptible to bovine norovirus infection (GIII Norovirus) and can be infected by 
HuNoV (Souza et al., 2008, Woode and Bridger, 1978). A mouse model for HuNoV 
was also developed (Taube et al., 2013). However, HuNoV replication in humanised 
mice is independent of the presence of human immune cells but depends on the 
immunocompromised status of mice. 
1.5.3 Surrogate systems to study norovirus biology 
In addition to in vivo models of HuNoV, surrogate systems are also important tools to 
study norovirus biology (reviewed in (Vashist et al., 2009)). Cell culture systems have 
been developed for the following caliciviruses: porcine sapovirus (PoSaV), Tulane virus 
(TV), RHDV, FCV, MNV (Parwani et al., 1991, Flynn and Saif, 1988, Farkas et al., 2008, 
Liu et al., 2007, Kreutz et al., 1994, Karst et al., 2003). PoSaV, previously known as 
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porcine enteric calicivirus, is one of the few cultivatable caliciviruses which causes 
diarrhoea, and the prototypic Cowden strain was first isolated by serially propagating 
the virus isolated from gnotobiotic pigs in tissue culture (LLCPK cells) (Flynn et al., 
1988, Flynn and Saif, 1988). Bile acid or GCDCA is required for infection, and 
subsequent studies showed their roles in inhibiting STAT1, which is one of the key 
factors in type I IFN response (Parwani et al., 1991, Chang et al., 2004, Chang et al., 
2002). However, our recent development of a reverse genetics system for PoSaV 
argues against it, because in the presence of bile acids, PoSav replication is still 
restricted by STAT-1-mediated type I IFN responses (Chang et al., 2005, Hosmillo et 
al., 2015). TV infects rhesus macaques and causes diarrhoea, and a reverse genetics 
system has also been developed (Sestak et al., 2012, Wei et al., 2008). Although 
RHDV was discovered in 1990, a cell culture and reverse genetics system was only 
available since a decade ago (Parra and Prieto, 1990, Ohlinger et al., 1990, Meyers et 
al., 1991b, Liu et al., 2008). In addition, RHDV infections in lagomorphs are systemic 
and usually lethal, therefore it is not a good model to study HuNoV pathogenesis, which 
mainly causes gastroenteritis (Meyers et al., 1991b, Forrester et al., 2007). FCV was 
the most frequently used surrogate system to study norovirus biology due to the early 
development of cell culture, reverse genetics system, and shared similarities with 
norovirus in protein functions and virus life cycle (Kreutz et al., 1994, Sosnovtsev and 
Green, 1995). However, FCV is not a suitable model system to study norovirus 
pathogenesis, as it causes lower respiratory tract or systemic infections. 
MNV was the only cultivatable norovirus prior to the development of HuNoV culture 
system (Karst et al., 2003, Thackray et al., 2007). MNV infects macrophages, dendritic 
cells and B cells in vitro and in vivo (Wobus et al., 2004, Jones et al., 2014). The first 
MNV was isolated from the brain of immunocompromised (STAT1/RAG-/-) mice. The 
lethal and systemic infection was caused by the loss of innate immune response. In 
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STAT1-/- mice MNV-1 causes lethal infection, whereas homologous RAG1/2 deficiency 
leads to systemic persistence (Karst et al., 2003). In immunocompetent mice, sub-
clinical MNV-1 infection is restricted by STAT1-mediated innate immune responses 
(Mumphrey et al., 2007). Mice are natural hosts of MNV, and the majority of MNVs 
isolated from immunocompetent mice cause persistent infections (Hsu et al., 2007, 
Hsu et al., 2006). MNVs were found in mice from both laboratory and the field, 
indicating their wide distribution (Ohsugi et al., 2013, Farkas et al., 2012, Kitajima et 
al., 2009). In terms of genome similarity, MNV shares more than 50% nucleotide 
sequence identities with HuNoV, and structurally and functionally conserved nucleotide 
sequences and genes were reported (Vashist et al., 2009, Bull et al., 2011, Lin et al., 
2015, Subba-Reddy et al., 2012). Both DNA-based and RNA-based reverse genetics 
have been developed for MNV, allowing virus manipulation to study virus replication 
and virus-host cell interactions (Chaudhry et al., 2007, Ward et al., 2007, Arias et al., 
2012). Both HuNoV and MNV are enteric pathogens, but unlike HuNoV, MNV infections 
in mice are usually asymptomatic (Mumphrey et al., 2007). Despite its biological 
diversity, MNV comprises a single genogroup and a single serogroup, limiting its 
applications as a model system for vaccine development (Thackray et al., 2007, Hsu 
et al., 2006). 
 
1.6 Norovirus life cycle 
Compared to other small RNA viruses, relatively little is known about the life cycle of 
HuNoV, primarily due to the lack of a cell culture system. Studies using surrogate 
viruses, especially MNV and FCV, started to review details of each stage of the 
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calicivirus life cycle. PSaV, RHDV and BoNoV are also used. Figure 1.3 is an overview 
of the calicivirus replication cycle and each stage will be discussed in detail, primarily 
using MNV as the model system. 
 
Figure 1.3 Overview of the calicivirus life cycle. 1) Viral binding to attachment factors and 2) 
translocation to receptors. 3) Viral entry and 4) uncoating through unknown mechanisms. 5) Pioneer 
round of translation and 6) polyprotein processing by viral and cellular proteases to 7) establish viral 
replication complex (RC). 8) Synthesis of negative-sense replication intermediate by de novo initiation 
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of RdRp, followed by 9) VPg-dependent initiation to produce genomic and subgenomic RNA. 10) Virion 
assembly by VP1 and VP2 11) Exit by cell lysis. 
1.6.1 Attachment and entry 
The norovirus capsid (T = 3 icosahedral) comprises 180 copies of the major capsid 
protein VP1, and the capsid is stabilised by 2 copies of minor capsid protein VP2 
associated with VP1 shell domain (Glass et al., 2000, Vongpunsawad et al., 2013). 
Therefore, VP1 is thought to bind cellular receptors and mediate viral entry. 
The norovirus major capsid protein VP1 can be divided into three domains, Figure 1.4A 
and (Prasad et al., 1999). The functions of the N-terminal domain is unknown, the shell 
domain is sufficient to assemble capsid, whilst the P domain stabilises the capsid 
(Bertolotti-Ciarlet et al., 2002). The P domain can be further divided into two 
subdomains. The P1 domain forms the basis of the arch and is heavily involved in 
dimerisation of P particle formation (Tan and Jiang, 2005b). The P2 domain is the least 
conserved region of VP1 and is thought to contain the receptor binding site, Figure 
1.4B and (Chakravarty et al., 2005). Analysis of the capsids of MNV and other 
caliciviruses revealed a similar structural arrangement (Katpally et al., 2010, Laurent 
et al., 2002, Yu et al., 2013, Wang et al., 2013). 
The molecular details of how human norovirus enters susceptible cells are not fully 
understood, mainly due to the lack of known tropism. There is increasing evidence 
suggesting that norovirus entry is a multi-step process coordinated by an attachment 
factor and a proteinaceous receptor. 
The correlation between secretor status and resistance to infection of certain HuNoV 
strains has been long observed. In one volunteer study, certain individuals are 
completely resistant to Norwalk virus infections, and pre-existing antibodies does not 
correlate with protection (Parrino et al., 1977). In norovirus outbreaks, the resistant 
individuals cluster in families, despite similar exposure as did the infected, suggesting 
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a genetic factor possibly contributes to norovirus resistance (Koopman et al., 1982). 
Histo-blood group antigens (HBGAs) are carbohydrates present on the cell surface. 
They were first identified as the receptor of RHDV, followed by showing the prototype 
Norwalk virus binds the HBGAs on the surface of intestinal epithelial cells (Ruvoen-
Clouet et al., 2000, Marionneau et al., 2002). This observation was then supported by 
an investigation of a norovirus outbreak, where fucosyltransferase 2 (FUT2) non-
secretor genotype was associated with the resistance to norovirus infections (Thorven 
et al., 2005). Secretor-negative individuals do not express HBGAs on the epithelial cell 
surface due to non-functional FUT2 genes (usually homozygous G428A non-sense or 
A385T missense mutations), which is required for synthesising H1 antigen (blood type 
O) and subsequently A and B antigens (blood types A and B) (Thorven et al., 2005). 
Between secretor-positive individuals and HuNoV strains, blood group-dependent 
binding patterns were observed (Marionneau et al., 2002, Huang et al., 2003, Tan et 
al., 2008). However, secretor status-independent outbreaks and the binding of 
intestinal epithelial cells were also observed (Nordgren et al., 2010, Murakami et al., 
2013). GII.4 HuNoV can also infect non-secretor individuals, suggesting alternative 
entry mechanisms (Tamura et al., 2004, Carlsson et al., 2009, Rydell et al., 2009). 
Importantly, there is early evidence suggesting a proteinaceous receptor for Norwalk 
virus entry, where most studies of norovirus-HBGA interactions focus on binding (White 
et al., 1996). Therefore, it is possible that norovirus binds to an attachment factor, 
followed by entry via a proteinaceous receptor. 
For other caliciviruses, bovine norovirus binds carbohydrate Galα epitope which is 
not present on human cell surface (Vildevall et al., 2010, Zakhour et al., 2010, Mauroy 
et al., 2011). MNV binds to glycolipid and glycoprotein in a strain-dependent manner 
(Taube et al., 2009, Taube et al., 2012). However, a recent study identified CD300ld 
and CD300lf as proteinaceous receptors of MNV (Orchard et al., 2016, Haga et al., 
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2016). Permissive BV-2 cells depleted of CD300lf showed complete resistance to MNV 
infection. Therefore, for MNV there are attachment factors glycolipid and glycoprotein, 
and cellular receptors CD300ld and CD300lf. FCV is the only other calicivirus with an 
identified functional receptor. FCV binds α2,6-linked sialic acid then enters cells via 
junctional adhesion molecule 1 (JAM-1) (Stuart and Brown, 2007, Makino et al., 2006). 
Porcine sapovirus also binds α2,6-linked sialic acid in addition to α2,3-linked sialic 
acid, and bile acid is crucial for viral entry (Shivanna et al., 2014, Kim et al., 2014). 
The details of which entry pathway(s) norovirus utilise are unknown. For MNV, 
endocytosis is dynamin and cholesterol dependent, but independent of pH, clathrin, 
and caveolae, which excluded most of the major pathways (Perry et al., 2009, Perry 
and Wobus, 2010, Gerondopoulos et al., 2010). The cellular entry of FCV is by clathrin-
mediated endocytosis and is dependent on acidification of endosomes (Stuart and 
Brown, 2006). 
 
Figure 1.4 Norovirus interaction with HBGA. A) Crystal structure of Norwalk virus VP1, PDB ID: 1IHM, 
adapted from (Prasad et al., 1999). VP1 is divided into N-terminus, shell domain and P domain. The P 
domain can be further divided into P1 and P2 subdomains. B) Norwalk virus P domain interaction with 
H type 1 antigen (PDB ID: 2ZL7, adapted from (Choi et al., 2008)). 
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1.6.2 Translation and polyprotein processing 
Norovirus genomic RNA is covalently linked to a cap-substitute viral protein VPg and 
polyadenylated at the 3’ end, thus functionally mimicking cellular mRNAs (Figure 1.5). 
Following viral entry and uncoating, the incoming genomic RNA is translated to 
establish viral replication complex (RC). To initiate translation, norovirus VPg functions 
as cap-substitute to recruit translation initiation factors (Daughenbaugh et al., 2006, 
Goodfellow et al., 2005, Daughenbaugh et al., 2003). This translation initiation 
mechanism is different from many small positive-sense RNA viruses, where a highly 
structured internal ribosome entry site (IRES) at the 5’ end of genomic RNA recruits 
translation initiation factors (Belsham, 2009). In addition, picornavirus VPg is mainly 
used as a protein primer for viral genome replication (Pathak et al., 2008). Prior to 
norovirus, VPg-dependent translation initiation was not observed in other animal 
viruses, instead this mechanism is used by some plant RNA viruses such as those 
within the family Potyviridae (Leonard et al., 2004). 
Both the HuNoV and MNV VPgs interact with eIF4F components. In particular, both 
VPgs interact with the cap-binding protein eIF4E and the scaffold protein eIF4G 
(Chaudhry et al., 2006, Daughenbaugh et al., 2003). However, VPg-dependent 
translation initiation is insensitive to eIF4E depletion (Chaudhry et al., 2006), and a 
followup study showed that a conserved C-terminus of VPg interacts with the HEAT-1 
domain of eIF4G to direct translation initiation (Leen et al., 2016). Together, it appears 
that VPg can recruit translation initiation factors independent of eIF4E, and there may 
be additional functions of the VPg-eIF4E interaction in norovirus life cycle. As the 
norovirus RNA is highly structured, the RNA helicase eIF4A, which is another 
component of the eIF4F ternary complex (eIF4A/eIF4E/eIF4G), was thought to help 
unwinding the RNA secondary structure to promote translation. Accordingly, the 
translation of MNV VPg-linked RNA is sensitive to a dominant-negative eIF4A 
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(Chaudhry et al., 2006). In addition to the eIF4F components, the norovirus VPg also 
interacts with eIF3, which may help recruiting the 43S pre-initiation complex 
(Daughenbaugh et al., 2006, Daughenbaugh et al., 2003). To date, with all the initiation 
factors, eIF3, eIF4E and eIF4G directly bind VPg (Leen et al., 2016, Goodfellow et al., 
2005, Daughenbaugh et al., 2003), co-immunoprecipitation of eIF4A with VPg likely 
occur via the eIF4G-eIF4A interaction, as the VPg-eIF4A complex was not observed 
(Leen et al., 2016). For porcine sapovirus and FCV, VPg interaction with eIF4E is 
essential for translation initiation, as a eIF4E inhibitor 4E-BP1 reduces the translation 
of VPg-linked RNA (Chaudhry et al., 2006, Goodfellow et al., 2005). 
The translation of the norovirus ORF1 polyprotein is processed primarily by viral 
protease NS6 or its precursor forms, some of which have been shown to be 
enzymatically active in vitro (Emmott et al., 2015, Scheffler et al., 2007, Sosnovtsev et 
al., 2006, Blakeney et al., 2003, Belliot et al., 2003, Liu et al., 1999, Liu et al., 1996). 
For MNV, the cleavage of NS1/2 by cellular protease caspase 3 was observed at late 
stage of infection, the significance of which is unknown (Sosnovtsev et al., 2006). Viral 
proteins VP1 and VP2 (and VF1 in MNV) are thought to translate from the subgenomic 
RNA. Given the presence of the larger abundance of subgenomic RNA, this could 
provide a mechanism by which more structural proteins are synthesised for capsid 
assembly (Yunus et al., 2015). The translation of VP2 occurs via a termination-
reinitiation mechanism, as demonstrated in MNV, FCV and RHDV (Napthine et al., 
2009, Luttermann and Meyers, 2007, Meyers, 2003). Upon termination of ORF2 (VP1) 
translation, a proportion of ribosomes are thought to remain associated with the 
subgenomic RNA and initiate ORF3 (VP2) translation via a start codon overlapping 
with the ORF2 stop codon. A termination upstream of ribosomal binding site (TURBS) 
sequence which is partially complementary to the 18S rRNA was also observed in MNV, 
which also contributes to the efficient translation of VP2 (Napthine et al., 2009). The 
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translation of VP1 via a similar termination-reinitiation mechanism at the ORF1/ORF2 
junction was only observed in bovine norovirus (McCormick et al., 2008). 
 
Figure 1.5 Cap- and VPg-dependent translation initiation. A) eIF4F complex is first assembled 
(eIF4A, eIF4E and eIF4G), then cap-binding protein eIF4E binds to m7GTP at 5’ end of mRNA. PABP 
binds poly(A) tail at 3’end of mRNA, then interacts with eIF4G to circularise mRNA. Helicase eIF4A 
scans mRNA to locate the start codon. eIF3 then binds eIF4G and recruits the 40S ribosomal subunit. 
B) VPg-dependent translation initiation. Most of the processes are the same except that VPg replaces 
m7GTP. Also VPg interacts with eIF4G and eIF3. Adapted from (Thorne and Goodfellow, 2014). 
1.6.3 Viral genome replication 
1.6.3.1 Assembly of viral replication complex 
Following initial translation of viral proteins, norovirus establishes viral replication 
complex (RC) to facilitate viral genome replication (Figure 1.6). Like many other small, 
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positive-strand RNA viruses, the norovirus RC is cytoplasmic and originates from re-
arrangement of cellular membranes. 
Early studies of the HuNoV N-terminal nonstructural protein p48 (NS1/2 in MNV) 
suggested possible roles in re-organising cellular membranes to establish viral RC 
(Fernandez-Vega et al., 2004, Ettayebi and Hardy, 2003). Another nonstructural protein 
p22 (NS4 in MNV), was shown to inhibit cellular secretory pathways (Sharp et al., 2012, 
Sharp et al., 2010). When expressed in cells, MNV NS1/2 co-localises with the ER 
marker calnexin, whilst NS4 co-localises with Golgi apparatus and endosomes (Hyde 
and Mackenzie, 2010). Recently, together with others we showed that norovirus NS1/2 
contains a mimic of phenylalanine-phenylalanine-acidic-tract (FFAT) motif that co-opts 
the cellular proteins VAMP-associated protein A (VAP-A) and VAP-B to establish RC 
(McCune et al., 2017). The membrane-redistribution function was also observed in 
picornaviruses (Dorobantu et al., 2015). Although initial investigation showed no clear 
co-localisation of MNV NS3 with ER, Golgi apparatus or endosomes (Hyde and 
Mackenzie, 2010). HuNoV NTPase and MNV NS3 were then shown to associate with 
lipid and microtubule to form replication complex-like structure when expressed in cells 
(Cotton et al., 2017). MNV VP1 was shown to redistribute the microtubules during 
infection. Although morphological changes of microtubules were observed at later 
stages of infection, the disruption of microtubules prior to infection or at early stages 
post infection inhibited MNV replication, indicating that the VP1-microtubule interaction 
is also important for RC formation (Hyde et al., 2012). Together, norovirus proteins 
rearrange cellular membranes and utilise cytoskeleton networks to establish the viral 
RC. For other caliciviruses, FCV viral proteins p32 (NS1/2 in MNV), p39 (NS3 in MNV) 
and p30 (NS4 in MNV) initiate RC formation via rearranging ER membranes, which is 
different to norovirus (Bailey et al., 2010a). 
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Figure 1.6 Norovirus replication complex. Raw264.7 cells were infected with MNV-1, the arrows 
indicate MNV-containing membraneous RCs. Figures adapted from (Wobus et al., 2004). 
1.6.3.2 Two modes of initiation by the norovirus RdRp 
Like other small positive-strand RNA viruses, the norovirus genome replication begins 
by the synthesis of negative-sense replication intermediates. The negative-sense 
genomic and subgenomic RNAs are then used as the template to synthesise the 
positive-sense genomic and subgenomic RNA. 
The norovirus RdRp plays a central role in the viral genome replication. To date several 
crystal structures are available, including those of the prototypic GI.1 Norwalk virus 
and the GII.4 HuNoV, which account for the majority of norovirus outbreaks since 2000 
(Ng et al., 2004, Zamyatkin et al., 2008, Zamyatkin et al., 2009, Hogbom et al., 2009, 
Mastrangelo et al., 2012, Croci et al., 2014b, Croci et al., 2014a). In addition to HuNoV, 
the crystal structures of other calicivirus RdRps were also determined (Ng et al., 2002, 
Fullerton et al., 2007, Lee et al., 2011, Alam et al., 2012). All of the characterised 
calicivirus RdRps display a partially closed right hand-like structure with fingers, palm 
and thumb subdomains (Figure 1.7), which is highly conserved among positive-strand 
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RNA viruses (Ng et al., 2004, Zamyatkin et al., 2008, Hogbom et al., 2009, Alam et al., 
2012). 
Detailed structural information reveals a 5-step RNA synthesis reaction of the norovirus 
RdRp which is common among viral RdRps. The apo-enzyme has its C-terminus 
bound to the active site, Figure 1.7A and (Ng et al., 2004). The RNA synthesis is 
initiated by a template-bound RdRp recruiting an NTP complementary to the template 
base. Then conformational changes of the thumb subdomain of RdRp are induced to 
accommodate the RNA primer and form a closed ternary complex, Figure 1.7B and 
(Zamyatkin et al., 2008). The active site of RdRp is located within the palm subdomain 
and coordinates two divalent metal ions to mediate the catalysis of nucleotide linkage 
(Ng et al., 2004, Ng et al., 2002, Vazquez et al., 2000). Following catalysis the RdRp 
remains in a closed complex, but the thumb subdomain returns to a similar 
conformation as in the apo-enzyme. Conformational changes of the thumb subdomain 
then release the pyrophosphate and translocates the RNA duplex to the next position. 
In addition to structural similarity, norovirus RdRps are functionally similar (Bull et al., 
2011). This supports the use of the MNV RdRp to study norovirus replication. 
The norovirus RdRp can initiate RNA synthesis by two distinct mechanisms, named de 
novo initiation and VPg-dependent initiation (Rohayem et al., 2006b). De novo initiation 
is primer-independent with the first nucleotide providing the ribose 3’ OH for the 
subsequent nucleotide linkage and the synthesis of the full length RNA (Beerens et al., 
2007, Kao et al., 2001). Recombinant norovirus RdRps can initiate RNA synthesis in 
vitro using homopolymeric and heteropolymeric templates (Belliot et al., 2005, Fukushi 
et al., 2004, Rohayem et al., 2006a). 
The norovirus RdRp can also initiate RNA synthesis using VPg as a protein primer 
(Rohayem et al., 2006a). Structural and functional analyses suggest a compact helical 
core structure of VPg is central for mediating the VPg-RdRp interaction, but further 
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conformational changes of the RdRp are likely required to accommodate VPg at the 
primer binding pocket (Leen et al., 2013). How the norovirus RdRp interacts with VPg 
is unknown, because a crystal structure of the RdRp-VPg complex is not yet available. 
As the norovirus genomic and subgenomic RNAs are covalently linked to VPg 
(Schaffer et al., 1980), it is believed that the nucleotidylylation of VPg is the first step 
of VPg-primed RNA synthesis. A recombinant norovirus RdRp can catalyse 
nucleotidylylation of VPg in vitro (Rohayem et al., 2006b, Belliot et al., 2005). 
Interestingly, despite the first nucleotide of both genomic and subgenomic RNA of all 
noroviruses is invariably guanosine, both guanylylation and uridylylation were 
observed in an in vitro nucleotidylylation assay. It is therefore possible that VPg also 
primes negative-sense RNA synthesis by generating VPg-poly(U) which is 
complementary to the poly(A) tails at 3’  ends of positive-sense genomic and 
subgenomic RNAs. However, using a mass spectrometry-based approach 
guanylylated VPg was detected from both MNV- and FCV-infected cell lysates, and 
there was no evidence of uridylylation of VPg (Olspert et al., 2016). Although the 
absence of uridylylated VPg may be due to the quantity difference between the 
positive- and negative-sense RNAs in infected cells (Vashist et al., 2012b), it is also 
possible that the biochemical nucleotidylylation assay of the norovirus RdRp does not 
confer the functional specificity of VPg nucleotidylylation in vivo. For example, in one 
study the tyrosine 117 was identified as the uridylylation site of MNV VPg (Han et al., 
2010), yet multiple evidence suggest the conserved tyrosine 26 (27 in HuNoV, 24 in 
FCV) is important for nucleotidylylation, genome linkage and infectivity (Medvedev et 
al., 2017, Belliot et al., 2008, Leen et al., 2013, Subba-Reddy et al., 2011). Together, it 
is generally accepted that the norovirus RdRp synthesises the negative-sense 
genomic RNA via de novo initiation, and VPg-primed initiation is required for the 
synthesis of the positive-sense genomic and subgenomic RNAs. 
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Figure 1.7 RNA-dependent RNA polymerase. Crystal structures of the A) Apo-enzyme (PDB ID: 1SH0) 
and B) Replicative form (PDB ID: 3BSN) of the Norwalk virus RdRp (fingers: green, palm: grey, thumb: 
blue, template: red, RNA primer: yellow). Note the different locations of the C-terminus of the thumb 
subdomain (red square) in the replicative form, exposing the active site during RNA synthesis. 
1.6.3.3 Directed initiation of replication 
In addition to the different modes of initiation, it is crucial that the norovirus RdRp 
initiate the RNA synthesis at an accurate site to preserve viral genetic information. Not 
much is known about how norovirus directs an accurate initiation of the positive-sense 
genomic RNA. However, due to the similarity of RNA sequence at both extremities, the 
positive-sense subgenomic RNA is usually used as a surrogate to understand the 
molecular details of norovirus genome replication. 
Two models have been proposed for the initial synthesis of norovirus subgenomic RNA 
(Figure 1.8). The pre-mature termination model proposed an unidentified termination 
signal leading to the synthesis of negative-sense subgenomic RNA, which is then used 
as the template to synthesise the positive-sense subgenomic RNA. Evidence 
supporting this model includes the identification of the negative-sense subgenomic 
RNA in Norwalk virus replicon-bearing HG23 cells (Chang et al., 2006), in RNA 
synthesis assay using enzymatically active replication complex purified from FCV-
infected cells (Green et al., 2002), and also in MNV-infected cells (Yunus et al., 2015). 
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Another model of initiation, named the internal initiation model, suggests that a highly 
conserved RNA stem loop upstream of the subgenomic start site binds to the norovirus 
RdRp and directs an accurate initiation. Bioinformatic and functional analyses 
suggested the presence of a highly conserved stem loop structure in the negative-
sense genomic RNA upstream of the subgenomic start (Simmonds et al., 2008). The 
following structural and biochemical investigation showed the norovirus RdRp binds to 
the conserved stem loop to direct the subgenomic RNA synthesis (Yunus et al., 2015, 
Lin et al., 2015). The presence of the negative-sense subgenomic RNA can be argued 
as the products of additional rounds of replication using the newly synthesised positive-
sense subgenomic RNA as templates. The presence of both templates, together with 
its smaller size, can contribute to the larger abundance of the subgenomic RNA 
compared with the full length genomic RNA (Vashist et al., 2012b, Yunus et al., 2015). 
1.6.3.4 Regulation of genome replication by viral factors 
Besides the RdRp, other norovirus proteins are also involved in regulating the viral 
genome replication. Together with the Kao lab (Indiana University), we previously 
developed a cell-based reporter assay (NoV-5BR assay) to indirectly measure the 
norovirus RdRp activity. In addition to the norovirus RdRp, firefly luciferase is 
expressed under an IFN-β promoter, which is activated upon the expression of the 
norovirus RdRp. In the NoV-5BR assay, VPg can stimulate the RdRp activity (Ranjith-
Kumar et al., 2011). This stimulation is independent of the mode of initiation, i.e. VPg 
interacts with RdRp to promote a state where RdRp is more competent in RNA 
synthesis. In addition to VPg, three more norovirus proteins were shown to modulate 
RdRp activity. NS1/2 (p48 in HuNoV) and VP1 enhance the RdRp activity, whereas the 
RdRp interaction with the minor capsid protein VP2 is inhibitory. Additive enhancement 
on the RdRp activity was not observed when VP1 and NS1/2 were co-expressed, 
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indicating a possible functional redundancy. Moreover, all of these interactions are 
genogroup-specific, indicating a functional conservation of these interactions through 
the differed residues. 
In a follow-up study, the norovirus VP1-RdRp interaction was further characterised 
(Subba-Reddy et al., 2012). Both HuNoV and MNV VP1 interact with their cognate 
RdRp and enhance the RdRp activity in a VPg-free NoV-5BR assay. The shell domain 
(SD) of VP1 is sufficient and necessary to stimulate the RdRp activity. Further mapping 
using chimeric SDs showed genogroup-specific residues of the flexible loops 1, 3, 5 
and 7 confer the specificity of the enhancement. The biological significance of the VP1-
RdRp interaction in the norovirus life cycle was demonstrated by complementing the 
expression of the SD in trans to stimulate norovirus RNA replication using an otherwise 
replication-deficient MNV replicon system. Because this stimulation is also 
concentration-dependent, it is thought to be important for promoting the synthesis of 
the negative-sense genomic RNA at the early stages of infection, where VP1 is present 
at low concentration, either from incoming capsid or translated from the subgenomic 
RNA de novo. The VPg-linked subgenomic RNA has been observed in FCV and RHDV 
viral particles (Meyers et al., 1991a, Neill, 2002). Therefore, it is possible that the 
translation of ORF2 from the incoming subgenomic RNA produces a small amount of 
VP1 sufficient to stimulate the RdRp activity. Moreover, in bovine norovirus (GIII 
Norovirus), VP1 can be synthesised from the genomic RNA via termination-reinitiation 
between the ORF1 and the ORF2, suggesting an alternative mechanism to synthesise 
VP1 via a less efficient means (McCormick et al., 2008). Together, these results 
demonstrate a non-structural role of a viral structural protein, supporting the hypothesis 
that small, positive-sense, single-stranded RNA viruses encode multifunctional 
proteins to compensate for the limited coding capacity of the small genomes. In fact, 
characterisation of the non-encapsidation functions of viral structural proteins have 
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become an increasingly important subject in RNA virology (reviewed in (Bol, 2008) and 
(Ni and Cheng Kao, 2013)). 
 
Figure 1.8 Regulation of genome replication. A) Two models of initiation of the norovirus subgenomic 
RNA. The premature termination model requires a termination signal on the positive-sense genomic 
RNA. RNA synthesis is terminated by this signal and the positive-sense subgenomic RNA is synthesised 
from the negative-sense, subgenomic RNA. The internal initiation model suggests a subgenomic 
promoter in the negative-sense genomic RNA. The positive-sense subgenomic RNA is synthesised 
through the RdRp recognising the sg promoter. B) Directed initiation of the synthesis of subgenomic 
RNA. Artificial RNA templates (proscripts) containing the conserved stem loops on the negative-sense 
genomic RNA of MNV-1 (Mps, left panel) and a GII.4 HuNoV (Gps, middle panel) can direct accurate 
initiations at the highlighted nucleotide, generating RNA products with defined length (Mps and Gps on 
right panel). C to A mutations of the initiation site nucleotide abolished the synthesis of DN products 
(MpsIM and GpsIM). This is adapted from (Lin et al., 2015). C) The norovirus capsid shell domain can 
enhance the RdRp activity in a genogroup-specific manner. The activity of the MNV RdRp can be 
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enhanced by the MNV SD in a concentration-dependent manner, but not by the GII.4 HuNoV SD, vice 
versa. This is adapted from (Subba-Reddy et al., 2012). 
1.6.4 Assembly and exit 
Not much is known about the details of the norovirus viral particle assembly and exit. 
Using different expression systems, recombinant norovirus virus and other 
caliciviruses VP1 can self-assemble into virus-like particles (VLPs) morphologically 
indifferent to the infectious viral particles, suggesting that VP1 is sufficient for virus 
assembly (Tresset et al., 2013a, Souza et al., 2013, Oka et al., 2009, Almanza et al., 
2008, Yan et al., 2005, Han et al., 2005, Nicollier-Jamot et al., 2003, Lochridge and 
Hardy, 2003, Baric et al., 2002, Guo et al., 2001, Geissler et al., 1999, Green et al., 
1997, Sibilia et al., 1995, Nagesha et al., 1995, Jiang et al., 1995, Jiang et al., 1992, 
Prasad et al., 1999, Prasad et al., 1994). The crystallisation of the Norwalk virus VP1 
proposed a virus assembly model initiated by the subunits A, B and C forming A/B and 
C/C dimers. The pentameric A/B dimers then recruited C/C dimers around the 5-fold 
symmetry centre. The resulting intermediates assemble into capsids via binding at the 
3-fold symmetry centres (Prasad et al., 1999). This model is supported by a biophysical 
characterisation of self-assembly kinetics which identified three main species: dimers, 
intermediates comprising of some 11 dimers, and icosahedral T = 3 capsids containing 
90 dimers (Tresset et al., 2013b). Although the shell domain is sufficient for assembly, 
the P domain enhances the stability of viral particles (Bertolotti-Ciarlet et al., 2002). 
The minor capsid protein VP2 is not required for VLP self-assembly but can also 
enhance the capsid stability, and the 3’ UTR of the Norwalk subgenomic RNA can 
stimulate VP1 expression in cis (Bertolotti-Ciarlet et al., 2003). In norovirus capsid, a 
highly conserved Isoleucine (Ile52 of the Norwalk virus) at the N terminus of the shell 
domain is essential for the VP2 association (Vongpunsawad et al., 2013). Only a few 
copies of VP2 were packaged into capsids, although 90 icosahedrally equivalent Ile-
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52 pairs are present in the capsids. The reason for this substoichiometry distribution is 
still unknown (Glass et al., 2000, Sosnovtsev and Green, 2000). Another unanswered 
question is the packaging mechanism of norovirus genome. Due to the absence of 
appropriate sized holes in the capsid structure, the viral genomic RNA is unlikely 
encapsidated after capsid assembly (Prasad et al., 1999). The norovirus VP2 is long-
speculated to be involved in viral genomic RNA packaging due to its highly basic nature, 
yet it was only shown in FCV that VP2 is required for the production of infectious virions 
(Sosnovtsev et al., 2005). 
The mechanistic details about norovirus exit is not fully understood, but MNV, together 
with RHDV and FCV, induces apoptosis during infection (Herod et al., 2014, Furman 
et al., 2009, Roberts et al., 2003, Alonso et al., 1998). Three putative caspase 3 
cleavage sites were identified in MNV NS1/2, and two were found to be cleaved during 
MNV infection (Sosnovtsev et al., 2006). These cleavages separate NS1 from NS2. 
MNV infection is paralleled with down regulation of apoptosis inhibitor survivin (Bok et 
al., 2009), and VF1 was shown to delay apoptosis during MNV infection (McFadden et 
al., 2011). But it could be argued as extending the window for replication before the 
final apoptosis and exit stages. 
1.6.5 Interactions with cellular factors and pathways 
1.6.5.1 Translation control 
Many small RNA viruses interact with cellular factors and pathways to facilitate 
productive virus replications (Nagy and Pogany, 2011). Several previous studies have 
started to fill in the knowledge gaps of host factors of norovirus replication. 
The structured extremities of the norovirus genome provide binding sites for cellular 
proteins to regulate translation and/or to regulate between translation and viral genome 
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replication. Poly(A)-binding protein (PABP) was shown to bind the 3’ extremities of 
mammalian mRNA and can stimulate translation (Kahvejian et al., 2005). PABP also 
binds the 3’UTR of Norwalk virus RNA, suggesting a possible role in norovirus 
translation or replication (Gutierrez-Escolano et al., 2003). Other RNA-binding proteins 
identified to bind the norovirus genome include but are not limited to poly(rC)-binding 
protein 2 (PCBP2), La, polypyrimidine tract-binding protein (PTB), heterogeneous 
nuclear ribonucleoprotein L (hnRNP L), hnRNP A1, and DDX3 (will be discussed in the 
next section). The functions of these factors in norovirus translation remain to be 
determined. RNA-binding factors also regulate translation and replication of other 
caliciviruses. For example, nucleolin promotes FCV viral RNA translation (Hernandez 
et al., 2016). Polypyrimidine tract binding protein (PTB) is a negative regulator of FCV 
translation but is required for efficient FCV replication. It is possible that PTB clears 
ribosomes from viral RNA at later stages of infection to stimulate viral genome 
replication (Karakasiliotis et al., 2010). 
Because of the different requirements for translation initiation factors, norovirus can 
alter host cell translation without impacting viral translation. Our latest study of host 
cell proteome changes during MNV infection showed that MNV infection decouples 
host translation from transcription (Emmott et al., 2017). Transcripts of interferon-
stimulated genes (ISGs) were induced during MNV infection, yet defects were 
observed in expression of the corresponding genes. The protease NS6 cleaves PABP, 
contributing to a global translation shut down (Figure 1.9A). In addition, apoptosis 
paralleled with MNV infection cleaves eIF4G, disassociating the 43S initiation complex 
from the eIF4F complex (Herod et al., 2014, Bok et al., 2009, Emmott et al., 2017). 
However, norovirus translation is not impacted, as VPg binds eIF3 directly to recruit 
the 43S preinitiation complex (Daughenbaugh et al., 2006, Daughenbaugh et al., 2003). 
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This distinct mechanism allows MNV to efficiently translate viral proteins, to suppress 
host cell translation and to subvert innate immune response at the same time. 
Norovirus VPg also binds the cap-binding protein eIF4E, but eIF4E depletion has no 
impact on MNV translation (Chaudhry et al., 2006). Therefore, the functional 
significance of this interaction remains unknown. eIF4E binds the m7G cap at the 5’ 
termini of eukaryotic mRNAs. Due to the limiting amount of functionally-available 
proteins, eIF4E is considered as the rate limiting step of cap-dependent translation 
initiation (Rau et al., 1996). The activity of eIF4E can be regulated by eIF4E binding 
proteins (4EBPs), or by phosphorylation at serine 209 position (Ueda et al., 2004). 
It is still debatable whether eIF4E phosphorylation promotes or inhibits translation. 
Early biochemical studies showed that eIF4E phosphorylation increases the 
electrostatic repulsion against 5’ cap which should inhibit cap-dependent translation 
initiation (Zuberek et al., 2004, Zuberek et al., 2003). However, the global translation 
efficiency is not altered in MEF cells with homozygous eIF4E S209A mutations, which 
abolish the phosphorylation. Instead, the translation of a subset of mRNAs is altered 
(Furic et al., 2010). Biochemical analysis of the pathways modified in these cells 
showed the mRNAs sensitive to eIF4E phosphorylation contain cap and a 5’-terminal 
hairpin structure (Korneeva et al., 2016). Therefore, it appears that eIF4E 
phosphorylation specifically regulate the translation of mRNAs with structured 5’ UTR. 
A previous study of our laboratory showed that MNV infection reprogrammes global 
translation by phosphorylating eIF4E, Figure 1.9B and (Royall et al., 2015). MNV 
infection activates the p38-MNK pathways to phosphorylate eIF4E, which alters the 
translation states (TS) of several cellular mRNAs. Also, MAP-interacting 
serine/threonine kinases (Mnks) also binds eIF4G to phosphorylate eIF4E (Shveygert 
et al., 2010). Together with the direct interaction between VPg and eIF4G, and the 
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cleavage of eIF4G at the late stage of MNV infection (Emmott et al., 2017), it is possible 
that VPg with cleaved eIF4G mediates translation control by bringing eIF4E and Mnk 
to a physical proximity. 
 
Figure 1.9 Translation control. A) The cleavage of eIF4G during MNV infection induced-apoptosis 
separates the N-terminus and the PABP-binding domain of eIF4G from the middle domain, which 
contains the binding sites for eIF3, eIF4A and eIF4E. Also, norovirus protease cleaves PABP. Adapted 
from (Emmott et al., 2017). B) Phosphorylation of eIF4E at Serine 209 by Mnk to facilitate the translation 
of a subset of mRNAs. Mnk binds eIF4G and phosphorylates eIF4E at serine 209, leading to enhanced 
translation of a subset of mRNAs, including NF-κB inhibitor IκBα.  
1.6.5.2 Host factors for virus replication 
The norovirus genome is known to be highly structured at both extremities, and studies 
have identified several host proteins binding to these regions (Vashist et al., 2012a, 
Bailey et al., 2010b, Sandoval-Jaime and Gutierrez-Escolano, 2009, Gutierrez-
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Escolano et al., 2000). PCBP2, La, PTB, and hnRNP L interact with the Norwalk virus 
genome (Gutierrez-Escolano et al., 2003, Gutierrez-Escolano et al., 2000). Using 
riboproteomics, PCBP2, La, and PTB were also identified to bind to MNV genomic 
RNAs (Lopez-Manriquez et al., 2013, Vashist et al., 2012a, Bailey et al., 2010b). 
Additionally, RNA-binding proteins (RBPs) like DDX3 and hnRNP A1 are proviral host 
factors for MNV. PCBP2 and hnRNP A1 are required for circularisation and replication 
of the MNV genomic RNA (Lopez-Manriquez et al., 2013). RNA-inhibition (RNAi)-
mediated knock down of the RBPs La, PTB and DDX3 negatively impacted MNV 
replication (Vashist et al., 2012a). MNV replication in vivo is attenuated when the 
polypyrimidine tract stem loop at the 3’ end of MNV genome is mutated, suggesting 
viral RNA-host protein interaction is important for norovirus pathogenesis (Bailey et al., 
2010b). As for norovirus, PTB is also important for FCV replication, where PTB 
negatively regulates FCV translation to promote virus genome replication 
(Karakasiliotis et al., 2010, Karakasiliotis et al., 2006). 
Interactions with cholesterol pathways have also been implicated in norovirus 
replication. In Norwalk virus RNA replicon-bearing cells cholesterol biosynthesis is 
down-regulated (Chang, 2009). Lowering cholesterol with simvastatin promotes 
HuNoV replication in a gnotobiotic pig model (Bui et al., 2013, Jung et al., 2012). The 
epidemiological correlation between the severity of HuNoV infections and the use of 
anti-cholesterol drugs suggests statins may be a risk factor for norovirus patients 
(Rondy et al., 2011). Although the gnotobiotic pig model of HuNoV infection suggested 
simvastatin antagonises innate immunity, the molecular details of how cholesterol 
biosynthesis affects norovirus replication is still unknown (Jung et al., 2012). 
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1.6.5.3 Interactions with host immune pathways 
Subverting host cell immune responses is another important function of norovirus-host 
cell interactions. Innate immune responses are the first line of defence against acute 
norovirus infections. Norwalk virus RNA replication is sensitive to type I IFNs (Chang 
et al., 2006, Chang and George, 2007). Treating infected gnotobiotic pigs with IFN-α 
reduces HuNoV faecal shedding (Jung et al., 2012). Because of the established tissue 
culture system and the mouse model, there are more details of how MNV interacts with 
type I IFN responses. First of all, MNV replication is sensed by helicase melanoma 
differentiation-associated protein 5 (MDA-5), which recognises double stranded RNA 
(dsRNA) produced during replication (McCartney et al., 2008). The activation of MDA-
5 leads to signalling cascades mediated by mitochondrial antiviral signalling protein 
(MAVS), followed by the activation of transcription factors IRF-3, IRF-7 and NF-κB 
(Seth et al., 2005). Accordingly, MDA-5-, IRF-3/IRF-7 double-, and IRF-3/IRF-5/IRF-7 
triple knock-out enhance MNV replication in vivo (Lazear et al., 2013, Thackray et al., 
2012, McCartney et al., 2008). The expression of interferon-stimulated genes (ISGs) 
are initiated by IFN-α and IFN-β binding to the type I IFN receptor IFNAR and 
signalled through the JAK-STAT pathways (Ivashkiv and Donlin, 2014). Genetic knock-
out of the type I IFN receptor IFNAR promotes MNV pathogenesis in mice (Wobus et 
al., 2004, Karst et al., 2003). Similarly, STAT1 has been well documented to be crucial 
for controlling MNV infection (Niendorf et al., 2016, Karst et al., 2003, Wobus et al., 
2004). 
In response, MNV can antagonise innate immunity via virulence factor 1 (VF1), which 
is encoded by the MNV-specific ORF4 overlapping the ORF2 coding region (Thackray 
et al., 2007, Simmonds et al., 2008). VF1 localises to mitochondria and our preliminary 
results suggest that VF1 does not interact with any other MNV proteins (A. de 
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Rougemont, unpublished data). This observation supports an accessory role of VF1 to 
regulate host cellular innate immunity. Ectopic expression of VF1 reduces RIG-I-
mediated immune sensing (Zhu et al., 2013). In vitro, the loss of VF1 expression 
enhances type I IFN induction, paralleled with a fitness cost for MNV replication. In 
vivo, MNV lacking VF1 (MNV-1VF1-) is less virulent and the viral replication is 
attenuated (McFadden et al., 2011). However, this was observed in STAT1-/- mice, 
suggesting VF1 also interacts with cellular pathways other than STAT1 to promote 
MNV replication. To date a VF1 homologue protein is not found in HuNoV, at present 
it is unknown how HuNoV replication regulates host cell immunity. For other 
caliciviruses, the FCV p39 (NS3 in MNV) prevents IRF-3 activation (Yumiketa et al., 
2016). Recently, MDA-5 and RIG-I show important roles in innate immune sensing in 
the early and the late stages of Tulane virus infection, respectively (Chhabra et al., 
2017). 
Between type I and type III innate immune responses, it is believed that type I IFN 
responses are important for preventing systemic infections while type III IFN responses 
have more significant roles in controlling epithelial cell infections (Pott et al., 2011, 
Pervolaraki et al., 2017). The interactions between MNV and type III IFN responses 
have also been investigated. IFN-λ is important for controlling faecal shedding and 
enteric viral titre during persistent MNV infections. IFN-λ  treatment can cure 
persistent MNV infections in the absence of adaptive immune response, highlighting 
its potential as an antiviral drug (Baldridge et al., 2015). Moreover, a recent study 
confirmed the expression of IFN-λ receptor Ifnlr1 on intestinal epithelial cells are 
critical for its antiviral functions, suggesting a possible role of intestinal epithelial cells 
in persistent MNV infection (Baldridge et al., 2017). 
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The norovirus interactions with adaptive immune responses have been characterised 
with attempts to understand the mechanisms of protective immunity against norovirus 
infections. Volunteer challenge studies of the early days have already noticed that 
mucosal immune responses do not protect individuals against re-challenge of HuNoV 
(Parrino et al., 1977, Johnson et al., 1990, Okhuysen et al., 1995). As in HuNoV, 
primary high dose infection of an acute MNV does not provide protection against 
homotypic re-challenge (Liu et al., 2009). Antibody, B cell, CD4 and CD8 T cells are 
important for the clearance of MNV infection (Chachu et al., 2008b, Chachu et al., 
2008a) and the suboptimal CD8 T cell response contributes to MNV persistence 
(Tomov et al., 2013). However, the interaction between dendritic cells (DCs) and MNV 
is more complicated. DCs are permissive to MNV infection (Wobus et al., 2004). The 
depletion of DCs lead to increased intestinal replication of MNV, reduced viral 
dissemination and impaired antibody production (Elftman et al., 2013). Moreover, the 
depletion of IFNAR expression in DCs leads to a systemic MNV persistence despite 
enhanced adaptive immune responses, indicating that DCs may bridge the innate and 
adaptive immune responses (Nice et al., 2016). 
In addition to host factors, two viral genes have been shown to contribute to norovirus 
persistence. First of all, a single amino acid mutation on NS1/2 of an acute MNV results 
in persistent infections and alteration of viral tropism (Nice et al., 2013). Secondly, the 
minor capsid protein VP2 regulates antigen presentation cell maturation and protective 
immune response induction (Zhu et al., 2013). The VP2 of a persistent MNV-3 
antagonises B cell antigen presentation, leading to the impaired control of acute 
infections (Zhu et al., 2016). Together, immunity to control MNV infections require both 
mucosal and cellular immunity, and MNV antagonises both pathways to facilitate viral 
pathogenesis. 
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1.7 Antivirals and vaccines 
1.7.1 Antivirals 
Understanding the molecular details of norovirus life cycle has begun the intervention 
of norovirus antivirals. 
Interferons (type I/II/III) have shown various antiviral activities against norovirus 
replication (Chang and George, 2007, Maloney et al., 2012, Nice et al., 2015). 
Compared with type I IFNs, IFN-λ treatment may have greater specificity and less 
adverse effects because its receptor is largely restricted to epithelial cells. Although it 
has not yet been used for treating chronic HuNoV infections, IFN-λ treatment cures 
persistent MNV infection without the need of adaptive immune response, highlighting 
the antiviral potential in treating chronic HuNoV infection in the immunocompromised 
(Nice et al., 2015). 
Norovirus relies on efficient viral entry to initiate infection. Genetic knock-out of MNV 
receptor CD300 from MNV permissive cell line BV-2 confers resistance to infection 
(Orchard et al., 2016, Haga et al., 2016). Although HuNoV entry is not studied using a 
native virus, it is well known that HuNoV VLPs bind HBGAs (Marionneau et al., 2002). 
Porcine gastric mucin competitively inhibits the HuNoV VLP binding to intestinal 
epithelial cells (Tian et al., 2005), so as some small molecule inhibitors (Feng and Jiang, 
2007). This has been proposed as a prophylactic means for outbreak control, but the 
utility is likely limited. 
Due to its central role in norovirus replication, there is more information on the inhibitors 
of norovirus RdRp than that of any other norovirus proteins. Ribavirin is a nucleoside 
analogue widely used to treat RNA virus infections, including HCV (Te et al., 2007), 
RSV (Marcelin et al., 2014) and Lassa fever virus (Hadi et al., 2010). Ribavirin 
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efficiently inhibits MNV RdRp and increases quasispecies diversity (Arias et al., 2014, 
Julian et al., 2016, Alam et al., 2012). In a Norwalk virus RNA replicon, ribavirin inhibits 
the viral RNA replication and gene expression (Chang and George, 2007). Favipirivir 
is a nucleoside analogue which induces lethal mutagenesis during MNV replication in 
vivo (Jin et al., 2015, Arias et al., 2014, Rocha-Pereira et al., 2012b). Another potent 
RdRp inhibitor is 2’-C-Methyl-Cytidine (2CMC) (Rocha-Pereira et al., 2012a). In both 
MNV and Norwalk virus RNA replicon, 2CMC effectively inhibits the viral genome 
replication (Jin et al., 2015). The antiviral potential of 2CMC was further demonstrated 
by protecting the immunocompromised mice from lethal MNV infections, and 
preventing MNV transmission when used as a prophylactic treatment (Rocha-Pereira 
et al., 2015, Rocha-Pereira et al., 2013). 
An increasingly important target of antiviral intervention is the viral protease NS6. 
Polyprotein processing is important for the functions of ORF1 non-structural proteins 
(Emmott et al., 2015). Inferred from the crystal structures NS6 is a highly conserved 
cysteine protease (Oka et al., 2007, Zeitler et al., 2006). Structure-guided inhibitors 
design and biochemical characterisation have yielded some candidate drugs (Galasiti 
Kankanamalage et al., 2017b, Galasiti Kankanamalage et al., 2017a, Weerawarna et 
al., 2016, Galasiti Kankanamalage et al., 2015, Deng et al., 2013, Tiew et al., 2011), 
however more in vitro and in vivo functional studies are needed to evaluate the efficacy 
of these inhibitors (Kim et al., 2015, Emmott et al., 2015, Qu et al., 2014). 
1.7.2 Vaccines 
The development of a HuNoV vaccine will particularly benefit the high-risk groups, 
including health care workers, military personnel, the young, the elderly and the 
immunocompromised. Also, food-borne outbreaks can be potentially reduced by 
vaccinating food handlers. During norovirus outbreaks, rapid ring vaccination can 
 46 
establish herd immunity to aid disease control, especially when outbreaks occur in 
medical wards or in cruise ships. Currently there are no licensed vaccines for HuNoV. 
And due to the lack of a robust tissue culture system for HuNoV, vaccine designs are 
limited to inducing immunity against viral structural proteins with VLPs or P particles. 
There are several other challenges for developing a HuNoV vaccine. First, immunity 
against HuNoV infections is short-lived and the immune correlates of HuNoV infections 
remain unknown. It was speculated that primary HuNoV challenges elicit short-term 
protection against homotypic re-challenge, yet the results were complicated by the lack 
of pre-challenge exposure history and the screening of genetic susceptible factors 
(Johnson et al., 1990, Atmar et al., 2008). Second, HuNoV sequences are very diverse, 
with nucleotide sequence identity as little as 50% (Vashist et al., 2009). Different 
HuNoV strains or variants display distinct antigenicity, resulting in difficulties for both 
antigen-based diagnostics and the development of a vaccine providing broad 
protection (Lindesmith et al., 2005). Therefore, a multivalent vaccine may be needed 
(LoBue et al., 2006, Malm et al., 2015). Moreover, as previously discussed, HuNoV 
especially the GII.4 variants evolve quickly. Therefore it is important and challenging 
to antigenically characterise a new variant whilst to produce a reformulated vaccine in 
due course (Ramani et al., 2014). 
Several vaccine candidates are under clinical trials, all of which are based on either 
VLPs or P particles (Lucero et al., 2017). Recombinant HuNoV VLPs induce robust 
immune responses in mice, gnotobiotic pigs, chimpanzees, and human (Ball et al., 
1998, Bok et al., 2011, Souza et al., 2007b, Ball et al., 1999). In a previous study 
volunteers were vaccinated using monovalent Norwalk virus VLPs and challenged with 
homotypic virus. Immunisation reduces the severity of symptoms and provides partial 
protection, yet 37% of the immunised group developed gastroenteritis (Atmar et al., 
Introduction 
Jia Lu 47 2017 
2011). This study at least demonstrates the possibility of inducing protective immune 
responses with HuNoV VLPs. 
1.7.3 Rational attenuation of norovirus 
Live attenuated vaccines have been successfully developed for influenza virus 
(FluMist®) and other RNA viruses, including polio (OPV), measles, rotavirus, and 
yellow fever virus. Compared to inactivated or VLP-based vaccines, live attenuated 
vaccines induce more robust immunity because of multiple targets for immunisation 
(Lauring et al., 2010).  
Empirically attenuated viruses were obtained by blind passage in different cell lines. 
Virus attenuation is mediated by adapting to new cellular environment (Lauring et al., 
2010). However, the mechanism of attenuation is unknown, and immunisation in the 
natural host of the virus risks the reversion to a virulent strain. For example, oral polio 
vaccine (OPV) is known to accumulate mutations (Sahoo et al., 2017). Although OPV 
is more cost effective, inactivated polio vaccine (IPV) was chosen to eradicate 
poliomyelitis. Tissue culture adaptation was observed in MNV infection (Bailey et al., 
2008, Zhu et al., 2015), the mechanism of which is unknown. Without a cell culture 
system it is not yet possible to produce a live attenuated HuNoV. 
One possible strategy of rational attenuation is by generating replication defective 
viruses. This is achieved by targeting the viral genes or processes important for 
infection. This has been demonstrated in MNV that a genetic knock-out of VF1 
attenuates MNV replication in vivo (McFadden et al., 2011). However, as there is no 
VF1 homologue in the HuNoV genome this approach cannot be applied for the 
attenuation of HuNoV. Therefore, targeting the processes of infection which are 
functionally conserved between HuNoV and MNV not only enables the identification of 
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important viral and host factors but also lay the basis for the development of a live 
attenuated HuNoV. 
1.8 Project aims 
The rational attenuation of norovirus depends on the establishment of a cell culture 
system for HuNoV and characterising the host and viral factors important for norovirus 
replication. Therefore, the first part of this thesis focused on establishing a cell culture 
system of HuNoV. Based on previous results, different cell lines were screened to 
identify permissive cells. Also, the inhibition of innate immune responses was applied 
to promote HuNoV replication in the tested cells. 
Using MNV as the model system, the second and third parts of this thesis were focused 
on two aspects of norovirus life cycle: the role of eIF4E phosphorylation in norovirus 
translation control, and the role of the shell domain of the major capsid protein VP1 in 
regulating norovirus genome replication. Specifically, MNV elicits translational 
reprogramming by inducing eIF4E phosphorylation, which regulates innate immune 
response during virus infections (Royall et al., 2015, Herdy et al., 2012). This chapter 
aimed to determine whether eIF4E phosphorylation was involved in norovirus 
subverting the innate immune responses, and the impact on norovirus pathogenesis 
when eIF4E phosphorylation was inhibited. 
The biological significance of the structural protein VP1 in regulating norovirus genome 
replication was also investigated. The norovirus VP1 modulates the RdRp activity in a 
genogroup-specific manner (Subba-Reddy et al., 2012). Mutagenesis was applied to 
identify the residues in VP1 important in mediating the VP1-RdRp interaction. The 
attenuation of MNV has been achieved by mutating the VP1 with an unknown 
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mechanism (Bailey et al., 2008). By understanding the VP1-RdRp interaction in 
norovirus pathogenesis rational attenuation could be achieved by targeting the non-
structural function of this structural protein. 
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Materials and methods 
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2.1 Cells and bacteria 
Caco-2 cells were purchased from ECACC and maintained in Dulbecco’s-modified 
Eagles Medium (DMEM, Sigma-Aldrich) with 10% heat-inactivated foetal bovine serum 
(FBS), 2 mM L-glutamine (L-Gln, Gibco), 1× MEM non-essential amino acids (NEAA, 
Gibco), and 100 SI units/ml penicillin and 100 μg/ml streptomycin (P/S). LS174T (WT 
and dominant negative TCF4) cells were kindly provided by Hans Clevers (Hubrecht 
Institute, Utrecht, Netherland). Cells were maintained in DMEM with 10% FBS, 2 mM 
L-Gln, and P/S. Every month cells were selected with blasticidine (10 μg/ml) for 1 
week. In addition to blasticidin, the LS174T dnTCF4 were also selected with zeocin 
(500 μg/ml). 
Human intestinal epithelial crypt (HIEC) cells were obtained from ECACC and 
maintained in OptiMEM with 5% Cellect Fetal Bovine Serum (MP Biomedicals), 0.01 
M HEPES (Gibco), 1× Glutamax (Gibco), and 5 ng/ml epidermal growth factor (EGF). 
BJAB cells were kindly provided by Paul Farrell (Imperial College London) and 
Stephanie Karst (University of Florida, Gainesville, USA). Cells were grown in 
RPMI1640 (Sigma-Aldrich) with 10% FBS, P/S and 2 mM L-Gln. The cell density was 
maintained between 2.5 × 105 and 2 × 106  /ml in 6-well plates. 
Primary tonsillar cells were isolated based on previously published protocol (Cameron 
and Stent, 2001). Approximately 1 g tonsil tissues obtained from tonsillectomy was 
maintained in cold RPMI1640 media until use. The tissue was first divided into small 
pieces using scalpel and forceps, then digested with 25 μg/ml DNaseI and 2 mg/ml 
collagenase II at 37 ℃ using water bath. The digestion was stopped with 10 mM final 
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concentration of EDTA and ice-cold tissue culture media (RPMI1640 with 10% FBS, 
P/S and 2 mM L-Gln). Cells were filtered with 40 μm cell strainer and centrifuged at 
300 × g for 10 minutes at 4 ℃. Cells were then counted and infected with HuNoV. 
KBM7 cells were maintained in DMEM with 10% FBS, 2 mM L-Gln, and P/S. Cell 
density was maintained between 2.5 × 105 and 2 × 106  /ml. 
Differentiation of peripheral blood-derived γδ T cells was performed and kindly 
provided by Marta Barisa (J. Anderson lab, University College London). 5 to 10 ml 
peripheral blood was obtained from two healthy donors with consent. Inactivated E.coli 
was used to expand γδ T cell population. Two to three weeks post differentiation 
cells were phenotyped and transported to Cambridge. On the same day cells were 
infected by HuNoV. 
Primary duodenal organoids D196 and D353 were kindly provided by Matthias Zilbauer 
(University of Cambridge) and maintained by M. Hosmillo and Y. Goodfellow. Protocols 
for maintaining and differentiating intestinal organoids were based on previous 
publications with modifications (Sato et al., 2011). Organoids were maintained in 20 -  
40 μl per well of Matrigel® Matrix (BD Bioscience) adherent to the bottom of 48-well 
or 24-well plates, with 250 μ l proliferation media consisting of 50% v:v WNT-
conditioned media (M. Hosmillo and Y. Goodfellow), 100 ng/ml mouse recombinant 
noggin (Peprotech), 1× B-27 supplement minus vitamin A (Gibco), 1.25 mM N-Acetyl-
L-cysteine (Sigma-Aldrich), 10 mM Nicotinamide (Sigma-Aldrich), 50 ng/ml mouse 
recombinant EGF (Sigma-Aldrich), 2 μM A 83-01 (Tocris Bioscience), 3 μM SB 
202190 (Sigma-Aldrich), 1 mg/ml Primocin (InvivoGen), and ADF+++ (advanced 
DMEM/F-12 containing 0.01 M HEPES, 1×  Glutamax and P/S) to make up the 
volume. Every 48 hours 50% of the media was replaced by carefully removing the 
media without disturbing the Matrigel drops. Every 6-7 days the organoids were split 
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1:2 to 1:3. On the day of splitting, Matrigel stocks were kept on ice to remain in liquid 
phase, whilst cell culture plates were maintained at 37 ℃. Matrigel drops containing 
organoids were mixed with proliferation media and organoids were sheared into 
smaller clumps of 3 to 10 cells by pipetting up and down about 15 times with a crushed 
tip. Organoids suspension was then centrifuged at 800 × g for 5 minutes at 4 ℃. 
Proliferation media containing liquified Matrigel was removed by gentling pipetting 
without disturbing the organoids pellet. Tubes containing organoids were chilled on ice 
for 5 minutes before cold Matrigel was added and mixed. Matrigel containing organoids 
was then added at the bottom of cell culture plates without proliferation media. Plates 
were then returned to 37 ℃ upside-down for solidification of Matrigel, before adding 
fresh proliferation media and maintained at upright position. For differentiation of 
organoids, plates were coated with 40 μg/ml collagen (Sigma-Aldrich) in H2O at 37 ℃ 
for 2 hours. Proliferation media was removed and organoids were washed twice with 
cold EDTA in PBS, trypsinised for 3.5 minutes and stopped with ADF+++ media 
containing 10% FBS. Organoids were pipetted up and down and passed through a 40 
μm cell strainer. Cells were centrifuged at 800 × g for 5 minutes at 4 ℃  and 
resuspended in proliferation media with 10 μM Y-27632 (Sigma-Aldrich), and seeded 
at 1.7 × 104 cells per well of 48-well plates. On the second day, cell culture media 
was carefully removed and replaced with differentiation media containing ADF+++ with 
100 ng/ml mouse recombinant noggin (Peprotech), 1×  B-27 supplement minus 
vitamin A (Gibco), 1.25 mM N-Acetyl-L-cysteine (Sigma-Aldrich), 50 ng/ml mouse 
recombinant EGF (Sigma-Aldrich), 2 μM A 83-01 (Tocris Bioscience), and 1 mg/ml 
Primocin (InvivoGen). 10 μM Y-27632 (Sigma-Aldrich) was initially added in addition 
to differentiation media, and was removed as soon as a confluent monolayer was 
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observed. Differentiation media was replaced every 48 hours until infection (usually 5 
days post seeding). After infection cells were maintained in differentiation media. 
Baby Hamster Kidney (BHK) cells engineered to express T7 RNA polymerase (BSR-
T7 cells) were obtained from Karl-Klaus Conzelmann (Ludwid Maximillians University, 
Munich, Germany) and maintained in DMEM containing 10% FBS, 2 mM L-Gln, P/S, 
and 0.5 mg/ml G418 (InvivoGen). HEK293T and Raw264.7 cells were maintained in 
DMEM supplemented with 10% FBS, 2 mM L-Gln and P/S. Murine microglial BV-2 cell 
line was provided by Jennifer Pocock (University College London), maintained in 
DMEM with 10% FBS, 2 mM L-Gln, and P/S. 
Enteric bacteria Enterobacter cloacae was obtained from ECACC. The bacteria were 
revived in LB media and grown overnight at 37 ℃. Bacteria was then pelleted, washed 
with PBS, followed by heating at 70 ℃ for 40 minutes and mixed every 10 minutes. 
Serially diluted, pre-inactivated bacteria culture was plated and incubated at 37 ℃ 
overnight. Live bacterial density of the inactivated stock was calculated by counting the 
colonies and extrapolating to undiluted stock. 
2.2 Plasmids 
The second-generation lentiviral packaging plasmids psPAX2, pMD2.G, and lentiviral 
plasmids pdl-MCS, pdl-BVDV NPro, and pdl-PIV5 V were all provided by F. Sorgeloos. 
For cloning of FUT2 lentiviral plasmid, cDNA was synthesised from total RNA (digested 
with DNaseI and purified) from the following cell lines: Caco-2, HT-29 and BJAB. FUT2 
cDNA was sub-cloned into a pTM900 plasmid (provided by F. Sorgeloos). A secretor 
and a non-secretor FUT2 clones were selected. 
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HuNoV plasmids, pUC57: GII.4-flc, pUC57: GII.4-F/S and pUC57: GII.6-flc were 
previously generated (I. Goodfellow and L. Thorne, unpublished data). Plasmid pUC57: 
GII.6-F/S was generated by introducing a +2 frame shift at the active site of the RdRp 
coding sequence. 
The full-length cDNA clones of MNV-1 (pT7: MNV 3’Rz) and MNV-3 (pT7: MNV-3 3’
Rz) were reported previously with accession numbers of DQ285629.1 and JQ658375.1, 
respectively (Chaudhry et al., 2007, Arias et al., 2012). Derivative mutants of these two 
constructs were generated by overlap-extension PCR and restriction digestion. 
Specifically, chimeric MNV-1s or MNV-3s with combinations of SD flexible loops 
mutated to HuNoV VP1 sequences were named after the according loops mutated. 
For example, MNV-1 L1 indicates the loop 1 of SD was mutated to HuNoV sequence 
by mutating Threonine 74 into Alanine (Table 5.1). 
To generate expression constructs for LUMIER assay, first of all, VP1 cDNA sequences 
were amplified by PCR from chimeric MNV-1 infectious clones. A second round of PCR 
was performed to add recombination sites to PCR products. BP reactions were then 
performed using purified PCR product and pDONR227 entry clone plasmid following 
manufacturer’s instructions (ThermoFisher). Following recombination, plasmids were 
transformed into ccdB survival competent cells. Positive clones were selected and VP1 
coding regions were sequence verified. LR reactions were then performed to generate 
VP1 expression constructs in pcDNA3-GW-RL and pT-Rex-Dest30-PA backbones. 
Expression constructs of RdRp, positive controls (pcDNA3-RL-jun and pT-Rex-
Dest30-PA) and negative control pT-Rex-Dest30-PA-PA were provided by A. de 
Rougemont. pEGFP-RdRp was provided by S. Vashist. 
MNV shell domain expression constructs were generated by PCR amplifying WT and 
L1,7 SD cDNA from infectious clones into pTriEx 1.1 plasmid. Positive clones after 
ligation and transformation were sequence verified. 
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2.3 Reverse genetics 
DNA-based reverse genetics was reported previously (Chaudhry et al., 2007, Arias et 
al., 2012). Briefly, BSR-T7 cells were seeded the day before transfection to be more 
than 90% confluent on the day of transfection. Then cells were infected by fowlpox 
virus expressing T7 RNA polymerase (FPV-T7) at an MOI of 0.5-1 PFU per cell for 2 
hours at 37 ℃. 1 μg of plasmids containing MNV cDNA clones were mixed with 4 μ
l of Lipofectamine®2000 (ThermoFisher Scientific) in 200 μl OptiMEM (Gibco) for 15 
minutes at room temperature. After incubation, cells were washed once and replaced 
with 3 ml antibiotic-free media. Then transfection mix was added to the cells drop-wise. 
After 24-48 hours post transfection, cells were freeze-thawed at -80 ℃ and titrated by 
50% tissue culture infectious dose (TCID50). Total cellular protein was also harvested 
by lysing cells using radio immunoprecipitation assay (RIPA) buffer with 1 × protease 
inhibitors cocktail (Merck). 10 μ g total cellular protein or 5 μ l eluate from 
immunoprecipitation was analysed for SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis. 
2.4 Immunofluorescence microscopy 
For immunostaining of differentiated organoids, cells were seeded in 24-well trans-well 
plates (Corning), harvested by fixing with 4% paraformaldehyde (PFA) in PBS at room 
temperature for 15 minutes. Then cells were washed once with PBS, quenched using 
100 mM glycine at room temperature for 5 minutes and permeabilised with 0.2% Triton
™ X-100 in PBS at room temperature for 5 minutes. Cells were then blocked with 0.1% 
Tween 20 in PBS (PBST) containing 1% normal goat serum (Sigma-Aldrich), 1% 
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bovine serum albumin (BSA) at room temperature for 1 hour before primary antibody 
was added. After 1 hour incubation, cells were washed 3 times with PBST before 1 
hour incubation with secondary antibody. Following another 3 washes with PBST and 
once with 15mM Sodium Azide in PBS, trans-well membranes were carefully removed 
by a scalpel and mounted on coverslips with DAPI/MOWIOL. The apical sides of 
membrane should be in contact with coverslips. The coverslips were then mounted on 
glass slides and dried overnight at 4 ℃. Imaging of BMDM, Raw264.7 and BV-2 cells 
were performed similarly as of organoids, except that cells were seeded on coverslips 
instead of in trans-wells. All microscopy images were obtained using a Leica TCS SP5 
confocal microscopy at NIHR Cambridge BRC Cell Phenotyping Hub. 
2.5 Total RNA extraction 
Total RNA from cells or viruses was extracted following manufacturer’s instruction 
(GenElute Mammalian total RNA mini-prep kit, Sigma-Aldrich) and eluted in 50 μl 
MilliQ H2O. For RT-qPCR of Ifnb, total RNA was digested with DNaseI for 15 minutes, 
purified and eluted in 50 μl MilliQ H2O before RT. For faecal samples, stool pellets 
were weighted and resuspended in PBS to a final concentration of 100 mg faeces per 
ml PBS. After homogenisation and a 5-minute centrifugation using a table top 
centrifuge, 100 μl of supernatant was used for RNA extraction. Animal tissue samples 
were retrieved from -80 ℃ and thawed on ice, about 200 mg of tissues were added 
to 500 μl RNA lysis buffer with 500 μl silicon beads. Tissues were homogenised and 
250 μl lysate was used for RNA extraction. 
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2.6 Statistical analysis 
Unless indicated, all experiments were performed with at least three biological 
replicates, and representative experimental data was shown. Statistical analysis was 
performed using GraphPad Prism7.0.  
2.7 HuNoV-specific methods 
2.7.1 Purification of HuNoV 
HuNoV-positive faecal samples (about 1 g per sample) were resuspended in PBS at 
1:10 w:v. After vortex, the insolubles were centrifuged at 4000 RPM for 10 minutes at 
4 ℃. Polyethylene Glyco (PEG) 3000 and NaCl were then added to the supernatant 
at 10% w:v and 150mM, respectively. After overnight incubation at 4 ℃, precipitated 
HuNoV was centrifuged using a high-speed centrifuge at 15000 RPM for 10 minutes 
at 4 ℃. The pellet was resuspended using cold PBS and slowly overlaid onto 30% w:v 
sucrose cushion in PBS. The virus was then centrifuged using Beckman ultracentrifuge 
with SW55Ti rotor at 45 000 RPM for 18 hours at 4 ℃ . The pellet was then 
resuspended in PBS overnight at 4 ℃  with gentle swirling every a few hours. 
Insolubles were removed by centrifuge at maximum speed for 5 minutes at 4 ℃. The 
purified HuNoV was then aliquoted and stored at -80 ℃. 
HuNoV CDC4 and CDC14 were kindly provided by Stephanie Karst (University of 
Florida, Gainesville, USA). HuNoV A42DD was purified and provided by M. Hosmillo. 
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To generate concentrated virus stocks from reverse genetics, 48 hours post 
transfection BSR-T7 cells were freeze-thawed to release viruses. Cell debris was 
removed by centrifuging the lysates at 4 000 RPM for 5 minutes at 4 ℃ . The 
supernatant (about 30 ml in total for each virus) was then gently overlaid on top of 5 
ml 30% sucrose in PBS. Ultracentrifugation was performed at 25 000 RPM for 2 hours 
at 4 ℃. The supernatant was then removed and 200 μl PBS was added to each tube 
with gentle swirl overnight at 4 ℃. The insolubles were removed by centrifugation at 
maximal speed for 5 minutes at 4 ℃. The pellet was washed once more with 100 μl 
ice-cold PBS and the supernatant was combined with the first extraction. Together, 300 
μ l of 100×  concentrated virus was generated per construct. Viruses were then 
aliquoted and stored at -80 ℃ until use. 
2.7.2 Genotyping PCR for HuNoV 
The norovirus genotyping PCR was performed as published (Kojima et al., 2002). Total 
RNA was extracted from 1 aliquot of purified HuNoV sample using GenElute ™ 
mammalian total RNA miniprep kit and eluted in 50 μl RNase-free water. 2.5 μl RNA 
was used in a total volume of 25 μl reverse transcription (RT) reaction using M-MLV 
RT (Promega) following manufacturer’s instruction. The RT reaction was performed 
at 42 ℃ for 1 hour and stopped by 85 ℃ for 5 minutes. RT reactions without the 
reverse transcriptase were used as the negative controls. 
After the RT reaction, genotyping PCRs were set up using 5 μl of cDNA in a total 
volume of 50 μl reaction. G1SKF/G1SKR and G2SKF/G2SKR were used as the 
primers for PCR reactions of genogroups 1 and 2, respectively (Kojima et al., 2002). 
After PCR, samples were run on 2% agarose gel using TBE buffer. Samples with clear 
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PCR products at correct sizes were column purified and sequenced using 
corresponding PCR primers. The genotype was then assigned using the norovirus 
genotyping tool (http://www.rivm.nl/mpf/typingtool/norovirus/). 
2.7.3 HuNoV RT-qPCR 
The reverse transcription - real time quantitative PCR (RT-qPCR) of HuNoV was 
performed as previously published (Kageyama et al., 2003). Briefly, 2.5 μl RNA or 
1:10 serially-diluted in vitro-transcribed RNA standard was used in a total volume of 20 
μl RT reaction using M-MLV RT (Promega) following manufacturer’s instruction. The 
RT reaction was performed at 42 ℃ for 1 hour and stopped by 85 ℃ for 5 minutes. 
5 μl of 1:2 diluted cDNA was used in a 20 μl Real time PCR (qPCR) reaction in 
conjunction with 400 nM each primer, 100 nM Taqman probe and 1× PrecisionPLUS 
qPCR master mix (PrimerDesign). Thermal conditions for qPCR were as followed: 95 ℃ 
for 8 minutes, 50 cycles of 95 ℃ for 10 seconds and 60 ℃ for 1 minute. Signals were 
detected at the end of each 60 ℃ incubation. 
Relative qPCR was performed with 5 μl 1:2 diluted cDNA, 100 nM of each primer and 
1× SYBR Green I qPCR Core kit (Eurogentec). Thermal conditions were as followed: 
55 ℃ for 2 minutes, 95 ℃ for 10 minutes, 40 cycles of 95 ℃ for 15 seconds and 
60 ℃ for 1 minute. A melt curve analysis was performed immediately after PCR cycles. 
Gene expression was calculated using the ΔΔCt method (Rao et al., 2013). 
2.7.4 Lentivirus production and transduction 
The production of recombinant lentivirus encoding innate immune antagonists was 
performed following the second-generation lentivirus packaging protocol (Naldini et al., 
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1996). HEK293T cells were seeded at 5 × 106 cells per 10 cm dish in antibiotic-free 
media. The following plasmids were first mixed in 500 μl OptiMEM media: 6 μg of 
pxPAX2 packaging plasmid, 6 μg of lentiviral vector, 3 μg of pMD2.G VSV-G 
envelop plasmid. Then 45 μl of Lipofectamine®2000 in 500 μl OptiMEM was added 
and mixed. After a 10-minute incubation at room temperature, the transfection mix was 
added to 293T cells drop-wise. In addition to lentiviruses encoding BVDV NPro and 
PIV5 V, empty vector (MCS) and EGFP lentiviruses were also produced in parallel. At 
24 and 48 hours post transfection, supernatants were carefully harvested and replaced 
with 10 ml of warm media. Cell debris from the combined supernatant was removed 
by centrifugation at 4000 RPM for 5 minutes at 4 ℃. Then the supernatant was slowly 
overlaid on top of 5 ml of 30% sucrose in PBS. Lentivirus was centrifuged at 25 000 
RPM for 2 hours at 4 ℃ . The pellet was resuspended in 200 μ l PBS at 4 ℃ 
overnight. The insolubles were removed by centrifugation at maximal speed for 5 
minutes at 4 ℃. The pellet was washed once with 100 μl PBS and the supernatant 
was combined. The concentrated lentivirus was aliquoted and stored at -80 ℃. 
To titrate lentivirus, 1:5 serially diluted, unconcentrated (1×) and concentrated (100×) 
lentiviruses were added to 5 × 104 HEK293T cells and incubated at 37 ℃ for 3 days. 
Cells were then fixed and analysed by FACS analysis. The infectious unit (IU) was 
calculated as published (Kutner et al., 2009). 
For transduction of cell lines, adherent cells were seeded at 5 x 104 cells per well of 
24-well plate and infected with 5 μl of concentrated lentiviruses. Three days post 
transduction, the green fluorescence was confirmed in the LV-EGFP-transduced cells. 
Then the cell media was replaced by puromycin-containing media. After 3 passages of 
 64 
selection, no live cells were observed in the non-transduced well and selected, 
transduced cells were expanded used for experiments 
2.7.5 HuNoV infection of adherent cells 
For infection of adherent cells, 0.5-1 × 105 cells were seeded per well of 24-well plate. 
HuNoV were added to cells in a total volume of 250 - 300 μl. The cells were incubated 
at 37 ℃ for 1 hour. The cells were then washed twice and replaced with 500 μl 
complete media. At each time post infection, the cells were scraped off the plate and 
mixed by pipetting up and down. Then 100 μl of cell/media mixture was used for RNA 
extraction. HuNoV RNA was then determined by RT-qPCR. 
2.7.6 HuNoV infection of suspension cells 
The infection of suspension cells was adapted from previously published protocols 
(Jones et al., 2015, Jones et al., 2014). Briefly, in 100 μl of total volume, 1.3 × 105 
cells were incubated with 10 μ l of 1:10 diluted HuNoV at 37 ℃ for 2 hours. In 
experiments using binding factors (HBGA or enteric bacteria), HuNoV was pre-
incubated with stimulating factors at 37 ℃ for 1 hour before cells were added to the 
virus mix. After incubation, cells were centrifuged at 750 × g for 7.5 minutes and 
resuspended in 100 μl media. The cell suspension was then divided evenly and 
added to 48-well plates containing 950 μl media. At each time point, 500 μl cell 
suspension was used for RNA extraction by Trizol reagent (Invitrogen). 
2.7.7 Differentiation of LS174T cells 
The differentiation of LS174T dnTCF4 cells into goblet cell-like phenotype was 
previously published (van de Wetering et al., 2002). LS174T cells (wild type or dnTCF4) 
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were first selected with zlasticidin with or without zeocin for 1 week. Then cells were 
seeded at 5 × 105 cells/well for 6-well plate and 5 × 104 for 24-well plate. In addition 
to blasticidin and zeocin, doxycycline was added at 5 μg/ml for induction of dnTCF4. 
For cell growth analysis, cells were fixed on day 5 post differentiation and stained with 
toluidine blue. Total cellular RNA was extracted from samples of days 0, 1 and 5 post 
differentiation and gene expression was determined by RT-qPCR. Expression of 
MUC2 was normalised to housekeeping gene ACTB. For HuNoV infection, cells were 
infected on day 1 post differentiation and samples were harvested at the indicated time 
points. 
2.8 MNV-specific methods 
2.8.1 MNV RT-qPCR 
5 μ l eluted total RNA was used for RT reaction using MMLV-RT following 
manufacturer’s instruction. After RT, cDNA was diluted 1:2 using RNase-free H2O and 
5 μl diluted cDNA was used for qPCR as previously reported (Kitajima et al., 2010). 
Relative qPCR was performed as for human gene qPCR. 
2.8.2 TCID50 
Viral 50% tissue culture infectious dose (TCID50) was performed as published (Hwang 
et al., 2014). TCID50 by antigen were performed as follows: standard TCID50 assays 
were set up using Raw264.7 cells and were incubated at 37 ℃ for 5 days. Wells 
displaying cytopathic effect (CPE) were recorded and TCID50 by CPE were calculated. 
The tissue culture media was then carefully removed by multichannel pipette and 
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remaining cells were washed once with PBS, fixed using 4% PFA, quenched using 100 
mM Glycine (pH3) and permeabilised with 0.2% Triton X-100. Cells were then blocked 
with blocking buffer for 1 hour before primary antibody (rabbit anti-NS3 1:1000 diluted 
in blocking buffer) was added. Cells were washed 3 times with 0.1% PBST after 1 hour 
incubation, before another 1 hour incubation with secondary antibody (Alexa Fluor 568 
goat anti rabbit, ThermoFisher). 3 washes with 0.1% PBST were performed before 
keeping cells in 15mM sodium azide for visualisation. Wells with cells only and 
processed the same way as wells containing diluted viruses were first visualised under 
fluorescent microscope for evaluation of background staining. Then the wells with 
positive staining were recorded and the TCID50 by antigen was calculated the same 
way as TCID50 by CPE. 
2.8.3 Virus stock generation 
10 ml of virus from recovery was added to one T150 BV-2 cells and incubated at 37 ℃ 
for 1 hour. After infection, the inoculum was replaced with fresh media and cells were 
maintained at 37 ℃ until CPE was observed. Progeny viruses were released by 
freeze-thawing lysates and cell debris was removed by centrifugation at 4000 RPM for 
10 minutes at 4 ℃. Virus was passed through 0.2 μm filter and aliquoted. Titres of 
virus stocks were determined by TCID50. 
2.8.4 Viral growth kinetics analysis 
For growth kinetics analysis, BV-2 cells were infected by MNV-1 or MNV-3 at an MOI 
of 0.05 or 5 TCID50 per cell at 37 ℃ for 1 hour. The end of incubation was determined 
as 0 hour post infection (hpi). Then cells were washed twice with warm tissue culture 
media, resuspended to 5 x 105 cells/ml and plated in 96-well plates for titration and in 
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24-well plates for RNA extraction. At each time point, titration plates were frozen at -
80 ℃ to release viruses from cells, tissue culture media was removed from RNA 
plates and the total cellular RNA was extracted. 
2.8.5 Ethics 
Tonsil tissue was donated anonymously with consent. All HuNoV stool samples were 
obtained as leftover from diagnosis. 
Studies with mice were performed in the Department of Pathology Biological Support 
Unit (PCD 80/2802) after ethical review by the University of Cambridge Review Panel 
and subsequent approval by the UK Home Office (PPL70/7689). All animal procedures 
and care conformed strictly to the UK Home Office Guidelines under The Animals 
(Scientific Procedures) Act 1986. 
2.8.6 Animal experiment 
A breeding colony of mice containing heterozygous eIF4E S209A mutation (KI) was 
provided by Christos Gkogkas (University of Edinburgh). Sex and age-matched 
littermate were used for infections. Before challenge, tail blood was sampled and the 
body weight of each animal was recorded. 1000 TCID50 (low dose) or 100 000 TCID50 
(high dose) was inoculated peroral per mouse. Body weight changes were recorded 
and faecal samples were collected on the days indicated in each figure. At the end of 
experiment, mice were sacrificed and the organs were preserved in RNAlater solution 
at -80 ℃ until use. 
For primary challenge, 5-week old C57BL6/J mice were allocated 5 mice per group 
and inoculated peroral with 2.4 x 104 TCID50 by antigen (equivalent to 10000 TCID50 
determined by CPE) of MNV-3 viruses in a total volume of 100 μl. On the days 
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indicated faecal samples were directly collected from each mouse. In order to measure 
production of MNV-specific serum IgG, peripheral blood samples were collected by tail 
bleeding. Serum samples were obtained by spinning down the blood samples at 
maximal speed for 5 minutes using a table top centrifuge. Re-challenge experiment 
was performed by inoculating mice with 1000 TCID50 MNV-3. Faecal and serum 
samples were collected as above. 
2.8.7 eIF4E genotyping PCR 
The eIF4E genotyping PCR was reported previously (Furic et al., 2010). Ear biopsies 
were obtained from 2 to 4 week-old pups. 50 μl of solution 1 (25 mM NaOH, 0.2 mM 
EDTA) were added to the biopsies and boiled at 99 ℃ for 20 minutes. The reaction 
was neutralised by adding 50 μl of solution 2 (40 mM Tris-HCl), then vortex for 15 
seconds. 2 μl of the supernatant DNA was used for a genotyping PCR of 25 μl in 
volume, consisting of 1× Taq buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 1 μM of each 
primer, and 1.25 U Taq polymerase (Invitrogen). The thermal cycling conditions are as 
followed: 1) 94 ℃ for 4 minutes. 2) 35 cycles of 94 ℃ for 45 seconds, 58 ℃ for 45 
seconds, and 72 ℃ for 1 minute and 15 seconds. 3) 72 ℃ for 4 minutes. 5 μl of the 
PCR product was resolved on 2% agarose gel using TBE buffer. The PCR product 
from the ear biopsies of the first heterozygous breeding cage were used as the 
genotype markers. 
2.8.8 Primary BMDM differentiation 
Differentiation of BMDMs from primary bone marrow cells was reported previously 
(Trouplin et al., 2013). Briefly, mice were sacrificed using a schedule 1 method, and 
the femur bones were isolated from both thighs. The bones were kept in macrophage 
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complete media DMEM on ice during transport. The remaining tissues associated with 
the bones were removed using clean tissue paper. The bones were then washed once 
with 1× PBS, sterilised with 70% ethanol, and washed once more with 1× PBS. 
Scalpels were then used to cut open the bones and cells were flushed out with cold 
DMEM. Cells were passed through 40 μm cell strainer and centrifuged at 500 × g 
for 5 minutes at 4 ℃. Cells were then seeded at 0.5 - 1 × 107 cells per 150 mm 
untreated dishes, in BMDM differentiation media (macrophage complete media with 
10% CMG-14 conditioned media). Cell culture media was replaced every other day 
and cells were used on day 7 post differentiation. 
2.8.9 Purification of MNV 
10 T150 flasks of BV-2 cells were infected by MNV at MOI = 0.01 TCID50/cell until CPE 
was observed. Cells were freeze-thawed and cell debris was removed by 
centrifugation at 4000 RPM for 10 minutes at 4 ℃. Supernatant was then overlaid on 
5 ml of 30% sucrose in PBS and centrifuged using a ST32Ti rotor at 25 000 RPM for 
2 hours at 4 ℃. Pellets were resuspended in PBS and stored at -80 ℃. The titres of 
concentrated virus stocks were determined by thawing one aliquot of each virus and 
titrated by TCID50. 
2.8.10 Cell stimulation 
BMDM or Raw264.7 cells were seeded at 1 × 105 cells/well of 48-well plates and 
were transfected with different amounts of poly (I:C) using FuGENE® HD following 
manufacturer’s recommendation. IFN-β was pre-mixed with cell culture media and 
replaced the seeding media. At 12 hours post transfection, cell media was removed 
and total RNA was extracted. RNA was then digested with DNaseI and purified. 
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Relative gene expressions were determined by RT-qPCR and calculated by the ΔΔ
Ct method (Rao et al., 2013). 
2.8.11 ELISA 
ELISA for detecting MNV-specific serum IgG in peripheral blood from mouse was 
reported previously (Hwang et al., 2014, Wobus et al., 2004). Briefly, MNV3 VLP, kindly 
provided by Stephanie Karst (University of Florida, Gainsville, USA) was diluted 1:100 
using carbonate buffer at pH 9.6 and 50 μl VLP was used per well to coat the Nunc 
MaxiSorp™ 96-well plate overnight at 4 ℃. Serum collected from mice were used at 
1:100 dilution in 50 μl total volume. The reactions were developed by adding 100 μ
l 1-Step™ Turbo TMB-ELISA Substrate Solution (Life Technologies) or 50 μl 1× TMB 
solution (eBioscience) and stopped by adding equal volume of 1N sulphuric acid 
solution. The absorbance at 450nm were read and normalised absorbance were 
calculated by subtracting the mean absorbance of wells without primary antibody. The 
cutoff of positive results was determined as the mean + 3 × standard deviation of 
mock serum absorbance. 
2.8.12 Thermal inactivation assay 
MNV virus stocks were diluted 1:10 in PBS and kept on ice until the beginning of 
incubation. 100 μ l diluted virus was added to 96-well PCR plate (Axygen) and 
incubated at 60 ℃ for 3 minutes before keeping on ice immediately. Then 25 μl 
enzyme mix with or without RNaseA (final concentration 1 mg/ml) diluted in PBS was 
added to each well. The reaction mix was then incubated at 37 ℃ for 15 minutes 
before keeping on ice again. 25 μl reaction mix was used for TCID50 and the rest was 
used for RNA extraction. For control of RNaseA digestion, 108 genome equivalent (gEq) 
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of in vitro transcribed MNV3 RNA was diluted with PBS and processed the same way 
as other viruses. The unprocessed samples maintained on ice were used as the initial 
titres or vRNA. For each virus and each treatment, the experiment was repeated 3 
times and one-way ANOVA was used for statistical analysis. 
2.8.13 Immunoprecipitation assay 
The immunoprecipitation protocol was published previously (Emmott and Goodfellow, 
2014). Briefly, 293T cells were co-transfected with pEGFP-RdRp and pCDNA3-RL-
VP1 plasmids. Cells were harvested at 24 hours post transfection and lysed with GFP 
lysis buffer. After lysis on ice for 30 minutes, total lysates were centrifuged at maximal 
speed for 10 minutes at 4 ℃, and the protein concentration of the total soluble fraction 
was measured by BCA assay (Pierce). The input was then normalised using GFP 
dilution buffer. The anti-GFP agarose was prepared by washing 25 μl agarose per 
reaction 3 times with 1 ml GFP dilution buffer. Then the anti-GFP agarose was mixed 
with roughly 1:5-diluted total cell lysate at 4 ℃ rotating overnight. After binding, the 
agarose was centrifuged at 2500 x g for 5 minutes at 4 ℃ and the unbound fraction 
was carefully removed. The agarose was further washed 3 times with GFP dilution 
buffer before elution with 50 μl 2X loading buffer by heating at 95 ℃ for 5 minutes. 
10 μl input and 5 μl eluate were analysed on 12.5% polyacrylamide gel for SDS-
PAGE and western blot analysis. 
2.8.14 RNA synthesis analysis 
RdRp assays were performed as previously described (Yunus et al., 2015, Lin et al., 
2015) with minor modifications. All RNAs used in this study were chemically 
synthesized (Thermo Scientific). The MNV proscript was designed based on MNV 
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CW1 isolate (DQ285629) nucleotides 5012 to 5059. The RNA contains three non-viral 
nucleotides (GCG) at their 5′ termini to allow the incorporation of radiolabelled [α-
32P]CTP during RNA synthesis in vitro. The RNA synthesis reactions were of 20 μl 
containing 20 mM sodium glutamate (pH 8.2), 12.5 mM dithiothreitol (DTT), 4 mM 
MgCl2, 1 mM MnCl2, 0.5% Triton X-100 (v/v), 0.05 mM GTP, 0.05 mM ATP and 0.01 
mM UTP, 33.3 nM [α-32P]CTP (MP Biomedicals), 50 nM of template RNA and 250 nM 
of recombinant RdRp. The reactions were incubated at 30 ℃ for 2 hours, and then 
stopped by the addition of EDTA (pH 8.0) to a final concentration of 10 mM. RNA 
products were directly analysed with a 24% polyacrylamide gel containing 7.5 M urea.  
The radiolabelled RNA products were visualized and quantified by using a 
PhosphoImager (Typhoon 9210; Amersham Biosciences) and ImageQuant software. 
Statistical analysis was performed using excel t-test. 
2.8.15 Bioinformatic analysis 
Protein sequence comparison between GII.4 HuNoV and MNV VP1 was performed by 
searching the BLAST server for full length VP1 sequence using the reference 
sequences of GII.4 HuNoV VP1 (GenBank accession number ABG49509.1) and MNV 
VP1 (GenBank accession number ABB90154.1)(Johnson et al., 2008). For HuNoV and 
MNV, the organisms were restricted to norovirus GII.4 (taxid:489821) and norovirus 
GV (taxid:1246677), respectively. Default parameters were used except that the 
entries length searched were restricted to between 500 to 600 residues, and maximal 
target sequences were limited to 1000. Sequences were aligned using ClustalOmega 
and redundant sequences were removed using the CD-HIT server (Sievers et al., 2011, 
Fu et al., 2012). Conservations were represented by the WebLogo server (Crooks et 
al., 2004). 
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2.8.16 LUMIER 
LUMIER analysis was performed as previously described (Vashist et al., 2015). Briefly, 
293T cells were seeded in 96-well plates. 80-90% confluent cells were transfected with 
60ng of each of pcDNA3-GW-RL and pT-Rex-Dest30-PA plasmids with 0.3 μ l 
Lipofectamine®2000 and 30 μ l OptiMEM (LifeTechnologies). Experiments were 
performed in quadruplicate. Plasmids encoding c-jun and fos were used as positive 
control. Co-transfection of pcDNA3-GW-RL with pT-Rex-Dest30-PA empty vector was 
used as negative control, which was performed in octuplicate. Cells were harvested at 
24 hours post transfection with lysis buffer (PBS with 1% Triton X-100, 0.1% BSA, 1× 
Halt protease and phosphatase inhibitors cocktail (Novagen), 1mM DTT and 1:100 
benzonase). Soluble cell lysates were bound with sheep anti-rabbit IgG-coated 
magnetic beads (Invitrogen, Dynabeads M280) and luciferase reading of 10% total 
lysate was used as the expression control.  
2.8.17 Expression and purification of MNV SD 
SD expression plasmids were transformed into Rosetta™ 2 competent cells and grown 
in 500 ml LB media with ampicillin and chloramphenicol at 37 ℃ until OD600 reached 
between 0.5 and 0.6. SD expression was induced by 1mM IPTG at 37 ℃ for 24 hours. 
Cells were lysed by sonication in 0.5 mg/ml lysozyme with resuspension buffer (50 mM 
Tris-HCl pH8.0, 150 mM NaCl, 0.1 mM EDTA). Soluble proteins were purified by 
centrifugation at 20 000 × g for 15 minutes at 4 ℃ and passed through 0.45 μm 
filter. 1 ml 50% Ni-NTA resin was equilibrated with 10 column volume (CV) of 
resuspension buffer before soluble proteins were loaded. Bound resin was then 
washed sequentially with 10 CV of resuspension buffer with: 1) no imidazole, 2) 5 mM 
Imidazole, 3) 10 mM Imidazole, and 4) 40 mM Imidazole. Bound protein was eluted 
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with resuspension buffer containing 200 mM Imidazole in 1 ml aliquots. Eluates were 
analysed by SDS-PAGE and stained with commassie blue. Fractions with protein size 
matching theoretical molecular weight of SD (25 kDa) were pooled and dialysed 
overnight at 4 ℃  twice in 1 L resuspension buffer with 5% glycerol. Protein 
concentrations were determined by OD280 and flash frozen in liquid nitrogen at -80 ℃ 
until use. 
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Chapter 3 
Establishment of a cell culture 
system for HuNoV 
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3.1 Background 
The understanding of HuNoV biology has been hampered by the inability to cultivate 
HuNoV in cell culture. Many previous attempts, using different combinations of viruses, 
cell lines and additives (reviewed in (Duizer et al., 2004)) indicate that some 
fundamental requirements essential for virus replication are absent in most 
immortalised cells. 
There are numerous factors that could contribute to the lack of norovirus replication in 
vitro. First, a cell culture-permissive virus strain is needed, like the development of 
hepatitis C cell culture system by isolating the JFH-1 strain (Wakita, 2009). Therefore, 
to maximise the sequence diversity for screening, HuNoVs isolated from both acute 
and chronic patients should be tested. 
One inevitable drawback of using stool-purified HuNoV is biocontamination. In 
comparison, reverse genetics facilitate recovery of genetically defined HuNoV free of 
faecal contaminants. Several reverse genetics systems of HuNoV have been 
published to date, but due to the inability to culture HuNoV, indirect methods were used 
to validate the efficacy (Asanaka et al., 2005, Guix et al., 2007, Katayama et al., 2014). 
The development of reverse genetics systems for two MNV strains (MNV-1 and MNV-
3) raised the potential by adopting a similar rationale (Ward et al., 2007, Chaudhry et 
al., 2007, Yunus et al., 2010). The transcription driven by a vaccinia virus expressing 
T7 RNA polymerase (MVA-T7) inhibits MNV replication, yet T7 RNA polymerase 
expressed by a similar fowlpox virus (FPV-T7) enables the recovery of infectious MNV 
(Chaudhry et al., 2007). 
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The possible lack of a functional receptor also contributes to the inability of HuNoV to 
establish infection in various cell lines. The identification of attachment factors and a 
proteinaceous receptor for MNV suggest a possible multi-step entry process of 
norovirus (Taube et al., 2012, Perry and Wobus, 2010, Taube et al., 2009, Perry et al., 
2009, Orchard et al., 2016, Haga et al., 2016). Norwalk virus VLP can be internalised 
into Caco-2 cells (White et al., 1996), and a 105 kDa membrane protein was proposed 
to be the proteinaceous receptor (Tamura et al., 2000). However, apart from this it is 
generally recognised that HBGA is the cellular receptor for HuNoV, mainly due to the 
correlation between the secretor status and the resistance to HuNoV infection 
(Ruvoen-Clouet et al., 2013, Han et al., 2015, Tan and Jiang, 2014, Tan and Jiang, 
2011, Tan and Jiang, 2008, Tian et al., 2007, Tan and Jiang, 2005a, Tan et al., 2004). 
It is possible that whilst HBGA is important as an attachment factor for HuNoV, a 
proteinaceous receptor required for viral entry is missing in most cell lines. 
Moreover, the limited HuNoV replication in cells indicates the possible presence of 
intracellular restriction factors, or the possible absence of essential cellular factors. 
Norwalk virus RNA replicon replicates in Huh7 cells, and the viral genome replication 
is sensitive to type I IFNs (Chang and George, 2007, Chang et al., 2006). However, 
the establishment of infection is relatively inefficient and antibiotic selection is required 
to maintain the viral genome (I. Goodfellow, personal communication). Purified HuNoV 
genomic RNA can be transfected into cells, but the replication is only observable with 
abundant input RNAs (Asanaka et al., 2005, Guix et al., 2007, Qu et al., 2016). 
Together, these results indicate the replication of HuNoV in cells is inefficient and the 
cellular or viral factors required for replication may be missing. 
Two important papers were published during the development of this project. The first 
one is a B cell culture system (Jones et al., 2014). In this paper, Jones et al. showed 
that both MNV and HuNoV can infect B cells. However, instead of a purified virus, 
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unfiltered stool samples were required for productive infections (about 30-fold increase 
of viral RNA over five days). In addition to the increase of viral RNA, the expression of 
non-structural protein was observed, and a subsequent passage of infected cell lysate 
resulted in productive infection. Of the purified virus, pre-incubation with the enteric 
bacteria Enterobacter cloacae (E. cloacae) or soluble H antigen rescued the negative 
impact of sample purification on replication, suggesting a proviral role of enteric 
bacteria or HBGA to promote replication. Supporting this idea, certain enteric bacteria, 
including E. cloacae, express HBGA-like molecules on the cell surface (Miura et al., 
2013). Clinically, B cell deficient patients display less HuNoV faecal shedding, 
indicating a proviral role of B cells in a natural HuNoV infection (Brown et al., 2016). 
Together, this is the first direct evidence of a professional antigen presenting cell line 
permissive for HuNoV infection. 
In 2016, Ettayabi et al. established a primary ex vivo cell culture system for HuNoV 
(Ettayebi et al., 2016). This system, called human intestinal organoids (or enteroids), 
utilises the Lgr5+ stem cells derived from intestinal crypts of endoscopic biopsy 
samples to mimic the in vivo propagation and differentiation of intestinal epithelial cells 
(Sato et al., 2011). Intestinal organoids can be maintained continuously as three-
dimensional culture, and the differentiation can be achieved by modifying the culture 
conditions. The differentiation of intestinal organoids produces the following cell types: 
enterocytes, goblet cells, Paneth cells and enteroendocrine cells (Sato et al., 2011). 
The inoculation of HuNoV to differentiated intestinal organoids (duodenum, jejunum 
and ileum) resulted in robust HuNoV replication (1.5 to 2.5 log10 increase in viral RNA 
over four days) (Ettayebi et al., 2016). Different HuNoV strains were also tested and 
certain strains require bile for productive infection. Importantly, in this model 
enterocytes were found to be permissive for HuNoV. Compared with the B cell system, 
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HuNoV infection in primary intestinal organoids appear to be more robust. In addition 
to HuNoV, human rotavirus can infect intestinal organoids (Saxena et al., 2015). 
Both culture systems were established in our laboratory along with the screening of 
other cells for HuNoV replication. Attempts were made to validate the previous 
observation and to improve these methods if possible. 
3.2 Aims 
The aim of this chapter was to establish an in vitro culture system for HuNoV, using 
the following rationale: 
1. Previous attempt did not utilise sufficient sequence coverage. Therefore, 
HuNoVs from faecal samples of acute and persistent infections were both be 
tested for infection to increase the possibility of isolating a replication-competent 
HuNoV. If replication was observed, the according isolate was characterised. 
2. Intestinal epithelial cells and immune cells were tested for infection. 
3. To promote HuNoV replication, recombinant lentiviruses encoding innate 
immune antagonists was used to prevent innate immune activation during 
infection. 
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Figure 3.1 General procedure overview. A) HuNoV-positive stool samples were resuspended in PBS, 
HuNoV was precipitated by polyethylene glycol (PEG) and concentrated by ultracentrifugation. The 
samples from acute and persistent infections were combined separately as the acute and persistent 
pool, accordingly. B) Recombinant lentiviruses encoding empty vector (MCS) or BVDV NPro were 
generated and purified. Cell lines were transduced and positive cells were selected with puromycin. C) 
HuNoV was inoculated to lentivirus-transduced cells. The cells were then washed and incubated at 
37 ℃. At different time points post infection the cells were harvested in RNA lysis buffer. D) The total 
RNA was extracted from each sample and RT-qPCR was used to determine total HuNoV RNA in each 
sample. 
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3.3 Results 
3.3.1 Purification of HuNoV from faecal samples 
The primary source of HuNoV is clinical stool samples. To establish virus stocks for 
screening, 10 norovirus-positive faecal samples from acute infections and 6 from 
persistent infections were purified by PEG precipitation and ultracentrifugation. The 
genotype of each isolate was determined by RT-PCR of the ORF1/ORF2 junction and 
the genotypes were assigned using the norovirus typing tool 
(http://www.rivm.nl/mpf/typingtool/norovirus/), summarised in Table 3.1. Semi-purified 
viruses from patient samples of acute or persistent infections were then combined into 
two pools. The HuNoVs provided by others are: a42dd (M. Hosmillo), CDC4 and 
CDC14 (Stephanie Karst, University of Florida). 
Sample 
Name Acute/Persistent Genotype 
Titre 
(gEq/μl) 
Virus 
name 
11 Acute GII.4 Sydney_2012 2.61×107 
Apool 
12 Acute GII.4 Sydney_2012 6.46×107 
13 Acute GII.4 Sydney_2012 1.05×107 
14 Acute GII.4 Sydney_2012 5.19×108 
15 Acute 
GII.4 
New_Orleans_2009 1.63×104 
16 Acute GII.4 5.75×104 
17 Acute GII.4 Sydney_2012 3.34×106 
18 Acute GII.4 Sydney_2012 5.71×108 
19 Acute GII.4 Sydney_2012 2.81×108 
20 Acute GII.4 Sydney_2012 1.38×106 
AD17/04/13 Persistent GII.21 2.16×107 
Ppool 
DF19/04/13 Persistent GII.4 1.40×104 
RT18/04/13 Persistent GII.4 1.77×104 
RT03/05/13 Persistent GII.4 3.00×103 
MD01/05/13 Persistent GII.3 9.00×105 
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MD27/06/13 Persistent GII.3 1.19×104 
AD17/04/13 Persistent GII.21 3.28×107 GII.21 
01-15-0359 Persistent GII.1 3.24×107 GII.1 
a42dd Acute GII.4 ND a42dd 
CDC4 Acute GII.4 ND CDC4 
CDC14 Acute GII.4 ND CDC14 
 
Table 3.1 Genotypes of HuNoV samples 
3.3.2 Ribonuclease sensitivity of purified HuNoV 
After the acute and the persistent pools were produced, the viral RNA was determined. 
As shown in Figure 3.2A, the viral RNA of the acute pool is about ~1000 fold higher 
than that of the persistent pool with GII.4-Sydney 2012 being the dominant genotype. 
Purified HuNoVs were also diluted 1:10 and extracted, and the detection of similar viral 
RNA after extrapolation indicates minimal interference of HuNoV quantification by 
potential PCR inhibitors co-purified from the faecal samples. 
In order to assess the capsid integrity of the purified HuNoV pools, the sensitivity of 
the viral RNA to RNase was tested. This was used as a surrogate indicator based on 
the hypothesis that encapsidated RNA is resistant to ribonuclease (Arthur and Gibson, 
2015). Acute pool HuNoV was incubated with RNase A at 37 ℃ for various time 
(Figure 3.2B). Over 5 days little reduction of viral RNA was observed, indicating purified 
HuNoV RNA is protected from ribonuclease degradation. In contrast, three-hour 
incubation of in vitro transcribed MNV RNA with RNase A reduced vRNA to the limit of 
detection, indicating the efficient degradation of unprotected RNA. 
3.3.3 Recovery of infectious HuNoV by reverse genetics 
In addition to purification of HuNoV from faecal samples, previously developed DNA-
based reverse genetics for MNV was applied to recover contaminant-free HuNoV. Two 
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HuNoV cDNAs were cloned into a vector containing 5’ T7 promoter and 3’ ribozyme, 
allowing similar transcription and processing of mRNAs as the MNV reverse genetic 
system. BSR-T7 cells were infected with FPV-T7, followed by transfection of the GII.4 
or GII.6 HuNoV cDNAs. Progeny viruses were released from cell lysates by freeze-
thawing and concentrated by ultracentrifugation. As negative controls, HuNoV cDNAs 
with deleterious frame-shift (F/S) mutations in the RdRp were included. The synthesis 
of viral proteins was predominantly mediated by a FPV-T7 transcribing cDNA, therefore 
not affected by the mutations. However, the virus genome replications are abolished 
in the F/S mutants because of the truncated RdRps. The mature and precursor forms 
of HuNoV VPg were observed in all lanes except for the mock, indicating the successful 
translation of viral non-structural proteins (Figure 3.2C top panel). After ribonuclease 
digestion of cell lysates from recovery, viral RNA of infectious and non-infectious clones 
was compared. HuNoV RNAs from infectious clones were significantly more abundant 
than those of F/S, indicating infectious HuNoV cDNAs produce more nuclease-
resistant HuNoV RNAs (Figure 3.2C bottom panel). Because BSR-T7 cells are not 
permissive for HuNoV infection, FPV-mediated reverse genetics results in a single 
round of replication. 
The viral protein synthesis in the transfected cells was also compared between two 
reverse genetics systems (Figure 3.2D). FPV-T7-based reverse genetics generated 
significantly more VPg mature and precursor forms than EF-1α-driven recovery did, 
suggesting that FPV-T7 may be better for recovering infectious HuNoV. 
Together, the FPV-based reverse genetics appear to have generated encapsidated 
HuNoV RNA. However, as there was no direct evidence of infectivity of these viruses, 
HuNoV purified from faecal samples were used primarily to evaluate cell line 
permissiveness for HuNoV. 
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Figure 3.2 Recovery of HuNoV. A) Viral RNA of pooled HuNoV stocks. Individual HuNoV isolates were 
purified and combined into two pools. The viral RNA of each pool was measured by RT-qPCR. Purified 
HuNoVs were also diluted 1:10 and processed similarly to determine if PCR inhibitor was present in 
virus stocks B) Nuclease-sensitivity of purified HuNoV. HuNoV was treated with RNase A to examine 
RNase-protected HuNoV RNA. MNV RNA was used to evaluate the efficacy of RNase treatment. C) 
Recovery of HuNoV from BSR-T7 cells by DNA-based reverse genetics. HuNoV cDNA clones were 
transfected into FPV-T7-infected BSR-T7 cells. The expression of VPg indicate similar transfection 
efficiency and GAPDH was used as the loading control. * indicates the presence of mature and precursor 
forms of VPg. For nuclease treatment (bottom panel), viruses were released by freeze-thawing the cell 
lysates. After nuclease treatment and purification, RT-qPCR was used to determine the viral RNA of 
viable and non-viable (F/S) viruses. Statistical analysis was performed using one-way ANOVA and 
Dunnett test (*, p<0.05, **, p<0.01, ***, p<0.001) D) Comparison of helper virus-based (FPV-T7) and 
plasmid-based (EF-1α ) reverse genetics (Katayama et al., 2014). HuNoV cDNA clones were 
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transfected into BSR-T7 cells and the expression of VPg was used as the indication of translation. * 
indicates the presence of VPg-containing precursors. GAPDH was used as the loading control. ProM is 
the protease mutant of the GII.3 U201F. 
3.3.4 Antagonism of cellular innate immune responses 
Because norovirus replication is sensitive to type I IFN responses (Chang and George, 
2007), it is possible that the contaminants co-purified with HuNoV may activate the 
candidate cell lines and restrict replication. Accordingly, it was proposed that inhibiting 
type I IFN responses may promote HuNoV replication. Two innate immune antagonists 
were selected. The N-terminal protease fragment of bovine viral diarrhoea virus (BVDV 
NPro) degrades IRF-3 (Hilton et al., 2006). Our work showed that BVDV NPro 
enhances porcine sapovirus replication in vitro by inhibiting IRF-3-dependent type I 
IFN signalling (Hosmillo et al., 2015). The accessory V protein of parainfluenza virus 5 
(PIV5 V) inhibits both the sensing and the signalling pathways of type I IFN. PIV5 V 
binds to MDA-5 preventing the activation of IFNβ  promoter (Childs et al., 2007, 
Andrejeva et al., 2004). In addition, type I IFN signalling pathways are targeted via the 
degradation of STAT1 (Gitlin et al., 2010). Therefore, the stable expression of these 
proteins using lentiviral expression systems may potentially promote HuNoV 
replication by preventing the type I IFN responses. 
Recombinant lentiviruses encoding BVDV NPro or PIV5 V were produced using a 
second-generation lentivirus packaging system (psPAX2 + pMD2.G (Zufferey et al., 
1997)). Lentiviruses were indirectly titrated by producing and titrating a lentivirus 
encoding EGFP in parallel. The EGFP lentivirus was also used to determine the 
transduction efficiency. 
Two representative cell lines were chosen to demonstrate the transduction and 
validation procedures. First of all, both Caco-2 and BJAB cells were efficiently 
transduced to express EGFP (Figure 3.3A and B, left panels). After selection with 
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puromycin, the expressions of BVDV NPro and PIV5 V were functionally validated by 
examining the levels of endogenous IRF-3 and STAT1. BVDV NPro expression 
significantly reduced IRF-3 levels in both Caco-2 and BJAB cells (Figure 3.3A and B, 
right panels), whilst PIV5 V expression in BJAB cells abolished STAT1 expression. The 
reduction was not due to the lentivirus transduction, as a lentivirus encoding empty 
vector (MCS) showed no impact on the endogenous IRF-3 and STAT1 levels. 
Successfully transduced cell lines were then tested for HuNoV replication. 
 
Figure 3.3 Lentiviral transduction of cell lines. A) Caco-2 cells were transduced with concentrated 
lentiviruses produced from 293T cells, containing either empty vector (MCS), EGFP, or BVDV NPro. 
Microscopy pictures were taken 3 days post transduction. The right panel showed functional validation 
of lentivirus encoding BVDV NPro, which degrades IRF-3. B) The same batch of lentiviruses from panel 
A was used to transduce BJAB cells, and the left panel showed transduction efficiency of the lentivirus 
encoding EGFP. The right panel showed functional validation of lentiviruses encoding BVDV NPro and 
PIV5 V, which degrade IRF-3 and STAT1, respectively. 
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3.3.5 HuNoV infection in intestinal epithelial cells 
Based on the hypothesis that HuNoV likely infects intestinal epithelial cells or immune 
cells, first of all, several intestinal epithelial cell lines were selected and tested. 
Enterocytes and goblet cells are the most prevalent cell types of intestinal epithelia, 
constituting more than 80% and 4% of the total population, respectively (van der Flier 
and Clevers, 2009). Therefore, it was logical to determine if HuNoV can infect these 
cell types. 
Enterocyte-like cell line Caco-2 has been tested extensively previously with no success 
(Duizer et al., 2004). However, a low level of HuNoV replication was observed when 
VPg-linked HuNoV RNA was transfected into Caco-2 cells (Guix et al., 2007). 
To determine if the restricted HuNoV replication can be improved by suppressing 
innate immune sensing, Caco-2/BVDV NPro cells were inoculated with both the acute 
and the persistent pools HuNoVs and viral RNA was monitored over the course of 4 
days. However, no significant increase was observed in either cells infected by either 
virus (Figure 3.4A). 
To determine if goblet cells are susceptible to HuNoV infections, intestinal epithelial 
cell line LS174T expressing a dominant negative TCF4 (dnTCF4) was utilised. TCF4 
is involved in intestinal epithelial cell differentiation, and the expression of dnTCF4 in 
LS174 cells results in a goblet cell-like phenotype characterised by the elevated 
expression of MUC2 (van de Wetering et al., 2002). 
The expression of dnTCF4 in LS174T cells was induced by doxycycline resulting in 
cell cycle arrest. In a growth assay (Figure 3.4B, left panel), differentiated LS174T 
dnTCF4 showed less cell replication compared with LS174T WT or uninduced (-Dox) 
cells. The differentiation of LS174T dnTCF4 was also characterised by the increased 
expression of MUC2 (Figure 3.4B, right panel). It appeared that MUC2 was induced 
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24 hours post induction. Together, LS174T dnTCF4 can be differentiated, paralleled by 
the expression of goblet cell signature gene MUC2. 
The infection of HuNoV in goblet cells was then tested. The differentiation of LS174T 
did not result in increased viral binding at the beginning of infection, nor was an 
increase of HuNoV RNA observed over 5 days (Figure 3.4C). Therefore, under these 
experimental conditions, goblet cells are not permissive for HuNoV infection. 
Transformation of cell lines often results in modified gene expression, possibly 
including the host factors important for HuNoV replication. HuNoV binds to a related 
primary human intestinal epithelial crypt (HIEC) cells (HIEC-6) in a PCR-based 
neutralisation assay (Fan et al., 2015). Also, HIEC-6 was previously tested for HuNoV 
replication with only a low level of viral genome replication (less than 100 fold) 
observed (Leung et al., 2010). 
To test if HIEC cells can be infected by HuNoV and whether the inhibition of type I IFN 
responses can enhance this low-level replication, transduced HIEC cells were infected 
with the acute pool HuNoV (Figure 3.4D). The preliminary results showed significant 
variations. However, compared with viral RNA at 3hpi, there was no significant increase 
of HuNoV RNA at 48hpi. Together, HuNoV infection of primary or continuous intestinal 
epithelial cell lines showed no evidence of robust replication. 
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Figure 3.4 Infection of intestinal epithelial cells. A) Infection of Caco-2 cells by HuNoV. The acute 
and the persistent pool HuNoVs were inoculated to transduced, undifferentiated Caco-2 cells, and 
HuNoV RNA at indicated time points was determined by RT-qPCR. B) Differentiation of LS174T cells 
into goblet-cell like phenotype. WT LS174T or LS174T dnTCF4 were treated with or without doxycycline, 
and the picture on the left panel showed the growth of cells on day 5 post treatment. On the right panel 
showed the induction of goblet cell marker MUC2 in LS174T cells following doxycline induction. The fold 
induction was calculated by ΔΔCt method. C) Infection of LS174T cells by HuNoV.  1 day post 
doxycycline treatment the cells were infected by acute pool HuNoV. Viral RNA was determined by RT-
qPCR. D) Infection of primary human intestinal epithelial crypt (HIEC) cells by HuNoV. The acute pool 
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HuNoV was inoculated to transduced HIEC cells, and at different time points the HuNoV RNA was 
determined by RT-qPCR. 
3.3.6 HuNoV infection in immune cells 
In addition to intestinal epithelial cells, HuNoV infection in human immune cells was 
also investigated. This is because in an in vivo chimpanzee model of HuNoV infection, 
HuNoV antigens were detected in cells positive for DC-SIGN (dendritic cells) or CD20 
(B cells). Although, macrophages and dendritic cells (DCs) derived from peripheral 
blood were previously shown not to support Norwalk virus replication (Lay et al., 2010), 
the intestinal immune cells possess different phenotypes compared to circulating 
immune cells (Smythies et al., 2005, Lee et al., 1985, Liu and Nussenzweig, 2010). 
Therefore, immune cells from different sources should be tested for HuNoV replication. 
Tonsils are lymphoid tissues with enriched immune cell populations, and tonsillectomy 
is a possible source of obtaining a mixture of primary immune cells (mainly dendritic 
cells).There is evidence showing the heterogeneity of DC populations (Stent et al., 
2002, Summers et al., 2001). Therefore, primary tonsillar cells represent a 
heterologous primary immune cell model to examine HuNoV replication. Tonsillar cells 
were isolated from an anonymous donation of tonsillar tissues following elective 
tonsillectomy. The acute or the persistent pool HuNoVs were inoculated directly to the 
purified cells. A slight decrease, followed by a small increase in viral RNA was observed 
over 4 days (Figure 3.5A). Although the increase of HuNoV RNA was not statistically 
significant, it is possible that tonsils contain immune cells susceptible to HuNoV 
infection. 
Chronic human myelogenous leukaemia cell line KBM7 was also tested for HuNoV 
replication using an unpurified GII.1 HuNoV (Figure 3.5B). Through communication 
with the Karst laboratory (Jones et al., 2014) we learned that a pre-incubation with 
soluble HBGA enhances HuNoV replication in B cells. Since then, HBGA was included 
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as an additive during the screening of KBM7 and the primary γδ T cells for HuNoV 
replication. GCDCA is one of the components of bile. Porcine sapovirus requires bile 
acid for viral entry (Chang et al., 2004). To examine whether bile can also promote 
HuNoV entry and replication, HuNoV was mixed with GCDCA before inoculated to 
KBM7 cells. Compared to inoculation without additives, pre-incubation with HBGA 
slightly increased the bound vRNA (0hpi, HBGA). However, the increased binding did 
not increase HuNoV replication significantly. Although the difference is statistically 
significant, the fold increase on 72hpi is less than 10-fold in all experiments. 
A recent case of HuNoV infection in a paediatric patient following a bone marrow 
transplant showed that through the course of infection a particular strain of GII.6 
HuNoV became the dominant variant (J. Lockwood, University College London, 
unpublished data). This observation coincided with the enrichment of γδ T cells 
after the transplant (data not shown), raising the possibility of γδ T cells being 
infected by HuNoV. To test this hypothesis, γδ  T cells were expanded from 
peripheral blood of two healthy donors by Marta Barisa (J. Anderson lab, University 
College London), and were inoculated with the purified acute pool or an unpurified 
GII.1 HuNoV. Initially, a less than 10-fold increase of viral RNA was observed in the 
infected cells from the second donor (Figure 3.5C, left panel). In order to validate this 
observation, primary γδ T cells were expanded from donor 2 and infected by the 
acute pool and the GII.1 HuNoVs alongside concentrated HuNoVs from reverse 
genetics (Figure 3.5C, right panel). However, in this experiment no increase of vRNA 
was observed over 3 days. 
HuNoV RNA was readily detected on day 0 samples of immune cells, indicating the 
presence of an attachment factor on the surface of these cells. However, a robust 
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increase of viral RNA was not observed in cells, suggesting that HuNoV does not 
establish efficient infection in the tested immune cells. 
 
Figure 3.5 Infection of immune cells. A) HuNoV infection of primary tonsillar cells. Cells were isolated 
and were inoculated with the acute and the persistent pool HuNoVs. HuNoV vRNA from different 
samples was determined by RT-qPCR. B) HuNoV infection of near-haploid cell line KBM7. Unpurified 
HuNoV GII.1 was either directly incubated with KBM7 cells, or pre-incubated with HBGA or GCDCA 
before being added to the cells. The HuNoV RNA was determined by RT-qPCR. Two-way ANOVA 
analysis was performed using Dunnett test (* p<0.05, ** p<0.01, *** p<0.001) C) HuNoV infection of 
peripheral blood-derived γδ T cells. 10ml peripheral blood was obtained from two anonymous donors 
following expansion of γδ T cells. Differentiated cells were infected with purified acute pool HuNoV 
or unpurified GII.1 HuNoV. At 0 and 72 hpi, total RNA was extracted and the total HuNoV RNA was 
determined by RT-qPCR. D) Donor 2 γδ T cells infection by HuNoVs. After C), peripheral blood was 
again obtained from donor 2 and expanded. The two HuNoVs tested together with 100×-concentrated 
HuNoVs from reverse genetics were tested. At 0 and 72 hpi, the HuNoV RNA was determined. 
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3.3.7 Validation of HuNoV infection in B cells 
Since the discovery of a B cell culture for HuNoV, efforts have been made to validate 
and improve this culture system (Jones et al., 2014, Jones et al., 2015). Initially, the 
acute pool or a persistent GII.21 HuNoV (the main isolate in the persistent pool) were 
inoculated into BJAB cells. However, over the course of five days no significant 
increase of HuNoV RNA was observed (Figure 3.6A). 
Lentivirus encoding BVDV NPro was used to test if the induction of innate immunity 
inhibited HuNoV replication in BJAB cells (Figure 3.6B) Also, pre-incubation with heat 
inactivated enteric bacteria E.cloacae or HBGA was used to help HuNoV binding. In 
spite of these measures, no increase of HuNoV RNA was observed over 5 days. 
As suggested in the initial publication by Jones et al., HuNoV replication in BJAB cells 
is inefficient and subject to the stringent experimental set up of both cells and viruses 
(Jones et al., 2015, Jones et al., 2014). Therefore, HuNoV infection of BJAB cells was 
also tested during the visit of the Karst lab (University of Florida). Different HuNoVs 
were inoculated to BJAB cells from both laboratories. An average 10-fold increase of 
RNA was observed in an unpurified GII.4 HuNoV (CDC4)-infected samples (Figure 
3.6C). However, because this result was not yet available when the following 
experiment was performed (Figure 3.6D), instead of the CDC4, the HuNoV CDC14 
was chosen to test HuNoV replication in BJAB from the Karst lab (University of Florida), 
or from the Farrell lab (MCS and NPro). In this experiment, only CDC14 infection in 
transduced BJAB NPro showed statistically significant increase of vRNA 3 days post 
infection. However, this observation was confounded by significantly less vRNA on 0hpi. 
Therefore, it is possible that CDC14 replicates at low level in BJAB NPro, but a 
conclusion can only be drawn after independent validation. 
After establishing the BJAB propagation and HuNoV infection protocols in our 
laboratory, the effect of inoculation dose on HuNoV replication was tested (Figure 3.6E). 
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Inoculation of 10 μl unpurified GII.1 HuNoV showed slight increase of HuNoV RNA 3 
days post infection. Interestingly, similar to the infection in BJAB NPro (Figure 3.6D), 
this experiment also displayed more variations of day 0 vRNA. Further biological and 
technical repeats indicated that there was up to 9-fold increase in viral RNA, but 6 out 
of the 9 experiments showed limited viral genome replication (Figure 3.6F). 
These results together show some evidence of HuNoV replication in BJAB cells, but 
the consistency of the system needs to be improved, and more evidence of a 
productive infection (e.g. de novo translation of viral proteins, successive propagation 
of HuNoV from infected BJAB) is required to make this system viable. 
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Figure 3.6 Infection of BJAB. A) BJAB cells infection by the acute pool or the persistent GII.21 HuNoVs. 
BJAB cells were infected and HuNoV RNA was determined at the indicated time points post infection. 
B) BJAB infection with pre-incubation of E. cloacae or HBGA. Transduced BJABs were infected with the 
persistent GII.21 HuNoV. The total RNA was harvested on days 0 and 5, followed by detection of vRNA 
by RT-qPCR. C) Effect of viruses on BJAB infection. Different HuNoV were tested for HuNoV infection 
following the published protocol (Jones et al., 2015, Jones et al., 2014). Samples were harvested and 
HuNoV RNA determined by RT-qPCR. Two-way ANOVA was performed using Bonferroni test, ***, 
p<0.001 D) Effect of cells on BJAB infection. BJAB from the Karst lab and transduced BJABs from IG 
lab were infected by CDC14 and GII.21 HuNoV and the total RNA was extracted on 0 and 3 dpi. E) 
Titration of HuNoV. BJAB cells were infected with unpurified GII.1 HuNoV following published protocol 
with different volumes of virus. Total RNA extraction and RT-qPCR were performed on samples of 0 and 
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3 dpi. F) Summary of 9 biological experiments on BJAB infections using the published protocol. BJABs 
were infected with 10 μl unpurified GII.1 HuNoV and harvested on 0 and 3 dpi. In 3 biological triplicate 
experiments (total 9 repeats), the fold of increase was plotted. 
3.3.8 Maintenance and differentiation of intestinal 
organoids 
HuNoV replication in primary human intestinal organoids (or enteroids) was recently 
described (Ettayebi et al., 2016). Several genotypes of HuNoVs were shown to 
replicate in this system, and bile was identified as a host factor for certain HuNoV 
strains. Importantly, the replication of GII.4 but not GII.3 HuNoV depends on the 
secretor status of organoids. 
Following this, the primary intestinal organoids culture was established in our 
laboratory (M. Hosmillo, Y. Goodfellow, I. Goodfellow, unpublished results). Duodenal 
organoids D196 were maintained in proliferation media with Matrigel. The culture was 
propagated every week, and typically organoids started to appear one day after 
splitting (Figure 3.7A). There are between 50-100 cells per organoid, displaying multi-
lobulated or spherical structures. 
HuNoV effectively infects enterocytes obtained from differentiated intestinal organoids 
(Ettayebi et al., 2016). Therefore, the differentiation of organoids D196 was first 
characterised. Upon differentiation (n of 1 experiment), a reduction of stem cell marker 
LGR5, and an increase of enterocyte marker ALPI were observed (Figure 3.7B). This 
is consistent with previously published data (Saxena et al., 2015). 
Differentiation markers were also visualised by fluorescent microscopy. The 
expression of goblet cell marker MUC1 throughout differentiation was determined 
(Figure 3.7C). MUC1 was readily observable one day post differentiation. Starting from 
day 2, a change of sub-cellular expression patterns was observed. Cytoplasmic MUC1 
decreased while cell surface distribution of MUC1 increased. Five days post 
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differentiation, ubiquitous apical surface expression of MUC1 was observed. Because 
MUC1 is a recognised as a goblet cell marker, the significant proportion of MUC1 
positive cells may indirectly suggest that the number of enterocytes in this batch of 
differentiated organoids is suboptimal. However, it is important to mention that the 
differentiation of organoids is readily reproducible (M. Hosmillo and Y. Goodfellow, 
unpublished data). 
3.3.9 Replication of HuNoV in intestinal organoids 
The supply of organoids was limited, primarily due to the difficulty in maintaining the 
culture and slow replication kinetics. The initial test of HuNoV infection was performed 
using another duodenal organoids D353. Both D196 and D353 are secretor positive 
(M. Hosmillo, personal communication), therefore both organoids are less restricted to 
HuNoV genotypes. A GII.4 HuNoV a42dd (kindly provided by M. Hosmillo) was used 
to demonstrate HuNoV replication in organoids D353 and an 8.5-fold increase in viral 
RNA was observed over the course of 2 days (Figure 3.7D). It is important to mention 
that this is a n of 1 experiment, and increases in viral RNA more than 1000-fold are 
now routine but highly dependent on the state of monolayer differentiation (M. Hosmillo 
and Y. Goodfellow, unpublished data). 
GII.4 HuNoV recovered by reverse genetics was also tested for replication in intestinal 
organoids (Figure 3.7E). The first passage of the GII.4 HuNoV in duodenal organoids 
D196 showed a modest level of replication (Passage 1). Passaging was performed by 
inoculating cell lysates from passage 1 to differentiated organoids and HuNoV RNA 
levels on day 0 and day 3 were determined. Compared to passage 1, there was much 
less cell-associated HuNoV RNA on day 0, whereas comparable viral RNA was 
observed on day 3, resulting in an average of more than 2000-fold increase of vRNA. 
The variation of this experiment was significantly lower than that seen in the BJAB 
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infections, and the significant increase of HuNoV RNA indicates that FPV-mediated 
reverse genetics recovers infectious GII.4 HuNoV. 
In summary, primary intestinal organoids may be the most robust method for cultivating 
HuNoV. Using this system, FPV-mediated reverse genetic system showed recovery of 
infectious GII.4 HuNoV, which opens new avenues for infectious virus generation, 
rather than using faecal samples. 
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Figure 3.7 Infection of intestinal organoids. A) Proliferating organoids. Picture was taken on day 3 
after splitting, the arrows indicated individual organoids. Scale bar represent 50 μm. B) Differentiation 
of organoids (n=1). Duodenum organoids D196 was differentiated and on days 2 and 7 post 
differentiation, the expression of stem cell marker LGR5 and enterocyte marker ALPI were determined 
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by qRT-PCR. C) Differentiation of goblet cells. Duodenum organoids D196 was differentiated, and on 
days 1, 2 and 5 post differentiation, cells were fixed and stained with the goblet cell marker MUC1. 
Arrows indicate a typical cytoplasmic distribution of MUC1 and a goblet cell morphology. Scale bar 
represents 10 μm. As differentiation progressed, surface expression of MUC1 was observed. D) 
Infection of differentiated organoids with HuNoV. Duodenum organoids D353 was differentiated and 
HuNoV a42dd inoculated (n=1). On days 0 and 2 post infection, HuNoV RNA was determined by RT-
qPCR. E) Infection of differentiated organoids with HuNoV recovered from reverse genetics. RGS GII.4 
HuNoV was inoculated to differentiated duodenal organoids D196. On days 0 and 3 post infection, 
HuNoV RNA was determined by RT-qPCR. Following passage 1, cell lysates was used for infection of 
passage 2. And the samples were processed accordingly. HuNoV infections and RT-qPCR in E) was 
performed by M. Hosmillo. 
3.4 Discussion 
In this chapter, extensive efforts have been attempted to establish an in vitro culture 
system for HuNoV. HuNoV was either purified from clinical specimen or generated de 
novo using reverse genetics. Recombinant lentiviruses encoding innate immune 
antagonists were used to prevent potential activation of innate immune responses 
during infection to enhance HuNoV replication. Different cell types, mainly the intestinal 
epithelial cells and immune cells, were tested for HuNoV replication. Following two 
recent publications, HuNoV infections were tested in the B cell and primary enteroids 
systems. Some of the presented evidence agreed with the published results, whilst the 
caveats of others indicate that more efforts are required to develop a robust culture 
system to study HuNoV biology. 
3.4.1 HuNoV can be recovered from different sources 
One clinical characteristic of HuNoV is robust faecal shedding of viral RNA. In fact, 
most of the acute infection faecal samples possessed high viral load even after semi-
purification (Table 3.1). RNase sensitivity assay showed that the purified acute virus 
pool is highly RNase-resistent (Figure 3.2B). 
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Compared to faecal samples from acute infections, samples of persistent infections 
showed diverse genotypes and variations in viral RNA. The majority of the acute pool 
samples were genotyped as GII.4_Sydney_2012. As these samples were collected 
during similar time (2013), it was not surprising that Sydney 2012 dominated the 
genotypes of the acute pool stock. In comparison, in the persistent viruses there was 
a chronic patient with high viral RNA but non-diarrhoea sample (GII.21). Sequential 
samples collected from this patient had lower titres but likely great genetic diversity 
than the acute infections (Debbink et al., 2014, Doerflinger et al., 2017, Hasing et al., 
2016). The development of hepatitis C virus tissue culture system highlights the 
importance of a cell culture-adaptive virus isolate (Wakita, 2009). Therefore, although 
persistent pool was of lower titre, it increased the diversity of HuNoV strains being 
screened. It is important to mention that the GII.21 sample has more than 100 times 
higher titres than the rest of the persistent samples. Therefore, in the persistent pool 
over-represented GII.21 was the dominating genotype. The development of the 
primary intestinal organoids as HuNoV cell culture system enabled culturing different 
HuNoVs (Ettayebi et al., 2016). GII.3 and GII.4 HuNoVs, together with GII.1 and GII.21 
HuNoVs were purified in this study. The replication of these isolates in organoids was 
yet to be characterised. 
DNA-based reverse genetics system was also tested as an alternative method to 
generate infectious HuNoV. The success of this method will facilitate the production of 
genetically defined HuNoV, with the potential of genetically manipulating HuNoV to 
study the details of HuNoV replication and virus-host interactions. HuNoV recovered 
by reverse genetics will also be free of contaminants from faecal matter, which 
preventing activation of cells during infection. The transfection of two HuNoV cDNA 
clones (GI.4 and GII.6) using FPV-T7 reverse genetics system showed robust 
production of viral proteins (Figure 3.2C). A previous study showed a similar MVA-T7 
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inhibits MNV replication, whereas FPV-T7 enabled recovery of infectious MNV 
(Chaudhry et al., 2007). It remains to determine whether the similar constraint applies 
to the recovery of HuNoV. 
3.4.2 Antagonism of innate immunity 
The development of the Norwalk virus RNA replicon started to reveal details of the 
intracellular life cycle of HuNoV, one of which is the sensitivity of norovirus replication 
to type I IFN responses (Chang et al., 2006). The characterisation of norovirus RdRp 
using a cell-based NoV-5BR assay also showed that active norovirus RdRp triggers 
type I IFN responses. In one study a lack of IFN responses was observed in norovirus 
RNA replication (Qu et al., 2016). However, the number of replicating cells was low 
and this conclusion should only be drawn when similar observations were obtained in 
a more robust replication system, e.g. the primary intestinal organoids. 
BVDV NPro and PIV5 V were used to antagonise innate immune sensing during 
infection. Lentiviruses encoding BVDV NPro and PIV5 V effectively degrade IRF-3 and 
STAT1, respectively (Figure 3.3). However, the only direct evidence of recombinant 
lentivirus aiding HuNoV replication was that in BJAB NPro infected with HuNoV CDC14 
showed significant replication compared to BJAB MCS (Figure 3.6D). This finding was 
also confounded by significantly less viral RNA on day 0, despite that vRNA on day 3 
was slightly higher. In all the other cell lines tested, it can only be concluded that neither 
IRF-3 or STAT1 is the key restriction host factor for HuNoV replication in the tested 
cells. 
HuNoV infection in primary intestinal organoids show promising results. It will be 
interesting to determine if BVDV NPro or PIV5 V improves HuNoV replication in these 
cells. HuNoV infection in organoids was performed with ruxolitinib, which is a JAK 
inhibitor (Mesa, 2010) as our preliminary results showed that ruxolitinib enhances 
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HuNoV replication (M. Hosmillo, unpublished data). Therefore, it is possible that PIV5 
V can functionally replace ruxolitinib due to the similarly targeted JAK/STAT pathways. 
3.4.3 Roles of B cells in HuNoV pathogenesis 
Since the publication of the B cell culture system for HuNoV, extensive efforts were 
invested to establish this model in our laboratory. It was proposed that HuNoV can 
replicate in BJAB at low level, and a robust HuNoV cell culture system can be 
established by improving this system. It was observed that patients with congenital B 
cells deficiency showed reduced HuNoV infection (Brown et al., 2016). Also, B cells 
were found in intestinal lamina propria, suggesting that HuNoV can be in close physical 
proximity to B cells during infection (Schlissel, 2013). Moreover, in a chimpanzee 
infection model system, B cells and dendritic cells were found to co-localise with 
Norwalk virus capsid signals (Bok et al., 2011). MNV was also found to infect B cells 
(Jones et al., 2014), supporting the idea that B cells are a possible tropism of HuNoV. 
However, histopathological analysis of biopsies from immunocompromised patients 
with chronic norovirus infection showed no evidence of HuNoV-infected B cells present 
in the samples screened (Karandikar et al., 2016). This study supported the hypothesis 
that HuNoV mainly replicated in enterocytes, while macrophages, T cells and dendritic 
cells can also be infected. 
Our investigation of HuNoV infection of BJAB cells showed some evidence of virus 
replication (Figure 3.6C, D and F). However, in agreement with the previous data 
(Jones et al., 2015, Jones et al., 2014), significant variations were observed. This 
variable, low level replication unlikely facilitates the robust HuNoV infections clinically. 
However, in MNV the antigen presentation function of B cells is antagonised by viral 
protein VP2 (Zhu et al., 2016), highlighting the multiple functions of B cells in norovirus 
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pathogenesis. Therefore, it is still important to understand the roles of B cells in HuNoV 
life cycle. 
3.4.4 Host factors for HuNoV infection remain to be studied 
The development of a cell culture systems for HuNoV is the first step towards filling the 
knowledge gaps in understanding the molecular details of HuNoV replication. Now that 
a permissive cell type is identified, the next obvious question is what makes these cells 
susceptible to HuNoV infections, i.e. what host factor(s) are essential for B cells or 
organoids to support HuNoV infections? 
First of all, both B cells and organoids may express sufficient cellular receptors for 
HuNoV entry. From screening of intestinal epithelial cells and professional antigen 
presenting cells, it became clear that HuNoV binds to all cells tested to different 
degrees. These results indicated the presence of attachment factors on cell surface, 
likely the HBGAs. However, it was unclear whether the inoculated HuNoV is 
internalised in these cells. In BJAB and organoids HuNoV replication was observed, 
which must be accompanied with successful viral entry. These two systems can 
therefore potentially be used to identify entry factors of HuNoV. 
In BJAB, pre-incubation with enteric bacteria or HBGA enhances viral replication 
(Jones et al., 2014). Therefore, it is logical to propose that the limiting factor for viral 
entry in BJAB is cell surface HBGA expression. One enzyme recognised to be 
important for HBGA synthesis is FUT2, which adds a fucose group to the HBGA 
precursors, generating H antigens (de Graaf et al., 2016). Individuals with non-
functional FUT2 genes, known as non-secretors, confer a certain degree to innate 
resistance to norovirus infections (Le Pendu et al., 2006). To test the hypothesis 
whether H antigen was the limiting factor for HuNoV entry in BJAB cells, the FUT2 
gene was cloned from enterocyte HT-29 cells into lentivirus expression construct. 
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Preliminary experiments using a norovirus pseudovirus particle entry assay showed 
that the overexpression of FUT2 in BJAB led to significant increase of HuNoV entry (L. 
Meredith, unpublished data), indicating that BJAB is a potential model to identify 
HuNoV entry factors. 
In addition to viral entry, other host factors required for HuNoV replication remain to be 
characterised. Despite the possible lack of receptor expression on the cell surface, 
HuNoV replication in cell culture was not robust, as a low level of replication was 
observed in 293T cells transfected with HuNoV VPg-linked RNA (Qu et al., 2016). 
During the screening of cell lines for HuNoV infection, the replication of HuNoV 
genomic RNA in cell culture was also tested. The total RNA was purified from the acute 
pool stock or from Norwalk virus replicon-bearing BHK cells (clone G6). Transfection 
of both RNAs into BV-2, BHK and BJAB cells led to no increase in viral RNA (data not 
shown), indicating that HuNoV RNA does not replicate in cell lines efficiently. The 
primary intestinal organoids so far showed the most promising evidence of HuNoV 
replication. Therefore, by comparing gene expression profiling of differentiated 
organoids with BJAB or immortalised intestinal epithelial cell lines (e.g. Caco-2, HT-29, 
LS174T), genes up-regulated in organoids may be the factors important for HuNoV 
replication. 
3.4.5 Improving the intestinal organoids system 
With the development of the two cell culture systems, for the first time there is hope in 
understanding all the mystery of the ‘uncultivatable’ HuNoV. As discussed previously, 
BJAB may be useful to identify cellular receptor, whereas organoids are useful to 
understand the intracellular life cycle of HuNoV. 
Despite all the exciting findings, there is room to improve the cost effectiveness and 
efficiency of the primary intestinal organoids system. In the current system, some 
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reagents are not commercially available, and the cost and efforts to maintain organoids 
are significant. All primary organoids were originally obtained from biopsies, with 
inevitable individual variations and the lack of a ‘gold standard’. Given that organoids 
double every six to seven days, and the large number of cells required per experiment, 
even simple experiments like the titration of HuNoV require significant input and 
advance planning. Therefore, in addition to using organoids to identify factors required 
for HuNoV replication, it is important to translate this knowledge to establish a more 
robust and cost-effective cell culture system for HuNoV. For example, differentiated 
organoids could potentially be immortalised and experiments performed to determine 
if they maintain susceptibility to HuNoV infection. Also, the differentiation of organoids 
can be directed to generate a higher proportion of enterocytes, which are infected by 
HuNoV in organoids (Ettayebi et al., 2016). Moreover, established intestinal epithelial 
cell lines like Caco-2, HT-29, LS174 or T84 could be modified so that they 
phenotypically mimic primary enterocytes. The development of any of these 
approaches could significantly lower the technical barrier of HuNoV culture and 
facilitate more studies of HuNoV using this system. 
In summary, in this chapter attempts were made to establish an in vitro culture system 
for HuNoV. First of all, infectious HuNoV was obtained from either norovirus-positive 
faecal samples or from DNA-based reverse genetic system. Recombinant lentiviruses 
were applied to promote HuNoV replication by antagonising cellular innate immunity. 
Intestinal epithelial cells and immune cells were tested for HuNoV infection with little 
evidence of robust virus replication. Two HuNoV cell culture systems, the B cell and 
the primary intestinal organoids were tested and showed that the FPV-mediated 
reverse genetic system recovered infectious HuNoV. Although further efforts are 
needed to optimise the organoids system, the results demonstrate great potential of 
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engineering HuNoV to interrogate the details of HuNoV replication and dissect the 
norovirus-host cell interactions. 
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4.1 Background 
In the previous chapter, attempts were made to cultivate HuNoV in vitro. Because the 
two culture systems are in the early stages of development, surrogate systems remain 
invaluable tools to understand norovirus biology. 
Viruses are intracellular obligate parasites. During infection, host cellular pathways are 
hijacked by viruses to facilitate the replication of viral genes and to overcome the 
cellular defence mechanisms. Compared to transcriptional control, translation control 
is an effective mechanism for viruses to antagonise and subvert host responses at the 
protein level, resulting in direct modulation host proteome during infection (Roth et al., 
2017). 
The majority of eukaryotic translation initiation is cap-dependent, for which the 
interaction between the cap-binding protein eIF4E and the 5’ cap of mRNAs is 
essential for recruiting the eIF4F complex (eIF4A, eIF4E and eIF4G). eIF4E is 
recognised as the rate-limiting step for cap-dependent translation initiation and its 
activity can be regulated by both host cellular and viral pathways. The main regulator 
of eIF4E is the eIF4E-binding proteins (4E-BPs) which binds eIF4E on its dorsal 
surface, sharing the binding site with eIF4G (Marcotrigiano et al., 1999, Peter et al., 
2015). These mutually exclusive interactions are thought to regulate the eIF4G:eIF4E 
interaction. Besides binding to 4B-BPs, the activity of eIF4E can also be regulated by 
phosphorylation at Serine 209 by the MAP kinase-interacting serine/threonine-protein 
kinase 1/2 (Mnk1/2) (Shveygert et al., 2010). Whilst 4E-BPs regulate cap-dependent 
translation initiation by competing with eIF4G to bind eIF4E, phosphorylation of eIF4E 
is thought to modulate the translation of a subset of mRNAs with long, structured 5’ 
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UTRs, including genes encoding growth regulatory proteins (Feoktistova et al., 2013). 
Besides in cancer progression, phosphorylation of eIF4E has also been observed 
during several infections of several DNA viruses (Zaborowska and Walsh, 2009, Walsh 
et al., 2005, Walsh and Mohr, 2004, Furic et al., 2010). Later, it was proposed that both 
DNA and RNA viruses hijack the phosphorylation of eIF4E to translationally regulate 
type I IFN responses during infection (Herdy et al., 2012). 
MNV infection induces phosphorylation of eIF4E via the p38-Mnk1 signalling pathway 
(Royall et al., 2015). Inhibition of this pathway using pharmaceutical drugs reduces 
MNV replication in immortalised cells. In addition, the phosphorylated eIF4E relocates 
to polysome and changes the translation state of several mRNAs during MNV infection. 
One of the mRNAs with increased translation state is Nfkbia, which encodes NF-κB 
inhibitor IκBα. Increased translation of IκBα inhibits NF-κB activity, resulting in 
impaired innate immunity and enhanced virus replication. As norovirus replication is 
sensitive to type I IFN responses (Thackray et al., 2012, Chang et al., 2006), the 
phosphorylation of eIF4E induced by MNV infection may be a viral mechanism to 
induce translational bias during infection. 
Several questions remain to be answered with the hypothesis. Can the initial 
observations be reproduced in a more biologically relevant, in vivo model? Is MNV 
replication impacted by genetically inhibiting phosphorylation of eIF4E? In addition to 
modulating type I IFN responses, how does norovirus infection elicit translation control 
through the phosphorylation of eIF4E? 
To understand the translational bias induced by eIF4E phosphorylation during MNV 
infection, the phosphorylation site of eIF4E (Serine 209) was genetically engineered 
into a non-phosphorylatable alanine (S209A) (Furic et al., 2010). eIF4E S209A knock-
in mice (referred as the KI mice hereafter), showed reduced tumorigenesis and cancer 
progression (Furic et al., 2010). In MEF cells derived from KI mice, the global 
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translation is not impacted. However, the reduced translation of IκBα results in 
enhanced type I IFN responses, inhibiting both RNA and DNA virus replications (Herdy 
et al., 2012). This observation highlights the potential of the KI mice as a model system 
to study the antiviral role of eIF4E phosphorylation during MNV infection. 
4.2 Aims 
The aim of this chapter was to understand the translational bias by norovirus to subvert 
host immune pathways. Based on the previous observations, it was proposed that the 
loss of eIF4E phosphorylation due to the S209A mutation should lead to enhanced 
type I IFN responses, attenuating MNV replication in vivo. 
4.3 Results 
4.3.1 Introduction of the eIF4E S209A mouse model 
Mice were bred from parents carrying heterozygous S209A mutation of eIF4E, to 
exclude interference of host-microbiome interactions in the study (Stappenbeck and 
Virgin, 2016). Sex- and age-matched littermates were used for in vitro and in vivo 
studies. Two heterozygous breeding trios were introduced to establish a breeding 
colony. Ear biopsies taken from the initial breeding trios and WT C57BL/6 mice were 
used for establishing and validating the genotyping PCR (data not shown). 
For all experiments, mice were genotyped and WT or KI mice were used for bone 
marrow differentiation or MNV infections per oral. Throughout this project, the total 
numbers of each genotype were as follow: 
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 WT (WT/WT) Het (WT/S209A) KI (S209A/S209A) 
Male 41 73 38 
Female 37 80 47 
Table 4.1 Number of pups of each genotype. 
4.3.2 Type I IFN signalling in KI BMDM 
MEF cells from the KI mice show stronger type I IFN response due to increased NF-
κB activity (Herdy et al., 2012). In order to validate this activation, primary bone 
marrow-derived macrophages (BMDMs) were differentiated from femur bones of KI 
and WT mice. On day 7 post differentiation, the cells were stimulated by poly I:C 
transfection (Figure 4.1). 
Upon stimulation, BMDMs from KI mice showed more than 2 times higher induction 
levels of Ifnb compared WT BMDMs (Figure 4.1A), nevertheless both of which were 
significantly lower than that of the Raw264.7 cells. The significantly higher induction of 
Ifnb in KI BMDMs is consistent with previously published results, which is thought to 
due to the increased NF-κB activity (Herdy et al., 2012). Therefore, it is possible that 
other genes whose expression are controlled by NF-κB activity would have elevated 
induction upon poly (I:C) transfection. Il6 is one of the NF-κB target genes (Libermann 
and Baltimore, 1990, Son et al., 2008). When BMDMs or Raw264.7 cells were 
stimulated with poly (I:C), significant inductions of Il6 were observed in all cells (Figure 
4.1B). However, there was no difference between WT and KI BMDMs. Significantly 
higher induction was again observed in Raw264.7 cells. These results indicate that 
although phosphor-ablative mutation of eIF4E induces stronger Ifnb induction upon 
stimulation possibly via elevated NF-κB activity, the enhancement does not apply to 
all NF-κB target genes. 
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The type I IFN responses through poly (I:C) stimulation were also assessed. The 
transfection of poly (I:C) did not induce transcription of Rsad2 mRNA in either BMDM, 
suggesting the production of IFNβ is the major effect of poly (I:C) stimulation of 
BMDMs. However, a significant induction was observed in Raw264.7 cells, suggesting 
the poly (I:C) concentrations used in the experiment can induce transcription of ISGs. 
In order to exclude the possibility of gene-specific effects, the induction of Isg15 was 
also determined (Figure 4.1D). In agreement with the observed induction of Rsad2, no 
significant induction was observed in WT or KI BMDMs, while in Raw264.7 cells 
significant Isg15 induction was observed. 
 
Figure 4.1 Type I IFN signalling of BMDM. Bone marrow cells were isolated from WT or KI littermates 
(n=2 of each genotype) and differentiated using conditioned CMG14-12 supernatant (Takeshita et al., 
2000). Differentiated BMDMs were transfected with different concentrations of poly (I:C). Raw264.7 cells 
were used as the positive control for transfection. Cells were harvested at 12 hours post-transfection 
and the total cellular RNA was extracted. RT-qPCR was performed to assess the induction of A) Ifnb, B) 
Il6, C) Rsad2, and D) Isg15. The expression level of each gene was normalised to that of Gapdh, and 
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the fold of induction was calculated using the ΔΔCt method (Livak and Schmittgen, 2001). Two-way 
ANOVA was performed using Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
4.3.3 Production of ISGs in BMDM 
To compare the type I IFN responses between differentiated BMDMs, different 
concentrations of recombinant IFNβ were added to the differentiated BMDMs and 
Raw264.7 cells, and the total cellular RNA was harvested at 12 hours post treatment. 
Figures 4.2A and B showed the induction of Rsad2 and Isg15, respectively. IFNβ 
treatment induced significant expression of Rsad2 and Isg15. Together with Figure 
4.1C and D, these results indicate that the low level of ISG induction in BMDMs upon 
poly (I:C) transfection was not due to the inability of BMDM to respond to IFN-β. In 
fact, BMDMs from both KI and WT mice responded better to IFNβ by producing more 
Rsad2 mRNAs than Raw264.7 cells did. 
In summary, in vitro characterisation of BMDMs from WT and KI mice showed 
observations consistent with data from others, yet it is possible that the effect of eIF4E 
S209A mutation on type I IFN pathways is more complicated than simply enhancing 
NF-κB-mediated signalling. 
 
Figure 4.2 ISG production of BMDM. BMDMs from WT or KI littermate were differentiated as in Figure 
4.1 (n=2 of each genotype) and different concentrations of IFNβ were added to cells. 12 hours post 
treatment the total cellular RNA was isolated and relative RT-qPCR was used to determine the induction 
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of two representative ISGs: A) Rsad2, and B) Isg15. The relative gene expressions were normalised to 
the housekeeping gene Gapdh and the fold of induction was calculated using the ΔΔCt method (Livak 
and Schmittgen, 2001). Two-way ANOVA was performed using Bonferroni test (* p<0.05, ** p<0.01, *** 
p<0.001). 
4.3.4 Infection of BMDM 
To assess the effect of phosphor-ablative eIF4E mutation on MNV replication, in vitro 
infection model was first established using the well-characterised MNV-1. MNV-1 
causes acute infection in immunocompetent mice without significant pathology. In cell 
culture, MNV-1 readily infects permissive macrophage (Raw264.7) and microglial (BV-
2) cell lines (Cox et al., 2009). In primary dendritic cells and macrophages, MNV-1 can 
still establish infection, though with a lower infection rate and virus yield (Wobus et al., 
2004). 
MNV infection of BMDM was assessed by staining for two markers of infection, NS3 
and dsRNA. As shown in Figure 4.3, BMDM and Raw264.7 cells were infected by 
MNV-1 at the same MOI (10 TCID50 per cell). At 12hpi, there are more NS3 and dsRNA 
positive cells in Raw264.7 cells than in BMDM, suggesting BMDM are less susceptible 
to MNV infection. 
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Figure 4.3 BMDM infection. Bone marrow cells were isolated and differentiated according to previously 
published protocols (Takeshita et al., 2000). On day 7 post differentiation, BMDMs or Raw264.7 cells 
were infected with purified MNV-1 at an MOI of 10 TCID50/cell. At 12hpi, cells were fixed and stained 
for dsRNA and NS3. The nuclei were stained with DAPI. Both dsRNA and NS3 co-localised in the 
perinuclear foci. Scale bar represents 10 μm. 
4.3.5 Infection of KI BMDM by MNV-1 
The ISG inductions following infection were determined by infecting BMDM with 
purified MNV-1. Productive infection of BMDM was seen from different MOIs (Figure 
4.4A to C). All inoculations led to increases in viral titres over time, peaking between 
104 to 105 TCID50/ml. Even at different MOIs, no significant difference in virus yield 
between WT and KI BMDMs was observed. 
MNV-1 infection of both BMDMs significantly induced transcription of Ifnb (Figure 4.4D). 
At MOI 0.5 and 5 TCID50/cell, the induction of Ifnb was significantly higher in KI BMDMs. 
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Increased Ifnb induction was paralleled with significantly higher induction of Rsad2 
(Figure 4.4E). MNV is known to uncouple host translation from transcription during 
infection (Emmott et al., 2017). To determine the production of ISGs in infected BMDMs, 
total protein from infected cells (MOI 0.5) were harvested at 12hpi. Cellular RNA from 
all MOIs was also extracted. The phosphor-ablative mutation in KI BMDMs was 
confirmed by the absence of p-eIF4E (Figure 4.4F). MNV-1 infection of both BMDMs 
induced significant expression of viperin compared to Raw264.7 cells, yet the 
production of viral protein NS3 was barely observable. In contrast, in Raw264.7 cells 
the NS3 signal was very significant. The significantly higher expression of both eIF4E 
and p-eIF4E was observed in Raw264.7 cells, but in this experiment MNV-1 infection 
did not increase the level of p-eIF4E in Raw264.7 cells. Together, these results suggest 
that a stronger type I IFN response was observed in MNV-1 infected KI BMDMs, but 
this had little effect on MNV replication. 
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Figure 4.4 Infection of KI BMDM by MNV-1. WT or KI BMDMs from littermates (n=6 of each genotype) 
were differentiated and infected by MNV-1 at different MOIs. Virus yield was determined at the indicated 
time points post infection (A to C). At 12hpi, the total RNA was extracted from each sample and the 
inductions of Ifnb and Rsad2 were determined by RT-qPCR (D and E). Two-way ANOVA was performed 
using Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). F) showed the production of viral protein NS3 
and induction of ISGs upon infection. 
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4.3.6 Infection of KI BMDM by MNV-3 
The initial characterisation of KI BMDMs showed a higher Ifnb induction upon poly (I:C) 
transfection and during MNV-1 infection, yet there was no impact on virus yield. MNV-
1 causes acute infection and was isolated from the brain of a IFNαβγR-/- mouse 
(Karst et al., 2003). Compared with MNV-3, MNV-1 CW1 p3 is a relatively attenuated 
virus (Zhu et al., 2013). Also, BMDM is one of the cell types infected by MNV in vivo 
(Wobus et al., 2004). Previous work has shown that MNV can be attenuated in vivo 
with no significant defect in replication in cell culture (Bailey et al., 2008). Therefore, it 
is possible that the effect of eIF4E phosphorylation on MNV replication was not shown 
in the acute infection model. 
MNV-3 was chosen as the model system to study the effect of phosphor-ablative eIF4E 
on norovirus pathogenesis in vivo. A mutant of MNV-3 was also used, MNV-3VF1-, 
containing stop codons at the N-terminus of VF1 coding region. The production of 
functional VF1 is consequently abolished without codon changes of the overlapping 
VP1 shell domain coding region. In vitro characterisation showed MNV-3VF1- 
replication to be comparable to WT MNV-3, but a stronger induction of type I IFN 
response was observed. In vivo replication of MNV-3VF1- in immunocompetent mice is 
attenuated (T. Christoudoulo, manuscript in preparation). Therefore, in KI mice MNV-
3VF1- replication should be further restricted because of the enhanced type I IFN 
responses. 
Initially, BMDMs from WT or KI mice were differentiated for 7 days before infection with 
either WT or mutant virus at different MOIs to determine the in vitro replication kinetics 
of MNV-3 and MNV-3VF1- (Figure 4.5). MNV-3 infection in WT BMDMs resulted in 
slightly higher viral titres compared with in KI BMDMs (Figure 4.5A, C and E). This 
result is most obvious at the early stages of infection at low MOI (Figure 4.5A). As 
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infection progressed, virus replication in both BMDMs reached comparable titres. At 
MOI=0.5 and 5 TCID50 per cell (Figure 4.5C and E), the infection kinetics are slower 
and the overall folds of replication are smaller compared with low MOI, possibly 
indicating that the infection has yielded the maximal virus. At all MOIs, titres at 48hpi 
are comparable to titres at 0hpi, possibly indicate the decaying of excessive input 
viruses and progeny viruses. 
The replication kinetics of MNV-3VF1- is slower in general than that of the MNV-3 WT 
(Figure 4.5 B, D and F). Gradually increasing virus titres were observed at different 
MOIs, except for MNV-3 at MOI = 0.5 TCID50 per cell at 48hpi (Figure 4.5D). This also 
resulted in the only data point with statistically significant differences in virus yield 
between WT and KI BMDMs. Apart from WT BMDM infected at MOI 0.5, virus yield of 
MNV-3VF1- at 48hpi was higher than that of MNV-3 WT. Overall, no significant 
difference was observed in the in vitro replication kinetics of two MNV-3s between WT 
and KI BMDMs. 
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Figure 4.5 Infection of KI BMDM by MNV-3. Differentiated BMDMs (n=2 of each genotype) were 
infected by MNV-3 WT (A, C and E) or MNV-3VF1- (B, D and F) at the indicated MOIs. The virus yields at 
different time points post infection were determined by TCID50. Statistical analysis was performed using 
two-way ANOVA with Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
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4.3.7 Infection of KI mice by MNV-3 
To characterise the effect of eIF4E phosphor-ablative mutations on MNV pathogenesis, 
MNV-3 was inoculated into WT or KI littermates per oral. Both male and female mice 
were tested for MNV-3 replication (Figure 4.6A). Prior to infection, no faecal shedding 
was detected in any mice. During acute infection (days 1 to 7), faecal shedding was 
detected from day 1 and peaked on 3 days post inoculation, resulting in more than 105 
gEq/mg faeces. The faecal shedding continued to decrease during the persistent 
infections, but remained readily detectable on 56 days post infection. However, no 
significant differences in faecal shedding were observed at any time points post 
infection. 
The body weight changes were compared to pre-infection and showed no evidence of 
significant pathology (Figure 4.6B), consistent with prior observations that the 
pathology of MNV-3 infections in immunocompetent mice is sub-clinical (Zhu et al., 
2013, Arias et al., 2012, Kahan et al., 2011). The production of MNV-specific serum 
IgG increased significantly starting from day 7 post infection and on day 14 reached 
levels comparable to 4 weeks post infection (Figure 4.6C). On day 56 post infection, 
high levels of serum IgG in both WT and KI mice were observed. In summary, MNV-3 
established persistent infections in WT and KI mice, but there was no difference in viral 
replication, pathogenesis and induction of mucosal immunity. 
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Figure 4.6 MNV-3 pathogenesis in KI mice. 4-6-week WT (n=9) or KI (n=10) littermates were infected 
by MNV-3 WT at 1000 TCID50 per animal and A) faecal shedding, B) weight change, and C) production 
of MNV-specific antibody were determined. No difference in MNV-3 replication, pathogenesis or mucosal 
immune response was observed between WT and KI mice. Two-way ANOVA was performed using 
Bonferroni test (* p<0.05, * p<0.01, *** p<0.001). 
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4.3.8 Low dose MNV-3VF1- challenge in KI mice 
In vivo replication of MNV-3VF1- in WT and KI mice is shown in Figure 4.7. During the 
acute infections, faecal shedding of MNV-3VF1- in WT and KI mice was significantly 
lower compared to MNV-3 WT. This is consistent with the previous observations that 
MNV-3VF1- is attenuated in vivo (manuscript in preparation). However, at 3 and 5 days 
post infection, faecal shedding of the KI mice infected with MNV-3VF1- is significantly 
higher than those of WT mice. This observation differs from the original hypothesis that 
eIF4E phosphor-ablative mutations led to more restriction in virus replication. No 
significant difference was observed during the persistent infections. The slight growth 
advantage of MNV-3VF1- in KI mice did not lead to more changes in body weight (Figure 
4.7B). 
The better infection of MNV-3VF1- in KI mice was also supported by the production of 
more MNV-specific serum IgG on 14 and 21 days post infection. (Figure 4.7C). This 
difference was not significant from 21 days post infection. Together, during the acute 
phase of infection, the phosphor-ablative mutations in the KI mice partially rescued the 
replication of an attenuated MNV-3VF1-, but the effect is marginal and does not restore 
the replication back to the level of MNV-3 WT. 
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Figure 4.7 MNV-3VF1- pathogenesis in KI mice. 4-6-week old WT (n=10) or KI (n=9) littermates were 
infected with 1000 TCID50 of MNV-3VF1- and A) faecal shedding, B) weight change and C) production of 
MNV-specific antibody was measured through 5-week period. For comparison in this experiment, KI 
(n=2) and WT (n=1) mice were infected with 1000 TCID50 of MNV-3 WT and the according data was 
collected together. Two-way ANOVA was performed using Bonferroni test (* p<0.05, * p<0.01, *** 
p<0.001). Note that a different TMB substrate was used in C) 
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4.3.9 Tissue tropism of MNV-3VF1- during persistent 
infection 
At 35 days post infection, the mice were sacrificed and the tissues harvested. The total 
RNA was extracted from colon (Figure 4.8A), caecum (Figure 4.8B) and MLN (Figure 
4.8C), which were previously reported to be the tropism of persistent MNV-3 infections 
(Arias et al., 2012). No significant difference was found in viral RNA between infected 
WT and KI mice. The colon and caecum viral RNA in mice infected with MNV-3VF1- is 
significantly lower than those infected with MNV-3 WT. Therefore, during the persistent 
infections the marginal growth advantage of MNV-3VF1- in the KI mice during acute 
infections was not reflected in the tissue tropism. 
 
Figure 4.8 Tissue tropism of MNV-3VF1- during persistent infection. On day 35 of the experiment in 
Figure 4.7, the according tissues were harvested and the viral RNA was determined by RT-qPCR: A) 
Colon B) Caecum and C) MLN. One-way ANOVA was performed using Dunnett test (* p<0.05, * p<0.01, 
*** p<0.001). 
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4.3.10 Tissue tropism of MNV-3VF1- during acute infection 
 
It was possible that the phosphorylation of eIF4E is more important for the replication 
of MNV-3VF1- during the acute infection. Therefore, WT or KI littermates were 
challenged with high dose of MNV-3VF1- (105 TCID50 per mouse by oral gavage), based 
on the hypothesis that a robust MNV-3VF1- replication may display more growth 
advantage in the KI mice over the WT mice. The mice were sacrificed on 3 days post 
infection and tissues were harvested to determine the viral RNA (Figure 4.9). The total 
RNA was extracted from faeces, duodenum, colon and mesenteric lymph nodes and 
the viral RNA was determined by RT-qPCR. No significant difference in faecal shedding 
was observed between WT and KI mice (Figure 4.9A). Faecal shedding of mice from 
high dose challenge is lower than that of mice challenged with low dose of MNV-3VF1-
(Figure 4.8A). MNV RNA was barely detectable in duodenum (Figure 4.9B). In tissues 
where MNV-3 establishes persistent infection (large intestine and MLN), MNV RNA 
was readily detected and there was no significant difference between WT and KI mice 
(Figures 4.9 C and D). The production of IFNβ in serum was also determined in 
uninfected and in infected mice. Although the faecal shedding was shown to be the 
highest on 3 days post infection (Figures 4.6A and 4.7A), no significant level of serum 
IFNβ was detected compared to uninfected mice. In summary, high dose challenge 
of an attenuated MNV-3VF1- reduced the peak titre of faecal shedding, and there is no 
difference in tropism of MNV-3VF1- in between WT and KI mice. No significant 
production IFNβ was observed on day 3 post infection. Together, the S209A mutation 
in eIF4E only appears to enhance replication of an attenuated MNV-3VF1- during acute 
infection in a dose-dependent manner. 
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Figure 4.9 Tissue tropism of MNV-3VF1- during acute infection. WT (n=7) or KI (n=9) littermates were 
infected with 105 TCID50 of MNV-3VF1- and the mice were sacrificed 3 days post challenge. A) Faecal 
shedding, and viral RNA of the following tissues were determined by RT-qPCR: B) Duodenum, C) Colon, 
and D) MLN. Serum IFNβ was determined by ELISA (E). For all experiments, one-way ANOVA was 
performed using Dunnett test (* p<0.05, ** p<0.01, *** p<0.001). 
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4.4 Discussion 
Our previous study of MNV translation control revealed a mechanism by which MNV 
activates the p38-Mnk1 pathways and re-programmes host translation via regulating 
eIF4E activity (Royall et al., 2015). This provides a possible explanation why norovirus 
VPg interacts with eIF4E in vitro and in vivo, but eIF4E is dispensable for MNV 
translation and infectivity (Chaudhry et al., 2006). Similarly, dengue virus replication is 
sensitive to the inhibition of the p38-Mnk1 pathway (Roth et al., 2017). In addition to 
re-programming host-cell translation, phosphorylation of eIF4E also enhances viral 
protein translation during infection. During Chikungunya virus (CHIKV) infection, 
phosphorylation of eIF4E at early stage of infection leads to enhanced translation of 
viral proteins (Joubert et al., 2015). Instead of activating the p38-Mnk1 pathway, the 
cross talk between the PI3K and the Mnks signalling pathways is responsible for 
phosphorylating eIF4E. In addition to using pharmaceutical drugs, the importance of 
eIF4E phosphorylation in virus-host cell interaction was also demonstrated by 
genetically mutating the phosphorylation site (Serine 209) into a non-phosphorylatable 
Alanine. In the KI cells, higher NF-κB activity leads to enhanced type I IFN responses, 
thereby restricts the replication of two positive-strand RNA viruses (Sindbis virus, 
EMCV), one negative-strand RNA virus (VSV), and one DNA virus (Vaccinia virus) 
(Herdy et al., 2012). Together, eIF4E phosphorylation is important in viral replication 
and in viral-host cell interaction. 
In this chapter, the hypothesis that norovirus infection induced translational bias by 
phosphorylating eIF4E was tested. It was thought that in the KI mouse model, MNV 
replication should be restricted, possibly due to the enhanced type I IFN responses. To 
determine the importance of eIF4E phosphorylation in MNV pathogenesis, the KI mice 
breeding colony was established, and type I IFN signalling pathways in KI BMDMs 
 132 
were characterised. The induction of Ifnb upon stimulation was enhanced compared 
with WT, which is consistent with previous observation (Herdy et al., 2012). The same 
study also proposed that increased NF-κB activity is responsible for the increased 
IFNβ  production. However, while poly (I:C) stimulation significantly induced Il6 
expression, there was no difference between WT and KI BMDM, indicating that this 
enhancement does not apply to all genes regulated by NF-κB activity. Therefore, more 
evidence is required to understand the induction of type I IFN in KI BMDM. 
Another observation is that with a significant induction of Ifnb, no ISG induction was 
observed in poly (I:C)-stimulated BMDMs (Figure 4.1C and D). Both WT and KI BMDM 
were able to produce ISGs when treated with IFNβ (Figure 4.2). Therefore, in BMDM 
the inability to express ISGs is possibly caused by poly (I:C)-induced translation shut 
down (Clavarino et al., 2012). In Raw264.7 cells significant Rsad2 and Isg15 inductions 
were observed, possibly due to better tolerance to translation shut down compared to 
BMDM. 
To determine if WT and KI BMDM have the same capacity to responded to IFNβ, 
expressions of ISGs were compared following IFNβ treatment. Induction of Rsad2 
and Isg15 were observed in both WT and KI BMDM, and there was no difference in 
the magnitude of responses (Figure 4.2A and B). Therefore, the enhanced type I IFN 
responses are likely due to more IFNβ produced in KI BMDM. 
A previous study showed that due to the increased production of IFNβ, VSV-infected 
KI mice have enhanced survival rates compared to WT mice (Herdy et al., 2012). MNV-
1 infection is sensitive to type I IFN responses, and in immunocompetent mice the 
induction of type I IFNs in intestinal homogenates and serum were observed starting 
from 1 day post infection (Wobus et al., 2004, Mumphrey et al., 2007). Therefore, it 
was thought that due to increased production of IFNβ, MNV replication should be 
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attenuated in KI BMDMs. In MNV-1-infected KI BMDM, the Ifnb induction was more 
significant than in WT BMDMs, resulting in higher induction of Rsad2 (Figure 4.4E). 
Also, more viperin was produced (Figure 4.4F). However, even at different MOIs, the 
impact of phosphor-ablative mutations on MNV-1 replication was trivial (Figure 4.4A to 
C). This indicates that at least in the current experiment set up, MNV-1 replication is 
not sensitive to enhanced Ifnb production in BMDM. In addition to the acute infection 
model, in vitro replication kinetics of persistent MNV-3 was compared between WT and 
KI BMDM. With different MOIs and viruses, there was minimal effect of eIF4E S209A 
mutation on MNV replication, with the only exception of MNV-3VF1-, MOI 0.5 at 48hpi 
(Figure 4.5D). Together, with the enhanced production of IFNβ, MNV replication in 
BMDM is minimally impacted by phosphor-ablative mutations of eIF4E. 
One of the possible explanations of the different observations between in Raw264.7 
cells and in BMDM is that the translation re-programming via phosphorylation of eIF4E 
is cell type-specific. It was observed that compared with BMDM, Raw264.7 cells have 
higher expression of both eIF4E and p-eIF4E (Figure 4.4F). Because of this, it is 
possible that the effect of eIF4E phosphorylation on MNV replication is different 
between the two cell lines. 
MNV infects macrophages, dendritic cells and B-cells both in vitro and in vivo (Wobus 
et al., 2004, Jones et al., 2015, Jones et al., 2014). It is possible that S209A KI may 
have more significant effect on MNV replication in other susceptible cell types, or on 
MNV pathogenesis systemically. MNV-3 was chosen as the in vivo infection model, as 
it causes persistent infection in immunocompetent mice, thereby mimicking a natural 
infection model (Perdue et al., 2007, Arias et al., 2012). Our previous study of MNV 
VF1 generated a mutant MNV-3VF1-. VF1 expression in MNV-3VF1- was abolished by 
introducing pre-mature termination of VF1 translation without changes in the VP1 
protein sequence. Like MNV-1VF1-, MNV-3VF1- is replication competent in vitro but 
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attenuated in vivo (McFadden et al., 2011). In addition, MNV-1VF1- showed increased 
type I IFN responses during infection. Therefore, infection of KI mice with MNV-3VF1- 
may amplify any type I IFN responses-related observations during infection. 
For MNV-3, there is no difference in faecal shedding, body weight change or production 
of MNV-specific serum IgG between WT and KI mice (Figure 4.6). However, for MNV-
3VF1- in the low-dose challenge experiment, KI mutation partially rescued the faecal 
shedding of MNV-3VF1- during acute infection (Figure 4.7). This observation is different 
to the hypothesis that enhanced type I IFN responses during MNV-3VF1- infection 
should suppress viral replication in KI mice, indicating the possibility of eIF4E 
phosphorylation having multiple roles on MNV replication. 
The multiple roles of dendritic cells in MNV pathogenesis is an example of 
multifunctional host factors. Dendritic cells (DCs) are a class of important antigen 
presenting cells, therefore they have a critical role in priming the type I IFN responses 
during MNV infection (Thackray et al., 2012). Nevertheless, MNV infects DCs in vivo, 
so the overall effect of DC depletion in vivo was unknown (Wobus et al., 2004). 
Depletion of DCs results in higher viral shedding, but viral dissemination into secondary 
lymphoid tissues is inhibited (Elftman et al., 2013). As eIF4E is also involved in host 
cell translation, genetically modified eIF4E S209A may have other unknown effect on 
host cell translation during MNV infection. Also, tissue-specific expression of eIF4E 
and phospho-eIF4E may also differentially impact MNV replication and host antiviral 
responses. 
During the persistent infections, there was no difference in faecal shedding of MNV-3 
or MNV-3VF1- between WT and KI mice, and no difference was observed in faecal 
shedding, tissue tropism or serum IFNβ when the mice were challenged with high 
dose MNV-3VF1- (Figure 4.9). Together, these results indicate that although 
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phosphorylation of eIF4E may have multiple functions in MNV pathogenesis, the 
overall effect of eIF4E S209A mutation is minimal. 
Previously microarray study has identified changes in steady state gene expression in 
S209A MEF cells (Furic et al., 2010). However, to reveal the global effect of S209A 
mutation on MNV pathogenesis, a gene expression profile during MNV infection or 
upon activation of type I IFN signallings is needed. MNV infection is known to inhibit 
cellular translation and uncouple transcription from translation (Emmott et al., 2017). 
Although whole cell proteomics changes during MNV infection has been reported 
before, it remains interesting to study the changes of mRNAs and newly synthesised 
proteins during MNV infection. 
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Chapter 5 
Replication control by the 
norovirus capsid shell domain 
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5.1 Background 
In the previous chapter, the role of eIF4E phosphorylation in regulating type I IFN 
responses during MNV infection was investigated. MNV pathogenesis in a mouse 
model with a phosphor-ablative mutation of eIF4E showed different observations 
compared with findings obtained from a previous in vitro study. These results suggest 
that eIF4E phosphorylation is likely to play multiple roles in norovirus pathogenesis. 
During virus replication, both host factors and viral factors are important for successful 
replication. Both HuNoV and MNV are known for the fast establishment of infection 
(Okhuysen et al., 1995, Gonzalez-Hernandez et al., 2014), which contribute to the 
rapid transmission during outbreaks. Avoiding host detection and subverting innate 
immune responses can contribute to this characteristic, but more likely this is due to 
efficient virus replication. Therefore, it would be important to understanding the 
molecular biology of norovirus replication. 
Norovirus encodes an RNA-dependent RNA polymerase (RdRp), which plays a central 
role during norovirus genome replication. The norovirus RdRp can initiate RNA 
synthesis in both primer-dependent and independent manners (Rohayem et al., 
2006b). The primer-dependent initiation utilises a viral protein VPg as a protein primer, 
whilst the de novo initiation of norovirus RdRp is primer-independent (Rohayem et al., 
2006a). The mechanistic details of how and when the norovirus RdRp switches 
between the two modes of initiation are unclear. In a cell-based assay, the norovirus 
RdRp activity was measured indirectly by ectopic expression of firefly luciferase under 
the control of IFN-β promoter, which was activated by retinoic acid-inducible gene I 
(RIG-I) sensing the production of double-strand RNA (dsRNA) replication 
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intermediates (Subba-Reddy et al., 2011). This assay, termed the NoV-5BR assay, 
showed genogroup-specific interactions between the norovirus RdRp and VPg, and 
that VPg can enhance the RdRp activity. The VPg-primed initiation of RNA synthesis 
in the NoV-5BR assay utilises cellular RNA as templates, while RNaseL processing is 
involved in sensing the VPg-linked RNA. In addition to VPg, other viral proteins also 
modulate the RdRp activity. NS1/2 (p48 in HuNoV) specifically promotes the HuNoV 
RdRp activity, whereas the effect of VP2 is inhibitory. The major capsid protein VP1 
showed the most significant enhancement on the RdRp activity. A following study 
showed that the capsid shell domain (SD) is necessary and sufficient for VP1 to interact 
with the RdRp and enhance the RdRp activity (Subba-Reddy et al., 2012). The 
biological relevance of this interaction was demonstrated by trans-complimenting the 
VP1 expression in an MNV replicon system to enhance viral genome replication, yet 
the importance of this interaction was not shown in an infectious virus system. 
Because in the latter NoV-5BR assay design, only VP1 was co-expressed with RdRp, 
thus the RNA synthesis is independent of VPg, it is thought that VP1 SD enhances the 
de novo initiation activity of RdRp. The function of this interaction in norovirus life cycle 
is unclear, but the dependence on a narrow range of VP1 concentrations suggests that 
it may be important at early stages of infection. After viral entry and uncoating, VP1 
from either incoming virions or the initial rounds of translation can stimulate the 
synthesis of negative-sense, genomic and subgenomic RNAs, coinciding with the most 
significant stimulatory effect at lower VP1 concentrations. The negative-sense RNAs 
then serve as the template for the synthesis of VPg-linked genomic and subgenomic 
RNAs. With the accelerated translation of VP1 from the subgenomic RNAs, the VP1-
VP1 interaction is preferred over the VP1-RdRp interaction, therefore the stimulatory 
effect on the RdRp is lost in favour of viral genome replication (Subba-Reddy et al., 
2012). The preferential synthesis of the negative-sense replication intermediate was 
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also demonstrated by studying temporal changes of genomic positive/genomic 
negative ratios during MNV infection using a strand specific real-time RT-qPCR 
(Vashist et al., 2012b). 
Both HuNoV and MNV SDs can only enhance their cognate RdRp activity. A 
subsequent mutagenesis study has mapped the domains of SD responsible for this 
species-selectivity to the flexible loops 1, 3, 5 and 7, which are all on one side of the 
capsid shell domain (Figure 5.1C). 
5.2 Aims 
The aims of this chapter were to understand the importance of temporal regulation of 
norovirus replication, the roles of VP1-RdRp interactions, and whether this functionally-
conserved interaction can be targeted for rational attenuation of norovirus.   
Based on the previous observations, the following hypotheses were proposed: 
1. Genogroup-specific residues on loops 1, 3, 5 and 7 of SD are responsible for the 
species-specific enhancement on the de novo initiation activity of the norovirus RdRp; 
2. Mutating these residues should affect the VP1-RdRp interaction, resulting in 
changes in the temporal regulation of norovirus genome replication. 
3. The altered norovirus genome replication should lead to a reduced norovirus 
pathogenesis in vivo. 
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Figure 5.1 Illustration of norovirus capsid shell domain. A) Genome organisation of MNV. 
Subdomains of VP1 and the relative positions of the SD flexible loops are indicated. B) Crystal structure 
of Norwalk virus capsid protein VP1 (PDB ID: 1IHM). This is adapted from (Prasad et al., 1999). C) A 
zoomed-in view of the highlighted region in B). The locations of flexible loops were indicated and the 
side chains of genogroup-specific residues were displayed. 
5.3 Results 
5.3.1 VP1-RdRp interaction is functionally conserved in 
norovirus 
To determine the sequence conservation of the odd-numbered flexible loops 1, 3, 5 
and 7, 509 GII.4 HuNoV and 91 MNV non-redundant VP1 amino acid sequences were 
analysed by ClustalOmega (Figure 5.2). The SD sequences were generally highly 
conserved separately in HuNoV and in MNV. This is consistent with the previously 
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published results (Chakravarty et al., 2005, Hutson et al., 2004, Cotten et al., 2014). 
Except for loop 7, loops 1, 3, and 5 are highly conserved between GII.4 HuNoVs and 
GV MNVs. Therefore, it is likely that the genogroup specificity for the norovirus SD to 
enhance the RdRp activity is conferred by these differing residues, as the chimeric 
MNV SD carrying HuNoV odd-numbered flexible loop sequences failed to enhance its 
cognate RdRp activity, and vice versa (Subba-Reddy et al., 2012). 
 
Figure 5.2 Sequence conservation of SD flexible loops. 509 GII.4 HuNoV and 91 MNV VP1 
sequences were aligned and the sequence conservation of the odd-numbered flexible loops of SD was 
demonstrated. 
5.3.2 Genogroup-specific residues are important for MNV 
replication 
The sequence conservation analysis indicate that the genogroup-specific residues are 
likely important for the specificity of VP1-RdRp interaction. It was then thought that 
swapping the residues of MNV SD with the corresponding HuNoV SD residues should 
negatively impact the VP1-RdRp interaction and allow the identification of functionally 
important domains. Combinations of HuNoV VP1 SD loop sequences were cloned into 
an infectious MNV-1 cDNA clone (GenBank accession number DQ285629.1) by 
overlap extension PCR. All mutant cDNA clones were verified by sequencing the VP1 
region. Chimeric MNVs were named after the according loop(s) replaced with GII.4 
HuNoV sequences (Table 5.1). For example, mutant L1 indicates the loop 1 of MNV 
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VP1 SD replaced by the loop 1 of GII.4 HuNoV VP1 SD, corresponding to a 
Threonine74 to Alanine mutation. Because the loop 3 is conserved between MNV and 
HuNoV (Figure 5.2), the mutant L1,5,7 represents a complete swap of the odd-number 
flexible loops. 
The production of infectious viruses was determined using an end-point titration assay 
(TCID50) following DNA-based reverse genetics (Figure 5.3A). The complete 
replacement of the flexible loops (mutant L1,5,7) was lethal for MNV replication (Figure 
5.3A). Two more passages were performed for the mutant L1,5,7. No infectious virus 
was detected using TCID50, nor was the viral genomic RNA detected using RT-PCR 
(data not shown), indicating mutant L1,5,7 is non-viable. While the virus yield of mutant 
L5,7 from recovery was under the detection limit, subsequent passage showed 
production of infectious virus (Figure 5.3B). These results showed that the mutated 
residues in loops 5 and 7 are important for MNV infectivity. 
All infectious chimeric MNVs were passaged twice more, then the VP1 and the RdRp 
regions were sequenced. Results showed no reversion of the mutated residues in VP1 
and no complimentary mutation in RdRp (data not shown). These results suggest that 
though some chimeric MNVs were attenuated in vitro, the mutations introduced are 
stable. 
Name Mutations (L1/L3/L5/L7) 
WT N/A 
L1 T74A 
L5 T153Q 
L7 T191A S193N P194A D196E E197D S198V V200T 
L1,5 T74A T153Q 
L5,7 T153Q T191A S193N P194A D196E E197D S198V V200T 
L1,7 T74A T191A S193N P194A D196E E197D S198V V200T 
L1,5,7 T74A T153Q T191A S193N P194A D196E E197D S198V V200T 
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Table 5.1 Chimeric MNVs and the corresponding mutations All the numbers correspond to VP1 from 
MNV-1 CW1 (GenBank accession number DQ285629.1). 
 
Figure 5.3 Recovery and propagation of chimeric MNV-1s. A) Virus yield of chimeric MNV-1s by 
DNA-based reverse genetics, where the active site of RdRp of mutant ΔRdRp was mutated to YGGG. 
The bottom panels showed the similar production of viral RdRp in all transfections and GAPDH was 
used as loading control. B) Passage of recovered chimeric MNVs. 250 μl of viruses from DNA-based 
reverse genetics were inoculated to BV-2 cells, virus yield was determined at 72 hpi. One-way ANOVA 
was performed using Dunnett test (* p<0.05, ** p<0.01, *** p<0.001). 
5.3.3 A point mutation in the SD reduces virus stability 
In addition to modulating the RdRp activity, the main known role of VP1 during the 
norovirus life cycle is encapsidation of viral genomic RNAs (Bertolotti-Ciarlet et al., 
2002). As the chimeric MNVs containing mutation in L5 were either attenuated or non-
viable (Figure 5.3), with the exception of L5, it was logical to access the capsid stability 
of these viruses. 
Capsid stability can be studied by assessing the infectivity of virus at high temperatures 
and the susceptibility of encapsidated viral RNA to degradation with RNase. Thermal 
inactivation conditions were determined based on previous literature and preliminary 
results (Arthur and Gibson, 2015). Replicative WT and chimeric MNVs (including 
mutant L5) were tested for thermal inactivation (Figure 5.4) and the results showed the 
mutant L5 lost significantly more infectivity and viral genomic RNA after heat treatment 
than did WT (-RNase groups in Figure 5.4). Together with RNase treatment (+RNase 
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group), no infectious mutant L5 was detected after 3 minutes thermal inactivation at 
60 ℃. This result clearly indicates that the VP1 T153Q mutation significantly increases 
the susceptibility of mutant L5 to thermal inactivation. Also, mutant L1 (T74A) showed 
slightly improved thermal stability compared to WT, demonstrating that the viral capsid 
is slightly more stable than the native virus. 
 
Figure 5.4 Thermal stability of chimeric MNV-1s. Similar amount of infectious MNVs were subjected 
to thermal inactivation (60 ℃ for 3 minutes) followed by RNase treatment (with or without 1 mg/ml 
RNaseA at 37 ℃  for 15 minutes). The reduction between initial and remaining A) infectivity was 
determined by TCID50, whilst B) genomic RNA changes were determined by RT-qPCR. One-way ANOVA 
was performed using Dunnett test (* p<0.05, ** p<0.01, *** p<0.001). 
5.3.4 Identification of domains important for MNV 
replication 
The replication kinetics of the various clones were assessed using a single-step growth 
kinetics analyses (Figure 5.5), The results showed the replication of mutant L5 was 
comparable to WT during the early stages of infection (Figure 5.5A and B). However, 
after 12 hours, a consistent 1 log10 difference of infectious titre compared to WT was 
observed, whilst the cellular vRNA of mutant L5 was comparable to that of WT MNV-
1. This observation indicates that mutant L5 is replication competent, but likely in the 
later stages of infection, the destabilised viral capsids result in faster decay of progeny 
viruses. 
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The mutants L1, L7 and L1,7 showed no clear defect in virion stability, however, the 
replication of all three mutants were significantly slower than that of WT (Figure 5.5). 
Generally, at the early stages of infection (6-12hpi), all three mutants showed 
significantly reduced infectivity (Figure 5.5A and C) and viral genomic RNA (Figure 
5.5B and D), indicating both the synthesis of infectious virus and the genome 
replication were impaired. These results suggest that the loops 1 and 7 are likely 
involved in the genogroup-specific enhancement of the norovirus RdRp activity at the 
early stages of MNV infection, when the de novo initiation of RdRp is needed to 
synthesise the negative-strand replication intermediate. 
 
Figure 5.5 In vitro growth kinetics of chimeric MNV-1s. BV-2 cells were infected by MNV-1 WT or 
mutants L1, L5, L7 or L1,7 (MOI = 5 TCID50/cell), where A) and C) showed virus yield at each time point, 
B) and D) showed cellular vRNA determined by RT-qPCR. Two-way ANOVA was performed for all 
analysis using Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
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5.3.5 Identification of domains important for VP1-RdRp 
interaction 
Based on the previous results, it was proposed that the mutations in loops 1 and 7 
reduced the enhancement on the RdRp activity via a decreased VP1-RdRp interaction. 
The norovirus VP1 can self-assemble into virus-like particles (VLP) when expressed, 
indicating a strong VP1-VP1 interaction (Bertolotti-Ciarlet et al., 2002, Tresset et al., 
2013b). Although the norovirus VP1 interacts with its cognate RdRp and modulates the 
RdRp activity, the interaction is relatively weak (Subba-Reddy et al., 2012). Therefore, 
a LUminescence-based Mammalian IntERactome (LUMIER) assay was introduced to 
measure the VP1-RdRp interaction and how it was affected by the VP1 mutations 
(Barrios-Rodiles et al., 2005). In LUMIER, renilla luciferase-fused “prey” and protein 
A-fused “bait” proteins are co-expressed and co-immunoprecipitated (co-IP) via 
protein A. The luciferase activity in the IP fraction indicate the strength of protein-
protein interactions between the prey and the bait proteins. LUMIER is designed to 
measure dynamic protein-protein interactions and to convey semi-quantitative data. In 
the preliminary survey of all viral protein-protein interactions of GI, GII and GV 
noroviruses, VP1-RdRp was observed as weak interactions (A. de Rougemont, 
unpublished data). Instead of LUMIER intensity ratio (LIR), a robust z-score was used 
to account for sample variations and represent qualitative measurement of VP1-RdRp 
interaction (Birmingham et al., 2009). 
For the purpose of high throughput screening, the WT and the mutant VP1 were 
amplified by PCR and sub-cloned into the Gateway entry clones by BP reactions, then 
the renilla luciferase (RL)- or the protein A-fused expression constructs were generated 
by LR reactions using entry clones. 293T cells were co-transfected with VP1 and a 
MNV RdRp constructs and the VP1-RdRp interaction was measured with VP1 being 
the prey or the bait protein. When VP1 was expressed as the prey protein (Figure 5.6A 
Replication control by the norovirus capsid shell domain 
Jia Lu 149 2017 
prey), L7, L1,7 and L1,5,7 VP1 had significantly reduced VP1-RdRp interactions. When 
VP1 was used as bait protein, L1, L7, L1,7 and L1,5,7 had significantly reduced VP1-
RdRp interactions (Figure 5.6A bait). The common presence of loop 7-containing VP1 
with reduced VP1-RdRp indicates possibly loop 7 is most important for mediating VP1-
RdRp interaction. 
To validate the LUMIER results, RL-fused VP1 was co-expressed with GFP-fused 
RdRp. Immunoprecipitation of the RdRp using anti-GFP antibody showed that VP1 can 
be co-IP with RdRp (Figure 5.6B VP1/RL of IP). Quantification of 3 independent 
repeats by densitometry of the VP1 protein in the co-IP fraction showed that the L7, 
L1,7 and L1,5,7 VP1 significantly reduced the VP1-RdRp interaction (Figure 5.6C). 
While L1 VP1 had reduced VP1-RdRp interaction the results are not statistically 
significant. Except for L1,5,7 VP1 (non-viable), these mutants were previously shown 
to replicate slower in vitro (Figure 5.5). Together, the mutations in loops 1 and 7 reduce 
the VP1-RdRp interaction in vitro. 
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Figure 5.6 Characterisation of VP1-RdRp interaction. A) VP1-RdRp interaction measured by 
LUMIER. The WT and chimeric MNV VP1s were co-expressed with the MNV RdRp in 293T cells, the 
RL-fused prey proteins were co-immunoprecipitated with the protein A-fused bait proteins. Luciferase 
activity in the IP fraction was measured and robust z-score was used to represent the strength of 
interaction. B) The RL-fused VP1 (WT and chimeras) were co-expressed with GFP-fused MNV RdRp. 
Immunoprecipitation of GFP-RdRp pulled down RL-VP1 differentially. C) Densitometry of co-
immunoprecipitated VP1 relative to WT, both normalised to input. The results showed mean±SEM of 
three independent experiments. One-way ANOVA was performed with Dunnett test (* p<0.05, ** p<0.01, 
*** p<0.001). LUMIER assay was performed by A. de Rougemont. 
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5.3.6 SD stimulates de novo initiation activity of RdRp 
A previously published RNA synthesis assay was used to measure de novo initiation 
activity of MNV RdRp, Figure 1.8B and (Yunus et al., 2015, Lin et al., 2015). The 
purified MNV RdRp was incubated with MNV RNA proscript to synthesise the 
beginning of positive-sense, subgenomic RNA. The MNV RNA proscript (promoter + 
transcript) consists of the subgenomic promoter on the negative-sense genomic RNA, 
the antisense sequence of the first 8 nucleotides (nt) of MNV subgenomic RNA and 3 
nonviral nucleotides (GCG) at the 5’ termini to allow incorporation of [α-32P]CTP. 
Through recognising the stem-loop of subgenomic promoter MNV RdRp initiate RNA 
synthesis de novo with defined product length (11nt). In addition to the de novo 
initiation product, a primer-extension product can be observed as incorporation of [α-
32P]CTP to the RNA template. 
To test whether the MNV SD can enhance the de novo initiation activity of the MNV 
RdRp, MNV-1 shell domain (SD) was cloned into a pTriEx1.1 backbone, expressed in 
bacteria and purified to >95% purity (data not shown). In Figure 5.7A, without SD (SD 
= 0) MNV RdRp can generate RNA products through primer extension (PE) and de 
novo initiation (DN). With low SD ratios (0, 1 and 2), the addition of purified MNV SD 
(WT or mutants) had little impact on DN:PE ratios (normalised DN in Figure 5.7B). As 
more SD was added, more DN products as well as higher DN:PE ratio were observed. 
These results suggest that MNV SD is sufficient to enhance the de novo initiation 
activity of MNV RdRp. Addition of L1,7 SD increased normalised SD, yet the 
enhancement was significantly less compared to the effect of WT SD. This observation 
suggests that the loops 1 and 7 were involved in modulating de novo initiation activity 
of MNV RdRp, and the mutations in L1,7 likely account for the species specificity. 
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Figure 5.7 Stimulation of RdRp by SD. A) The MNV RdRp was incubated with the purified WT or L1,7 
SD with different molar ratios to the MNV RdRp. After reaction, samples were separately by urea-
polyacrylamide gel. The RNA synthesis products were visualised by phosphoimager and were quantified 
by ImageQuant software. B) Quantification results from two independent experiments. The de novo 
initiation products were normalised to primer extension products, then were represented as the fold of 
normalised DN product without SD (SD of 0). Statistical analysis was performed using Excel t-test (* 
p<0.05, ** p<0.01, *** p<0.001). RNA synthesis assay was performed by Xiaoyan Lin (Indiana University). 
5.3.7 Recovery of chimeric MNV-3s 
Our previous observations demonstrated that the SD is important for both viral capsid 
stability and regulating the RdRp activity (Subba-Reddy et al., 2012). The mutant L5 
possesses less capsid stability, and it can be used to determine the impact of capsid 
stability on norovirus pathogenesis. Because VP1-RdRp interaction is conserved 
between HuNoV and MNV, it was used as a model system to study how norovirus 
pathogenesis would be impacted if the temporal regulation of replication was disturbed. 
Potentially, this can be exploited to generate an attenuated virus antigenically similar 
to the native virus. 
Because the coding region of the MNV SD also overlaps that of the MNV VF1 
(McFadden et al., 2011), the mutations in SD also affect VF1 protein sequences. In 
addition, it was shown that VF1 is not required for MNV replication in vitro and a VF1 
knock-out mutant showed attenuated replication in vivo (McFadden et al., 2011). In 
order to study the impact of chimeric SD in norovirus pathogenesis, the homologous 
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mutations were generated in an MNV-3 VF1 knock-out backbone (MNV-3VF1-). A 
previous in vivo characterisation showed that MNV-3VF1- is replication-competent in 
vitro. The VF1 mutations remain stable in vivo but the MNV pathogenesis is attenuated. 
The following mutations were cloned into the MNV-3VF1- backbone: L1, L5, L7 and L1,7, 
all of which are replication competent in MNV-1 (Figure 5.3). MNV-3VF1- recovered with 
similar titre to MNV-3 WT, as did mutant MNV-3VF1- L5 (Figure 5.8A). However, MNV-
3VF1- L1 showed defect in replication, whilst no observable CPE was seen in cells 
infected by mutants MNV-3VF1- L7 or MNV-3VF1- L1,7. To determine the infectivity of 
the loop 7 mutants, all the viruses were passaged once then titrated using a TCID50 
assay and also antigen staining (Figure 5.8B). TCID50 by antigen was carried out the 
same as TCID50 by CPE, only that after incubation immunofluorescent microscopy was 
used for detecting expression of NS3, one of the signatures of MNV infection. Similar 
differences in titre between CPE- and antigen-based TCID50 in WT and MNV-3VF1-, 
MNV-3VF1- L1, MNV-3VF1- L5, TCID50 of mutants MNV-3VF1- L7 and MNV-3VF1- L1,7 
were readily determined by NS3, indicating these mutants are infectious. 
 
Figure 5.8 Recovery and titration of chimeric MNV-3s. A) DNA-based recovery of chimeric MNV-3s. 
Chimeric MNV-3s were recovered using previously published protocols and the virus yields were 
determined by TCID50 (Chaudhry et al., 2007). Transfection efficiency was determined by measuring 
RdRp expression in total cell lysates. GAPDH was used as loading control. One-way ANOVA was 
performed using Dunnett test (* p<0.05, ** p<0.01, *** p<0.001). B) Titration of chimeric MNV-3s. 
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Chimeric MNV-3s from recovery were propagated in BV-2. The P1 virus was titrated using standard 
TCID50 protocol (Hwang et al., 2014). The same virus stocks were titrated and stained for viral antigen 
NS3 and visualised by immunofluorescent microscopy. TCID50 by antigen were calculated the same way 
as TCID50 by CPE. 
5.3.8 MNV-3VF1- L1,7 is infectious but attenuated in vitro 
Following titration, chimeric MNV-3s were characterised in vitro (Figure 5.9). To confirm 
that the mutant MNV-3VF1- L1,7 is infectious, based on TCID50 by antigen, Raw264.7 
cells were infected at an MOI of 0.5 TCID50 per cell for 12 hours. Infection markers 
(dsRNA and NS3) indicated the presence of infected cells in MNV-3VF1- L1,7 (Figure 
5.9A). Between different viruses, similar number of infected cells indicated that the 
MNV-3VF1- L1,7 is capable of establishing infection. 
The thermal inactivation and a multistep in vitro replication kinetics analysis were used 
to determine the virion stability and the replication capacity of chimeric MNV-3s, 
respectively. Heat inactivation reduced more viral RNA in the mutant MNV-3VF1- L5 
(Figure 5.9B), indicating the MNV-3VF1- L5 is more susceptible to inactivation 
compared with the parental MNV-3VF1-, despite that the magnitude of reduction is less 
than what was observed in MNV-1 L5 (Figure 5.4B). These results indicated that the 
same phenotype is observed in two MNVs. 
In a multistep growth curve (Figure 5.9C), BV-2 cells were infected by the chimeric 
MNV-3s (MOI 0.01 TCID50/cell) and the viral genomic RNA in infected cells was 
determined by RT-qPCR. Mutant MNV-3VF1- L5 showed comparable replication 
kinetics as MNV-3VF1-. While increased at 12hpi, vRNA of mutant MNV-3VF1- L1,7 
remained significantly less than that of MNV-3VF1- throughout the course of infection. 
Together, the reduced thermal stability of the mutant MNV-3VF1- L5 and the attenuated 
in vitro replication of the mutant MNV-3VF1- L1,7 suggested that the phenotypes 
observed in chimeric MNV-1s are reproducible in MNV-3. 
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Figure 5.9 In vitro characterisation of chimeric MNV-3s. A) Validation of TCID50 by antigen. Raw264.7 
cells were infected by MNV-3s (MOI=0.5 TCID50/cell) for 12 hours. The cells were fixed, permeabilised 
and stained with infection markers (dsRNA and NS3). DAPI was used to stain the nuclei. Infected 
Raw264.7 cells displayed co-localisation of dsRNA and NS3 staining at perinuclear foci. B) Thermal 
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stability of MNV-3s. Virus suspension was heated at 60 ℃ for 3 minutes, followed by incubation at 37 ℃ 
for 15 minutes, with or without RNase. Total RNA was then determined by RT-qPCR and compared with 
unprocessed virus stocks. One-way ANOVA was performed with Dunnett test (* p<0.05, ** p<0.01, *** 
p<0.001). C) In vitro replication kinetics of chimeric MNV-3s. BV-2 cells were infected with chimeric MNV-
3s at MOI=0.01 TCID50 per cell and total cellular RNA was extracted at indicated time post infection. 
MNV vRNA in infected cells were determined by RT-qPCR. Two-way ANOVA was performed with 
Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
5.3.9 VP1-RdRp interaction is important for MNV 
pathogenesis 
In order to determine whether the chimeric MNV-3s were attenuated in vivo, 5-week 
old C57BL6/J mice were orally challenged with 10000 TCID50 of MNV-3 WT, MNV-
3VF1-, MNV-3VF1- L5 and MNV-3VF1- L1,7. MNV-3 WT was replication competent, 
indicated by significantly higher faecal shedding of vRNA during both acute and 
persistent infections (Figure 5.10A). Compared with MNV-3 WT, both MNV-3VF1- and 
MNV-3VF1- L5 displayed reduced faecal shedding, suggesting both viruses are 
attenuated. At 8 weeks post primary challenge (56 dpi), vRNA was just detectable in 
faeces of mice infected with MNV-3VF1- and MNV-3VF1- L5. The faecal vRNA of mice 
infected with the mutant MNV-3VF1- L5 was slightly less than that of MNV-3VF1- during 
acute infection, but the difference was not statistically significant. For MNV-3VF1- L1,7, 
faecal shedding was only observed on Day 1 post challenge, indicating MNV-3VF1- L1,7 
is replication deficient in vivo. In agreement with other previous studies (Perdue et al., 
2007, Arias et al., 2012, Zhu et al., 2013), no clear impact on body weight changes 
upon MNV-3 infections was observed throughout the course of infection (Figure 5.10B). 
Induction of adaptive immune response was measured by serum IgG against MNV 
capsid proteins (Figure 5.10C). Over the course of 8 weeks significant production of 
MNV-specific serum IgG was observed in MNV-3-infected mice, which are more robust 
than in attenuated MNV-3VF1--infected mice. In the previous chapter (Figure 4.7A and 
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C), it was shown that in MNV-3 pathogenesis the induction of mucosal immunity 
correlated with virus replication, i.e. better virus replication induced quicker adaptive 
immune response. However, the correlation was not observed when comparing MNV-
3VF1- and MNV-3VF1- L5. During the acute infection (before 7dpi) the faecal shedding 
of MNV-3VF1- L5 remained less than that of MNV-3VF1-, whist in MNV-3VF1- L5 the 
serum IgG against MNV capsid remained slightly more than that of MNV-3VF1-. This 
trend was observable until 8 weeks post infection. Although the mutant MNV-3VF1- L1,7 
is infectious in vitro, no significant increase of MNV-specific serum IgG was observed 
in the 8-week period. 
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Figure 5.10 In vivo replication of chimeric MNV-3s. 5-week old C57BL6/J mice were mock infected 
or infected with MNV-3s, and A) faecal vRNA, B) body weight changes relative to pre-infection, and C) 
production of MNV-specific serum IgG were determined. Two-way ANOVA was performed with 
Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
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5.3.10 Infection of MNV provides partial protection against 
re-challenge 
To determine if any protection against re-infection was generated upon the initial 
challenge of live attenuated or replication-deficient chimeric MNV-3s, these mice were 
re-challenged with a low dose (1000 TCID50) of MNV-3 WT 8 weeks after primary 
challenge. This is sufficient to establish robust infection during primary challenge 
(Figure 4.6 and (Arias et al., 2012)). Prior to challenge, except for mice primarily 
infected with MNV-3, faecal shedding was barely detectable in other groups. 
On 3 days post re-challenge (Figure 5.11A day 3), compared with the primary infection 
(mock-infected mice challenged with MNV-3), primary challenge with replication-
competent MNV-3 and attenuated MNV-3VF1- significantly reduced faecal shedding, 
indicating that a primary challenge with MNV reduces virus replication upon re-
challenge with a homotypic (primary challenge with MNV-3) or a heterotypic virus 
(primary challenge with MNV-3VF1-). Mice previously infected with MNV-3VF1- L5 
showed reduced faecal shedding on day 3 post infection compared with mock-infected 
mice, but the difference is not statistically significant. A primary infection with the MNV-
3VF1- L1,7 or the MNV-UV did not reduce faecal shedding upon re-infeciton, indicating 
that no protection is generated during primary challenge. 
In all groups the re-challenge with MNV-3 established persistent infections (Figure 
5.11A day 21). Only the faecal shedding of the MNV-3 group was statistically 
significantly less than mock, but there was no significant difference between different 
groups, indicating that although primary challenge with MNV-3 or MNV-3VF1-
significantly reduced faecal shedding during acute infection, the partial protection 
cannot prevent MNV-3 from establishing persistent infection. 
The primary challenge with MNV-3, MNV-3VF1- and MNV-3VF1- L5 induced robust 
serum IgG against MNV prior to re-challenge (Figure 5.10C). One week post re-
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challenge (Figure 5.11B week 1), the serum IgG of the MNV-3VF1- group remained 
significantly lower than that of the MNV-3 group, whilst an addition a single amino acid 
mutation (MNV-3VF1- L5) showed a comparable serum IgG to MNV-3. Upon 3 weeks 
post re-challenge, serum IgG of these three groups was indistinguishable. Together 
with Figure 5.11A, primary challenge of MNV-3VF1- L5 partially reduced acute phase 
faecal shedding upon MNV-3 re-challenge, paralleled with comparable production of 
MNV-specific serum IgG, despite attenuated pathogenesis. 
MNV-specific serum IgG of mock, MNV-3VF1- L1,7 and MNV-UV groups were 
significantly lower than MNV-3 one week post re-challenge, suggesting no adaptive 
immunity activation upon primary challenge with MNV-3VF1-L1,7 or MNV-UV. 3 weeks 
post re-challenge induced significant production of MNV-specific serum IgG in the 
same mice, indicating these mice were capable of responding to MNV infection, and 
that mutant MNV-3VF1- L1,7 was likely replication defective in vivo, highlighting the 
importance of temporal regulation of norovirus genome replication by VP1-RdRp 
interaction and it subsequent impact on norovirus pathogenesis. 
 
Figure 5.11 Partial protection by primary challenge with MNV. A) Faecal shedding during acute (day 
3) and persistent (day 21) phases upon re-challenge. Mice initially mock infected or infected with MNV-
3, MNV-3VF1-, MNV-3VF1- L5, MNV-3VF1- L1,7 or MNV-UV were re-challenged with MNV-3. Faecal vRNA 
on day 3 and 21 post infection were determined by RT-qPCR. Two-way ANOVA was performed with 
Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). B) Induction of MNV-specific serum IgG upon MNV-3 
re-challenge. On day 7 (week 1) and day 21 (week 3) post re-challenge as described in A), serum was 
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taken from mice and ELISA against MNV-3 VLP was used to determine MNV-specific serum IgG. Two-
way ANOVA was performed with Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). 
5.3.11 Recovery of infectious GII.4 HuNoV with 
homologous SD mutations 
The importance of the VP1-RdRp interaction in regulating norovirus replication and 
pathogenesis inspired the exploration of attenuating HuNoV replication by mutating the 
corresponding domains in the HuNoV capsid shell domain. With the successful 
development of HuNoV cell culture system and our primary demonstration of 
recovering infectious HuNoV from a GII.4 full length cDNA clone ((Ettayebi et al., 2016) 
and Figure 3.7E), it was logical to determine if chimeric HuNoV carrying mutations 
important for species-specific recognition of VP1-RdRp interaction can be recovered. 
Although both loops 1 and 7 modulate the RdRp activity, the loop 7 contains more 
genogroup-specific residues than does loop 1 (Table 5.1) and results from both MNV-
1 and MNV-3 showed that MNV replication was impacted by more significantly by the 
L7 mutations. Therefore, chimeric GII.4 HuNoV L7 (referred as HuNoV L7 thereafter) 
was generated by replacing according residues with those of MNV. DNA-based reverse 
genetics was then used to recover infectious HuNoV. Western blot analysis (Figure 
5.12A) indicated the production of viral protein VPg and its precursors. As expression 
of viral proteins in DNA-mediated reverse genetics was mainly driven by FPV-T7, these 
results only indicate similar transfection efficiency between different cDNA clones. Also, 
a polymerase mutant F/S showed similar VPg expression as that of GII.4. 
It was proposed that reverse genetics generated encapsidated HuNoV RNA, and 
infectious HuNoV should show more nuclease resistance than a non-infectious virus. 
Upon treatment with benzonase (Figure 5.12B), viral RNA was reduced. However, 
similar reduction was observed between infectious (GII.4) and non-infectious (F/S) 
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HuNoVs. These results indicate that in the current experiment set up, it is unclear 
whether the HuNoV L7 is infectious or not. 
The recovered HuNoV was also used to infect differentiated duodenal organoids D196. 
In agreement with previous results (Figure 3.7), infection from recovered virus did not 
lead to obvious replication (Figure 5.12C). Due to the limiting availability, the slow 
replication cycle (doubling time 6-7 days) and complexity in culturing primary intestinal 
organoids, a subsequent passage of HuNoV L7 cannot be performed. Follow-up 
biochemical and in vitro characterisations are required to determine if the HuNoV L7 is 
infectious and whether HuNoV replication is impacted. 
 
Figure 5.12 Recovery of chimeric GII.4 HuNoV. A) Recovery of GII.4 HuNoV by reverse genetics. 
BSR-T7 cells were infected with FPV-T7, followed by transfection of HuNoV cDNA clones of full length 
(GII.4), polymerase frameshift mutant (F/S), and mutant L7 (L7). Total cell lysates were harvested and 
production of viral protein VPg was assayed by western blot. * indicates mature or precursor forms of 
VPg. GAPDH was used as loading control. B) Nuclease treatment of HuNoV. Cell lysates containing 
HuNoV cDNA plasmids and potentially HuNoV were treated with recombinant bensonase at 37 ℃ for 
2 hours and net HuNoV vRNA was determined by RT-qPCR. Two-way ANOVA was performed with 
Bonferroni test (* p<0.05, ** p<0.01, *** p<0.001). C) Primary infection of HuNoV in primary differentiated 
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duodenal organoids D196. Nuclease-digested GII.4, F/S and L7 were inoculated to differentiated 
organoids D196. Viral RNA of days 0 and 3 post infection were determined by RT-qPCR. Fold of increase 
was calculated by dividing total vRNA on day 3 over that on day 0. Mean fold of increase were 
represented above each sample. 
5.4 Discussion 
5.4.1 The multifunctional norovirus capsid shell domain 
A previous characterisation of the norovirus VP1-RdRp interaction suggested that the 
specificity was conferred by the genogroup-specific residues in the VP1 shell domain. 
The limited sequence variations also means a loss-of-function approach can be 
applied to identify the residues important for this interaction. In this chapter, the 
functional importance of the norovirus SD in regulating norovirus replication was 
investigated under the context of biochemical characterisation and virus infection using 
MNV as the model system.  
Different combinations of MNV SD flexible loop sequences were replaced by HuNoV 
sequences, and the importance of these domains was demonstrated by the 
observation that completely replacing the genogroup-specific residues abolishes MNV 
replication in vitro (Figure 5.3A). Subsequent characterisations identified a residue 
important for virus thermal stability in solution (Threonine 153) and domains important 
for VP1-RdRp interaction and regulation of genome replication (loops 1 and 7). The 
combination of mutations with different phenotypes resulted in additive effect in this 
end point assay. Mutants with single phenotype (L1, L5, L7 or L1,7) showed no defect 
in virus yield, but combinations of mutations in loop 5 and loops 1 or 7 generate 
attenuated viruses (L1,5 or L5,7), supporting the multiple roles of SD in norovirus life 
cycle. 
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5.4.2 Other domains important for VP1-RdRp interaction 
Shell domains from both HuNoV and MNV bind their cognate RdRps and regulate 
genome replication by modulating RdRp activity (Subba-Reddy et al., 2012). Norovirus 
RdRp can initiate RNA synthesis by both VPg-primed and de novo initiation, it is 
possible that the binding of VP1 to RdRp promotes the conformation favouring de novo 
initiation. 
Our study showed that the chimeric MNVs with mutated loops 1 and 7 reduce the 
enhancement of de novo activity of RdRp by reducing VP1-RdRp interaction (Figure 
5.6 and 5.7). This is likely to occur through the non-optimal VP1-RdRp interactions. It 
also suggests that in addition to the genogroup-specific residues, there could be more 
residues or domains important for VP1-RdRp interaction. This is because with both 
loops 1 and 7 mutated to HuNoV sequences, the MNV VP1 can still bind the MNV 
RdRp (Figure 5.6B) and enhance RdRp activity (Figure 5.7). The retention of the VP1-
RdRp interaction under this condition can be due to other highly conserved domains 
between the HuNoV- and MNV SD. For example, loop 3 is conserved between HuNoV 
and MNV (Figure 5.2 and Table 5.1) and is conserved among all noroviruses (data not 
shown), suggesting that this domain is evolutionarily conserved and can be crucial for 
norovirus replication. In a high-resolution functional profiling of the MNV genome, 
except for loop 7, loops 1, 3 and 5 cannot tolerate any insertions beyond P1 ((Thorne 
et al., 2012), supplementary). This result suggests that loops 1, 3 and 5 are all 
important for norovirus replication, whereas insertional tolerance of loop 7 may enable 
co-evolution of shell domain with RdRp without significant fitness cost. 
5.4.3 Characterisation of chimeric MNV-3s 
The impact on virus thermal stability and replication by SD mutations were observed 
in both acute (MNV-1) and persistent (MNV-3) chimeric MNVs. However, there are 
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variations between MNV-1 and MNV-3. For example, mutant L7 or L1,7 showed no 
defect in recovery in MNV-1 but failed to generate CPE in chimeric MNV-3VF1-s (Figure 
5.3A and 5.8A), indicating that the same mutations MNV-3 is more detrimental for virus 
replication in MNV-3. In addition, MNV-3VF1- L5 showed less reduction in infectivity 
when heated than did MNV-1 L5 (Figure 5.4 and 5.9B), indicating that the mutant MNV-
3VF1- L5 is more resistant to heat inactivation. Such differences suggest that though 
MNV-1 and MNV-3 are genetically similar, the impact of homologous mutations can 
result in variable outcomes. 
Although VF1 is nonessential for in vitro replication of MNV-1 and MNV-3, both MNV-
1VF1- and MNV-3VF1- showed reduced virulence and pathology in vivo (McFadden et 
al., 2011). In this study, VF1 expression is retained in the chimeric MNV-1s, whilst 
chimeric MNV-3s were produced in the MNV-3VF1-backbone to exclude the impact of 
VF1 mutation. VF1 shares the coding region with SD in MNV with a different reading 
frame, and it was not possible to introduce the studied SD mutations without changing 
the VF1 coding sequence. The current experimental set up cannot exclude the 
possibility that the mutated VF1 in chimeric MNV-1s contribute to the variations of the 
phenotypes, or the lack of VF1 expression affects the attenuation of chimeric MNV-3s. 
Despite this, MNV-3VF1- was used as the backbone for generating chimeric MNV-3s, 
because this mutant virus is replication competent in vitro. MNV-3VF1- causes 
persistent infection in immunocompetent mice, allowing us to test if the additional SD 
mutations result in additive effects, and whether the combination of mutations can 
result in clearance of persistent infection or can generate protective immune response 
against homotypic re-challenge. 
In vivo characterisation showed no further attenuation in MNV-3VF1- L5 compared to 
the already attenuated MNV-3VF1-, indicating the marginal impact of the T153A 
mutation on virus replication or the induction of mucosal immunity against MNV 
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infection. The observation that mutant MNV-3VF1- L5 still causes persistent infection in 
immunocompetent mice suggested that an acute strain MNV should be used in order 
to prevent persistence. 
5.4.4 Host and viral correlates of norovirus persistence 
MNV is an important model system to study host cell-virus interactions, as through 
different combinations of virus and mouse strain, outcome of infections can be lethal 
or asymptomatic, acute or persistent (Karst et al., 2003, Hsu et al., 2006, Smith et al., 
2012). Using MNV as a model system, both host and viral correlates of persistence 
have been identified. For host correlates, the lack of type I interferon receptor in 
dendritic cells enables an acute MNV to persist systemically (Nice et al., 2016). The 
recent discovery of the role of type III interferon pathways in MNV pathogenesis 
suggests that IFNλ  response in intestinal epithelial cells and gut microbiota are 
important for clearing persistent MNV infections (Baldridge et al., 2017, Baldridge et 
al., 2015, Nice et al., 2015). Viral correlates also contribute to persistence. For example, 
a residue in NS1-2 can affect viral tropism and is sufficient for an acute MNV to cause 
persistent infection (Nice et al., 2013). Compared to MNV-1 which causes acute 
infection, MNV-3 is less virulent but induces stronger mucosal immune response, and 
VP2 of MNV-3 antagonises antigen presentation of B cells, resulting in impaired control 
of acute infection (Zhu et al., 2013, Zhu et al., 2016). 
From our study, primary challenge of MNV-3 WT induces high level of MNV-specific 
serum IgG in immunocompetent mice, paralleled with reduced faecal shedding in re-
challenge study (Figure 5.10C and 5.11B). These results indicate that pre-existing 
mucosal immunity provides partial protection against norovirus infection, which agrees 
with previously published data (Liu et al., 2009). Despite this, persistent infections were 
established, indicating serum IgG is not a host correlate of persistence. Also, 
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attenuated MNV-3VF1-can persistently infect immunocompetent mice, indicating that 
neither is MNV-3VF1- a viral correlate of persistence. 
5.4.5 Recovery of chimeric HuNoV 
MNV-3VF1- L1,7 is not only non-cytopathic in vitro but also replication defective in vivo, 
highlighting the crucial role of the temporal regulation of norovirus genome replication. 
The results of the MNV studies, along with the functional conservation of the norovirus 
VP1-RdRp interaction, led to the attempts to recover chimeric GII.4 HuNoV L7. Our 
initial characterisation showed successful production of viral protein VPg, while the 
infection of the primary intestinal organoids showed increases in viral RNA over time 
(Figure 5.12C). However, more evidence is needed to confirm the recovery of 
infectious HuNoV. Also, it remains to be determined whether the VP1-RdRp interaction 
is impacted by the L7 mutations in HuNoV, and whether L7 SD can reduce the 
enhancement on de novo initiation activity of a HuNoV RdRp. In the long term, it will 
be interesting to determine if HuNoV L7 is attenuated and whether this can be applied 
in norovirus vaccine design. 
5.4.6 VP1-RdRp compatibility in norovirus evolution 
The importance of VP1-RdRp interaction in regulating norovirus replication suggests 
that the VP1-RdRp compatibility may be important during recombination of human 
norovirus. A recent bioinformatic study investigated the evolution of VP1 and RdRp of 
GII.2 HuNoV (Mizukoshi et al., 2017), demonstrating that the evolution of norovirus 
VP1 and RdRp are similar. This supports the hypothesis that the norovirus VP1 and 
RdRp may co-evolve. The recombinations of norovirus genome usually occur at the 
ORF1/ORF2 junction through hybridisation at this highly conserved region (Bull et al., 
2005). This may contribute to the emergence of new variants (Eden et al., 2013). The 
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functional compatibility requirement between the RdRp from ORF1 and the VP1 from 
ORF2 may therefore affect norovirus evolution by selecting only the variants with the 
compatible VP1 and RdRp pairs. It remains to determine whether the identified 
residues here show evidence of positive selection in HuNoV evolution. 
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6.1 Cell culture systems for HuNoV 
Viral gastroenteritis is a significant global cause of morbidity and mortality. Since the 
development of the rotavirus vaccine, norovirus has become the leading cause of 
gastroenteritis worldwide (Tam et al., 2012). In developed countries the main impact is 
an economic burden when outbreaks result in elevated healthcare costs and loss of 
productivity, with risks of severe outcomes in the young, the elderly and and the 
immunocompromised (Hall et al., 2013). In developing countries, where clean water 
supplies are limited, norovirus infection has a particularly higher risk of global mortality, 
though due to a lack of surveillance the morbidity rate in these countries is likely 
underestimated. The global impact of norovirus infections highlights the urgent need 
of antiviral interventions and vaccine development. The highly infectious nature of viral 
particles, fast onset of symptoms, prolonged faecal shedding in both symptomatic and 
asymptomatic infections, fast evolution by antigenic drift and recombination, and a lack 
of lasting immunity all contribute to the rapid and wide spread of the virus. In spite of 
this knowledge, details of some of the most basic aspects of norovirus life cycle are 
not known due to the inability to cultivate this important pathogen in cell culture. As 
such, the main goal of this project was to identify host and viral factors important for 
norovirus replication, and to provide information for rational attenuation of norovirus to 
permit better study of the virus in cell culture. 
The first part of the thesis focused on the development of a cell culture system for 
HuNoV. To this aim HuNoV replication was examined in a range of cell lines (Table 6.1), 
and our observations, together with previous unsuccessful attempts to cultivate HuNoV, 
provide insight into factors that restrict HuNoV replication in vitro. The results showed 
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HuNoV likely binds to most of the cell lines tested, as HuNoV RNA can be readily 
detected after inoculation. The bound RNA remained associated with cells and does 
not decrease significantly over the course of infection, suggesting that the purified 
HuNoV stocks likely contain encapsidated HuNoV RNA that is resistant to 
environmental degradation. However, the lack of HuNOV replication in these cells 
indicate that HuNoV likely associate with the attachment factor rather than a receptor, 
as indeed we would expect to see reduction of surface bound RNA as the virus 
internalises during the entry process. In BJAB cells (Jones et al., 2015), we observed 
that HuNoV replication in BJABs is highly variable. Stable expression of FUT2 likely 
increases levels of H antigen on cell surface, and significantly increases entry of 
HuNoV pseudovirus particle into BJABs, suggesting that in this system insufficient cell 
surface expressed HBGA could be a limiting factor, supporting previous observations 
that enteric bacteria or HBGA enhances HuNoV replication in BJAB ((Jones et al., 2014) 
and unpublished data from L. Meredith). It will be interesting to determine if over 
expression of FUT2 can functionally replace HBGA or E. cloacae in B-cell culture of 
HuNoV. Also, there are ongoing efforts in the groups aiming to identify the 
proteinaceous receptor of HuNoV, as preliminary results and previous reports indicate 
viral entry is impaired by protease treatment of the target cells, including BJAB. 
Type I IFNs are potent inhibitors of norovirus RNA replication, as shown in Norwalk 
virus RNA replicon systems, and in MNV infection (Chang and George, 2007, 
Changotra et al., 2009). Therefore, it was proposed that inhibiting innate immune 
response could promote low-level HuNoV replication. However, BVDV NPro 
expression had no positive effect on HuNoV replication in transduced cells, contrary to 
this hypothesis, replication of HuNoV in intestinal organoids can be enhanced by 
ruxolitinib, a JAK/STAT pathway inhibitor (M. Hosmillo, unpublished data), suggesting 
an antiviral role of JAK/STAT pathways in restricting HuNoV replication. Both type I and 
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type III IFN responses depend on JAK/STAT signalling pathways. Compared to type I 
IFN responses, type III IFN responses has been shown to be more important for 
mediating antiviral responses in epithelial cells (Pott et al., 2011, Hernandez et al., 
2015). Therefore, the interactions between type III IFN responses and HuNoV 
replication should be further investigated using intestinal organoids as a model system, 
as these more closely represent physiological conditions compared with cell lines. 
For the first time, this project demonstrated recovery of infectious HuNoV from a 
culture-based system. This was accomplished both by FPV-mediated DNA reverse 
genetics of HuNoV and from intestinal organoids in culture. Previously reported 
reverse genetic systems indirectly determined infectivity by detecting encapsidated 
viral RNA and observing viral particles (Asanaka et al., 2005, Katayama et al., 2014). 
HuNoV recovered using our reverse genetic system (RGS) showed virus replication in 
intestinal organoids, and importantly, progeny virus from primary infection could 
subsequently be propagated in culture, leading to more robust replication than 
observed in the published data (more than 2000 fold compared with 1.5 to 2.5 log10 
increase, (Ettayebi et al., 2016)). While different viruses and cell types may contribute 
to the observed enhancement, the results show the potential of recovering replication-
competent HuNoV from our reverse genetic system, and also provides the capacity to 
manipulate and recover genetically-defined HuNoV using standard molecular 
techniques. Cell culture-based recovery of HuNoV also prevents the introduction of 
potentially inhibitory contaminants from faecal samples, which may also contribute to 
the enhanced replication. 
Despite the exciting findings in the initial experiments, the RGS-intestinal organoids 
can be improved in the following ways. A robust method is needed to consistently 
maintain and differentiate intestinal organoids. Early experiments showed the 
challenges of differentiating a sufficient enterocyte population from proliferating 
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organoids. Variations in some non-commercial components of the cell culture media 
also indicates the importance of developing a routine quality control protocol for 
differentiation. Studies have shown intestinal organoids can be directed to differentiate 
into enterocytes (van der Flier and Clevers, 2009), which can be applied to potentially 
produce more susceptible cells for infection. In addition, more direct evidence is 
needed to validate the reverse genetic system in both organoids and cell culture, 
including detection of viral proteins and negative-sense replication intermediates in the 
cells, and visualisation and characterisation of released of progeny particles by 
electron microscopy. A standardised titration assay is also needed to quantitatively 
determine the infectivity of HuNoV, such as a plaque- or focus-forming assay or a 
TCID50 protocol. Current methods rely on detection of viral RNA and a RT-qPCR-based 
titration assay has been developed (Ettayebi et al., 2016). However, due to the 
complex nature of maintaining intestinal organoids traditional plate-based TCID50 
assays cannot be directly adopted. Possibly an infectious centre assay can be 
developed or adapted to quantify infectious HuNoV (Dutta and Myrup, 1983). However, 
all these issues, along with the limited availability of primary intestinal organoids 
highlights the need to identify cellular factors important for HuNoV replication to 
establish a robust, reproducible, immortalised cell culture system mimicking the 
expression of according factors in primary enterocytes. 
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Name 
Epithelial/ 
Immune cells 
Primary/ 
Immortalised cells 
Lentiviral 
transduction 
(Y/N) 
HuNoV replication 
(-/+/++/+++) 
Caco-2 Epithelial Immortalised Y - 
LS174T Epithelial Immortalised N - 
HIEC Epithelial Primary Y ? 
Tonsillar 
cells 
Immune Primary N + 
KBM7 Immune Immortalised N + 
γδ T 
cells 
Immune Primary N -/+ 
BJAB Immune Immortalised Y ++ 
Intestinal 
organoids 
Epithelial Primary N +++ 
Table 6.1 Summary of screened cell lines and outcome of infection. 
6.2 eIF4E phosphorylation and norovirus 
pathogenesis 
The second part of this thesis was focused on characterising the role of eIF4E 
phosphorylation in norovirus translation control during infection. Using MNV as a model 
system, it has been demonstrated that norovirus facilitates translation initiation via a 
virus-specific, VPg-dependent mechanism (Daughenbaugh et al., 2003). This enables 
norovirus to effectively modulate the global translation landscape without impacting 
virus translation, as there is a substantially different requirements compared with cap-
dependent translation (Chaudhry et al., 2006, Emmott et al., 2017). However, despite 
these differences, norovirus VPg interacts with cap-binding protein eIF4E, which is not 
essential for virus replication (Chaudhry et al., 2006). This, together with the 
observation that eIF4E phosphorylation is proviral in vitro, led to the hypothesis that 
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VPg-eIF4E interaction is a mechanism by which norovirus elicits translation control. 
eIF4E phosphorylation was previously proposed to be important for translation of a 
subset of mRNAs, including NF-κB inhibitor IκBα (Furic et al., 2010). Inhibition of 
eIF4E phosphorylation showed enhanced type I IFN response due to increased NF-κ
B activity, leading to restriction of several viruses (Herdy et al., 2012). We proposed 
that inhibiting eIF4E phosphorylation should negatively impact norovirus infection. 
A mouse model containing eIF4E S209A mutation was developed to study the effect 
of eIF4E phosphorylation on MNV pathogenesis. Compared to wild type (WT), BMDMs 
with eIF4E S209A mutation (KI) showed more robust induction of Ifnb but not Il6, 
suggesting different regulation mechanisms of the two NF-κB target genes. MNV 
replication in BMDMs was not impacted by KI mutations, despite increased Ifnb 
induction and ISG production. A replication-competent MNV-3 showed no difference in 
replication between WT and KI mice. Interestingly, acute phase faecal shedding of 
attenuated MNV-3VF1- was partially restored in KI mice. However, this phenotype is 
dose-dependent as a similar effect was not observed in a high-dose challenge model. 
There are several possible explanations of why our observations do not support the 
initial hypothesis. It is possible that the effect of eIF4E phosphorylation on MNV 
replication is specific to Raw264.7 cells. Compared to BMDM, Raw264.7 cells have 
higher expression of eIF4E and p-eIF4E, meaning inhibition of eIF4E phosphorylation 
may have a more significant impact on MNV replication in Raw264.7 cells than in 
BMDM, assuming that phosphorylation plays a direct role. As eIF4E phosphorylation 
has been implicated in controlling tumorigenesis and cancer progression (Furic et al., 
2010), it is also possible that the effect of eIF4E phosphorylation in the context of 
immortalised cell lines is different from those in primary cell or mouse model, relating 
more to cell-cycle control and proliferation. However, this contradicts previous 
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observations (Royall et al., 2015, Herdy et al., 2012), so the proviral effect of eIF4E 
phosphorylation is unlikely to be cell line specific or virus specific. A more feasible 
explanation is that eIF4E phosphorylation has multiple functions in MNV replication. 
For example, the differences between Ifnb and Il6 induction indicates that there are 
more factors involved than just eIF4E phosphorylation. Also, it remains to be 
determined whether type III IFN responses are regulated by eIF4E phosphorylation, 
and whether enhanced type I IFN responses have any feedback impacts on type III 
IFN-specific responses. 
The observed differences between in vitro and in vivo models also highlights the 
influence of model systems in studying host-virus interactions. Although MNV 
pathogenesis is minimally impacted by the S209A mutation, possible mechanisms of 
translation control by other viruses can be studied using the established model system. 
Previous study has established a steady-state gene expression profile of KI MEF cells 
using microarrays, it may be interesting to characterise changes of gene expression 
during activation of viral translation. This demonstrates that the in vivo model systems 
will have a great utility in future studies. 
6.3 A non-structural role of VP1 in norovirus 
replication 
The third part of this thesis aimed to characterise VP1 shell domain (SD) in regulating 
norovirus replication. A previous study demonstrated that a genogroup-specific VP1-
RdRp interaction modulates RdRp activity (Subba-Reddy et al., 2012). It was proposed 
that these genogroup-specific domains within the shell domain confer species 
restriction of this interaction and are important for norovirus replication. 
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Initially, domains important for VP1-RdRp interaction were identified by comparing the 
replication of chimeric MNVs with mutated genogroup-specific residues. The crucial 
role of these domains was demonstrated by the observation that a complete 
replacement abolished MNV replication. One mutant (L5) is replication competent but 
more susceptible to thermal inactivation. The point mutation in SD likely destabilised 
capsid, and thermal inactivation assays indicated that mutant L5 can be used together 
with WT MNV to evaluate the environmental stability of different MNVs. Mutations in 
another two domains (L1 and L7) resulted in both a reduced VP1-RdRp interaction and 
delayed virus replication kinetics. In an RNA synthesis assay, SD was sufficient to 
enhance the de novo initiation activity of RdRp, which is the first biochemical evidence 
of norovirus shell domain promoting a specific mode of initiation for RNA synthesis. 
MNV SD with HuNoV L1 and L7 showed less enhancement on RdRp activity, 
supporting the idea that the genogroup-specific residues in L1 and L7 confer species 
restriction of this interaction. In addition, MNV-3 carrying homologous mutations (MNV-
3VF1- L1,7) was replication defective in vivo, demonstrating the biological importance 
of this functionally-conserved interaction. Non-encapsidation activities of viral 
structural proteins have become an increasingly important subject (Ni and Cheng Kao, 
2013) and these results demonstrate that norovirus capsid shell domain not only 
encapsidates viral RNA but also regulate RNA synthesis. Therefore, the VP1-RdRp 
interface can be potentially targeted for antiviral intervention or vaccine development.  
In conjunction with the HuNoV reverse genetic system, we can now raise the possibility 
of characterising genetically-manipulated HuNoV in vitro. As a proof of concept, 
chimeric HuNoV with MNV L7 was also cloned and produced. There is evidence of 
encapsidated viral RNA produced. However, further characterisation is required to 
evaluate the potential of these mutations for rational attenuation of HuNoV. 
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Together, this thesis aimed to address one of the most challenging questions in the 
norovirus field and has demonstrated successful recovery of infectious HuNoV by 
reverse genetics. Using a stringent experiment set up to understand the role of eIF4E 
phosphorylation in norovirus pathogenesis highlights the importance of studying virus-
host interactions in a physiologically-relevant context. The characterisation of a non-
structural function of a viral structural protein probes the possibility of using surrogate 
systems to study functionally-conserved interactions for antiviral design and rational 
attenuation. Further investigations should focus on improving the organoids culture 
and reverse genetics system. Host and viral factors should also be characterised to 
better understand and control this clinically and economically important pathogen. 
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Antibodies 
Antigen name Species Polyclonal/monoclonal Manufacturer 
MNV RdRp rabbit polyclonal I. Goodfellow 
MNV/NV NS3 rabbit polyclonal I. Goodfellow 
LDV VPg rabbit polyclonal I. Goodfellow 
GFP N-terminal rabbit polyclonal Sigma-Aldrich 
IRF-3 rabbit polyclonal Santa Cruz 
STAT1 rabbit polyclonal Abcam 
MUC1 rabbit polyclonal Abcam 
viperin rabbit polyclonal Abcam 
phospho-eIF4E rabbit monoclonal Cell Signalling 
eIF4E mouse polyclonal Santa Cruz 
actin1 (C-2) mouse monoclonal Santa Cruz 
 222 
Primers and probes 
Primer name Sequence Experiment 
IGUC2756 cactggatcctaaccGGttgagtgcaatggc GII.6 F/S 
cloning IGUC2757 cgacgccatcttcattcacac 
IGUC3469 tacacgccactccgcacaaacagcccgggtgatgagtctt
ttgtgttcacagtctcttgtcg 
GII.4 L7 
cloning 
IGUC3470 cacaaaagactcatcacccgggctgtttgtgcggagtggc
gtgtacagcattgctatc 
G1SKF CTGCCCGAATTYGTAAATGA GI 
Genotyping G1SKR CCAACCCARCCATTRTACA 
G2SKF CNTGGGAGGGCGATCGCAA GII 
Genotyping G2SKR CCRCCNGCATRHCCRTTRTACAT 
IGUC1383 AAAACGTACGGCCACCATGCTGGTCGTTCAGATGCCTTTC FUT2 
cloning 
IGUC1384 AAAATCTAGATTAGTGCTTGAGTAAGGGGGACAGG 
COG1F CGYTGGATGCGNTTYCATGA GI qPCR 
COG1R CTTAGACGCCATCATCATTYAC 
RING1(b)-TP FAM-AGATCGCGGTCTCCTGTCCA-TAMRA 
COG2F CARGARBCNATGTTYAGRTGGATGAG GII qPCR 
COG2R TCGACGCCATCTTCATTCACA 
RING2-TP FAM-TGGGAGGGCGATCGCAATCT-TAMRA 
IGUC0963 ATGCCCTTGCGTCCATAACA hMUC2 
qPCR IGUC0964 ATGCCCTTGCGTCCATAACA 
IGUC0784 TTCTACAATGAGCTGCGTGTG hACTB 
qPCR IGUC0785 GGGGTGTTGAAGGTCTCAAA 
LGR5 Primer pair purchased from PrimerDesign LGR5 qPCR 
ALPI Primer pair purchased from PrimerDesign ALPI qPCR 
IGIC1076 GTTTTCCATCTCGCCTCGAAACGCACCAGGTGAAATACTG
TTTGATTTGG 
MNV-1 L1 
cloning 
IGIC1077 CCAAATCAAACAGTATTTCACCTGGTGCGTTTCGAGGCGA
GATGGAAAAC 
IGIC1078 CCACATGTCATGTGTGATGTGCGCCAACTGGAGCCCATTC
AACTCCC 
MNV-1 L5 
cloning 
IGIC1079 GGGAGTTGAATGGGCTCCAGTTGGCGCACATCACACATGA
CATGTGG 
IGIC1080 GCATGCTGTACACGCCACTCCGCGCCAACAACGCCGGTGA
GGATGTGTTTACGGTCTCTGGCCGCCTTCTTTCTAAGCCG 
Appendices 
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IGIC1081 CGGCTTAGAAAGAAGGCGGCCAGAGACCGTAAACACATCC
TCACCGGCGTTGTTGGCGCGGAGTGGCGTGTACAGCATGC 
MNV-1 L7 
cloning 
IGUC1979 GTTTTCCATTTCACCCCGAAACGCACCAGGTGAAATACTG
TTTGATTTGG 
MNV-3 L1 
cloning 
IGUC1980 CCAAATCAAACAGTATTTCACCTGGTGCGTTTCGGGGTGA
AATGGAAAAC 
IGUC2014 GTCATGTGTGATGTGCGCCAACTGGAGCCCATTCAACTTC
CC 
MNV-3 L5 
cloning 
IGUC2015 GGGAAGTTGAATGGGCTCCAGTTGGCGCACATCACACATG
AC 
IGUC1981 GCATGTTGTACACGCCACTCCGCGCCAACAACGCCGGTGA
GGATGTGTTTACGGTCTCTGGCCGCCTTCTTTCTAAGCCG 
MNV-3 L7 
cloning 
IGUC1982 CGGCTTAGAAAGAAGGCGGCCAGAGACCGTAAACACATCC
TCACCGGCGTTGTTGGCGCGGAGTGGCGTGTACAACATGC 
IGUC1889 ACTTCGTCTCACATGAGGATGAGCGACGGCGCAGCGCCAA
AAGCC 
MNV-1 SD 
cloning 
IGUC1890 CACCCTCGAGTCTCTCTATGGGGGGAGTTAGG 
IGUC1891 CACCCTCGAGCTATCTCTCTATGGGGGGAGTTAGG 
IGUC2993 GCAATGCAAGTCGAAATGTG 4E KI 
genotyping IGUC2994 TTTGAAATTGGTTTGTAAAGTTGG 
IGUC0339 ATGAACAACAGGTGGATCCTCC mIfnb qPCR 
IGUC0340 AGGAGCTCCTGACATTTCCGAA 
IGUC1904 GAAGTTCCTCTCTGCAAGAGACTTCCATC mIl6 qPCR 
IGUC1905 CAACTCTTTTCTCATTTCCACGATTTCCC 
IGUC1898 GGTTCAAGGACTATGGGGAGTATTTGGAC mViperin 
qPCR IGUC1899 GAAATCTTTCTGCTTCCCTCAGGGCATC 
IGUC1902 GGTAACGATTTCCTGGTGTCCG mIsg15 
qPCR IGUC1903 GCTCAGCCAGAACTGGTCTTCG 
IGUC0945 CATGGCCTTCCGTGTTCCTA mGapdh 
qPCR IGUC0946 GCGGCACGTCAGATCCA 
MNV-S CCGCAGGAACGCTCAGCAG MNV qPCR 
MNV-AS GGYTGAATGGGGACGGCCTG 
MNV-TP FAM-ATGAGTGATGGCGCA-TAMRA 
 
  
 224 
 
  
 225 
Selected publications 
  
 226 
 
 
 
Rapid outbreak sequencing of Ebola virus in Sierra
Leone identifies transmission chains linked to
sporadic cases
Armando Arias,1,#,† Simon J. Watson,2,# Danny Asogun,3,4,#
Ekaete Alice Tobin,3,4,# Jia Lu,1,# My V. T. Phan,2,# Umaru Jah,5
Raoul Emeric Guetiya Wadoum,5 Luke Meredith,1 Lucy Thorne,1
Sarah Caddy,1 Alimamy Tarawalie,5 Pinky Langat,2 Gytis Dudas,6
Nuno R. Faria,7 Simon Dellicour,7 Abdul Kamara,8 Brima Kargbo,8
Brima Osaio Kamara,8 Sahr Gevao,8 Daniel Cooper,9 Matthew Newport,9
Peter Horby,10 Jake Dunning,10 Foday Sahr,11 Tim Brooks,12
Andrew J.H. Simpson,12 Elisabetta Groppelli,12 Guoying Liu,13
Nisha Mulakken,13 Kate Rhodes,13 James Akpablie,14 Zabulon Yoti,14
Margaret Lamunu,14 Esther Vitto,14 Patrick Otim,14 Collins Owilli,14
Isaac Boateng,14 Lawrence Okoror,15 Emmanuel Omomoh,3,4
Jennifer Oyakhilome,3,4 Racheal Omiunu,3,4 Ighodalo Yemisis,3,4
Donatus Adomeh,3,4 Solomon Ehikhiametalor,3,4 Patience Akhilomen,3,4
Chris Aire,3,4 Andreas Kurth,4,16 Nicola Cook,4,17 Jan Baumann,4,18
Martin Gabriel,4,18 Roman Wo¨lfel,4,19 Antonino Di Caro,4,20,‡
Miles W. Carroll,4,17 Stephan Gu¨nther,4,18 John Redd,21 Dhamari Naidoo,14
Oliver G. Pybus,7,§ Andrew Rambaut,6,22,23,** Paul Kellam,2,24,*,††
Ian Goodfellow,1,5,* and Matthew Cotten2,*
1Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom,
2Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 3Irrua Specialist Teaching Hospital, Institute of
Lassa Fever Research and Control, Irrua, Nigeria, 4The European Mobile Laboratory Consortium, Bernhard
Nocht Institute for Tropical Medicine, Hamburg, Germany, 5University of Makeni, Makeni, Sierra Leone,
6Institute of Evolutionary Biology, Ashworth Laboratories, Edinburgh, United Kingdom, 7Department of
Zoology, University of Oxford, Oxford, UK, 8Sierra Leone Ministry of Health, Freetown, Sierra Leone,
9International Medical Corps, Los Angeles, CA, USA, 10Department of Medicine, Epidemic Diseases Research
Group Oxford (ERGO), Centre for Tropical Medicine and Global Health Nuffield, University of Oxford, Oxford,
VC The Author 2016. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1
Virus Evolution, 2016, 2(1): vew016
doi: 10.1093/ve/vew016
Rapid Communication
Downloaded from https://academic.oup.com/ve/article-abstract/2/1/vew016/1753554
by University of Cambridge user
on 13 April 2018
United Kingdom, 11Republic of Sierra Leone Armed Forces, Freetown, Sierra Leone, 12Rare and Imported
Pathogens Laboratory, Public Health England, United Kingdom, 13Thermo Fisher Scientific, South San
Francisco, CA, USA, 14WHO Ebola Response Team, Geneva, Switzerland, 15Federal University, Oye-Ekit,
Nigeria, 16Robert Koch Institute, Berlin, Germany, 17Public Health England, Porton Down, United Kingdom,
18Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, 19Bundeswehr Institute of
Microbiology, Munich, Germany, 20National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy,
21Sierra Leone and Division of Global Health Protection, CDC Country Office, Georgia Center for Global Health
Centers for Disease Control and Prevention, Atlanta, GA, USA, 22Fogarty International Center, NIH, Bethesda,
MD, USA, 23Infection and Evolution, Centre for Immunology, Ashworth Laboratories, Edinburgh, United
Kingdom and 24Division of Infection and Immunity, University College London, London, United Kingdom
#These authors are joint first authors.
* Corresponding authors. E-mail: pk5@sanger.ac.uk (P.K.), ig299@cam.ac.uk (I.G.), or mc13@sanger.ac.uk (M.C.)
†
http://orcid.org/0000-0002-4138-4608
‡
http://orcid.org/0000-0001-6027-3009
§http://orcid.org/0000-0002-8797-2667
**http://orcid.org/0000-0003-4337-3707
††
http://orcid.org/0000-0003-3166-4734
Abstract
To end the largest known outbreak of Ebola virus disease (EVD) in West Africa and to prevent new transmissions, rapid
epidemiological tracing of cases and contacts was required. The ability to quickly identify unknown sources and chains of
transmission is key to ending the EVD epidemic and of even greater importance in the context of recent reports of Ebola
virus (EBOV) persistence in survivors. Phylogenetic analysis of complete EBOV genomes can provide important information
on the source of any new infection. A local deep sequencing facility was established at the Mateneh Ebola Treatment Centre
in central Sierra Leone. The facility included all wetlab and computational resources to rapidly process EBOV diagnostic
samples into full genome sequences. We produced 554 EBOV genomes from EVD cases across Sierra Leone. These genomes
provided a detailed description of EBOV evolution and facilitated phylogenetic tracking of new EVD cases. Importantly, we
show that linked genomic and epidemiological data can not only support contact tracing but also identify unconventional
transmission chains involving body fluids, including semen. Rapid EBOV genome sequencing, when linked to epidemiologi-
cal information and a comprehensive database of virus sequences across the outbreak, provided a powerful tool for public
health epidemic control efforts.
Key words: Ebola virus; evolution; transmission; outbreak sequencing.
1. Introduction
Starting in December 2013, West Africa experienced the largest
known outbreak of Ebola virus disease (EVD). Sierra Leone was
the most widely affected country, with 14,124 cases and 3,956
confirmed deaths as of 21 February 2016 (WHO 2016). In the ab-
sence of large-scale vaccination and effective antiviral drugs,
controlling the epidemic and maintaining the zero transmission
status have relied on rapid patient identification and isolation,
contact tracing and quarantine, as well as the implementation
of safe burial practices (Kucharski et al. 2015; Nouvellet et al.
2015; Fang et al. 2016).
By January 2015, the decline in new cases in the three most-
affected countries (Sierra Leone, Guinea, and Liberia) suggested
that epidemiological containment efforts were succeeding, particu-
larly in Liberia which was initially declared free of EVD by the
WHO on 9 May 2015 (WHO 2015). However, the recurrence of EVD
in Liberia (WHO 2015) and Sierra Leone (WHO 2016) indicated that
sources of new infections remained; even after all recognized
chains of transmission had been extinguished. Worryingly,
evidence is accumulating that EVD survivors may harbor and
transmit EBOV for several months after recovery (Deen et al. 2015;
Christie et al. 2015; Mate et al. 2015; Blackley et al. 2016; Sow et al.
2016; Uyeki et al. 2016) raising the possibility that transmission
through exposure to bodily fluids and/or sexual transmission can
occur at times beyond the standard quarantine periods.
To facilitate the use of phylogenetics for tracing virus
transmission, a local EBOV sequencing facility was established
in a tent at the Ebola Treatment Centre in Makeni, Sierra
Leone. The facility provided local capacity for rapid real-time
sequencing of EBOV genomes directly from clinical samples
and contributed important information on the transmission
pathways of EBOV.
2. Methods
2.1. Samples
Samples were collected from patients being cared for in Ebola
isolation and treatment centers in Makeni (Bombali district),
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Port Loko (Port Loko district), Kambia district, Kerrytown
(Western Urban district), and Koinadugu district (see Fig. 1, sam-
ple details are summarized in Supplementary Table 1). The
study was conducted in compliance with principles expressed
in the Declaration of Helsinki, and ethical approvals for the use
of residual diagnostic samples for sequencing were obtained
from the Sierra Leone Ethics and Scientific Review Committee
and the Ministry of Health of Sierra Leone. The Sierra Leone
Ethics and Scientific Review Committee approved the use of di-
agnostic leftover samples collected by EMLab and correspond-
ing patient data for this study.
2.2. Logistics
Equipment and reagents for the establishment of the sequenc-
ing facility were initially shipped to the University of
Cambridge, Cambridge, UK, for testing and repacking prior to
transport to Makeni, Sierra Leone. These materials included re-
agents for sequencing, unassembled benches, PCR cabinets,
centrifuges, general molecular biology reagents, N2 canisters
(required for Ion Torrent sequencing), and the equipment re-
quired to perform the sequencing workflow, namely an Ion
Chef liquid handling robot and an Ion Torrent PGM sequencer.
The Ion Torrent PGM sequencer and Chef were unpacked, in-
stalled and tested in Cambridge by the users with the aid of a
Thermo Fisher Scientific engineer. Calibration sequencing runs
were performed to ensure the required reagents and equipment
functioned correctly, prior to repacking and transfer to East
Midlands Airport for transport to Makeni via UK Department for
International Development-funded humanitarian aid flights.
The equipment arrived in Makeni on 15 April 2015 and was in-
stalled in a lined, air-conditioned tent in the Mateneh Ebola
treatment centre (ETC) in Makeni, Bombali district, adjacent to
the Public Health England (PHE) operated diagnostic facility. The
sequencing facility was operational from 16 April 2015 and the
first data files were transferred to the UK on 20 April 2015.
2.3. Sample preparation and sequencing
Total nucleic acid extracts were prepared from plasma obtained
from collected blood samples or buccal swabs using either the
Qiagen EZ-1 automated nucleic acid purification platform or the
QIAamp manual RNA extraction procedure. Samples were tested
for the presence of EBOV RNA using as previously described
(Trombley et al. 2010) and were considered positive if Ct values
were<40. Nucleic acid extracts from EBOV PCR-positive samples
were then subjected to reverse transcription/PCR amplification
using the Thermo Fisher Scientific Ion Ampliseq workflow ac-
cording to the protocol manufacturer with EBOV specific re-
agents and the Ion Torrent sequencing platform. Following
nucleic acid isolation, all subsequent procedures were per-
formed within physically separated PCR cabinets dedicated for
either reagent preparation or sample manipulations, with a
30 min UV treatment cycle between uses. Briefly, 5–7 ml of nucleic
acid extract were reverse transcribed using the VILO reverse
transcriptase kit (Life Technologies) in a total volume of 10 ml.
Following reverse transcription, PCR amplification of the EBOV
cDNA was performed with two multiplex PCR reactions: pool 1
containing 73 EBOV-specific primer pairs and five human house-
keeping gene controls and pool 2 containing 72 EBOV-specific
primer pairs and the same five human housekeeping gene con-
trols. The amplicon sizes range from 80 to 237 bp (see
Supplementary Table 2 for primer sequences and mapping posi-
tions). Following PCR amplification, primer sequences were re-
moved from the amplicons and barcoded adapters ligated
according to the protocol of the manufacturer. Amplicon purifi-
cation and size selection were performed with the AMPure DNA
purification system, followed by library quantification by qPCR
using the Ion Library Quantitation Kit. Libraries were normalized
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Figure 1. Lineages circulating in sampled regions. Districts of Sierra Leone (blue), Guinea (green), and Liberia (orange) are indicated. Pie charts are drawn over districts
from which samples of this study were collected, with size relative to the number of samples, and segment area indicating the proportion of lineages (as defined in
Figure 2) observed at that location. The number of genomes from each location was the following: Bombali: 63, Kambia: 67, Koinadugu: 5, Port Loko: 98, Tonkolili: 4,
Western Area: 182, Unknown location: 135.
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to 85 pM, combined in pools of 10–24 samples per pool and tem-
plate libraries were prepared using the Ion PGM Hi-Q Sequencing
Kit on an Ion Chef Instrument (Thermo Fisher Scientific).
Libraries were subsequently sequenced on the Ion PGM System
using Ion Torrent Hi-Q sequencing reagents (500 cycles).
2.4. Data handling and genomes assembly
Short read sets were processed to remove short and low quality
reads, terminal primers were removed and the reads were
sorted to retain reads with length>125 nt and median Phred
score> 30 using QUASR (Watson et al. 2013). Chimeric reads
were resolved using a Python script and the final reads were
processed by de novo assembly using SPAdes 3.5.0 (Bankevich
et al. 2012). EBOV contigs were further assembled into complete
genomes (if not already complete) using Sequencher v5.3 (Gene
Codes Corporation, USA). Conflicts were resolved by direct
counting of the motif in the short read data set. Further details
of the genome assembly process are included in the
Supplementary material.
2.5. Phylogenetic methods
All available EBOV Makona genomes were downloaded from the
NCBI Ebolavirus Resource (NCBI 2016). These 1019 genomes
were combined with the 554 new genomes generated here, and
aligned manually using the AliView alignment editor (Larsson
2014). A maximum-likelihood phylogenetic tree was inferred
from this alignment using RAxML version 7.8.6 (Stamatakis
2014) under a general time reversible (GTR) substitution model,
with among-site heterogeneity modelled using a 4-category dis-
crete approximation of a gamma distribution, as previously
described (Gire et al. 2014; Ladner et al. 2015). Robustness of the
tree topology was assessed by bootstrap analysis of 1,000
pseudo-replicates, with support values for the topology calcu-
lated using the SumTrees program version 4.0.0 of the
DendroPy package version 4.0.0 (Sukumaran and Holder 2010).
The tree was rooted on the Gueckedou-C05 genome (GenBank
accession no. KJ660348) and visualised using FigTree version
1.4.2 (http://tree.bio.ed.ac.uk/software/figtree/).
From this tree, the well-supported clades were identified, in-
cluding the previously determined SL3 introduction into Sierra
Leone. Viruses derived from the SL3 introduction that were iso-
lated in Sierra Leone were extracted from the alignment. These
did not include those that were derived from a re-importation
of the virus from another country (e.g. Lineage B, which was de-
rived from a reintroduction from Guinea). A molecular clock
phylogenetic tree was inferred from these 1058 genomes using
a Bayesian Markov chain Monte Carlo (MCMC) approach imple-
mented in BEAST version 1.8.2 (Drummond et al. 2012). The
alignment was partitioned into a concatenated coding region,
containing the protein-coding sequences of the NP, vp35, vp40,
GP1, GP2, vp30, vp24, and L genes, and a non-coding inter-genic
region. The coding region was modeled under an SRD06 substi-
tution model (Shapiro et al. 2006) to allow for partitioning of co-
don positions 1þ 2 and 3, while the inter-genic region was
modeled under an HKYþC4 substitution model (Hasegawa
et al. 1985), as previously applied for molecular dating of EBOV
(Gire et al. 2014). The data were run under an uncorrelated log-
normal relaxed molecular clock (Drummond et al. 2006), and a
non-parametric Bayesian Skygrid coalescent model (Gill et al.
2013). Ten independent chains were run for a combined total of
at least 30 million states, then combined after burn-in. Burn-in
values were determined for each chain separately after
checking for convergence using Tracer version 1.6 (http://tree.
bio.ed.ac.uk/software/tracer/). The posterior tree sets were com-
bined using LogCombiner version 1.8.2, then summarised as a
maximum clade credibility tree using TreeAnnotator version 1.
8.2. This tree was visualised using FigTree version 1.4.2.
3. Results and discussion
We produced 554 contemporary EBOV genome sequences from
855 EVD samples (64% success rate) collected in Sierra Leone be-
tween December 2014 and September 2015. PCR-positive EBOV
samples were provided by EBOV diagnostic field laboratories
(PHE Makeni, PHE Port Loko, PHE Kerrytown, EML Hastings, EML
Kambia), collected primarily from the northern and western dis-
tricts of Sierra Leone (Fig. 1, Supplementary Table 1), reflecting
EVD case locations during this period (WHO 2016). Genomes
were successfully obtained from blood, buccal swabs, semen and
breast milk with successful genome yield dependent on EBOV
reads of greater than 10,000 (Supplementary Fig. 1). The se-
quenced genomes represent 4.5% of the EVD cases reported for
Sierra Leone, and 23.8% of all 2015 Sierra Leone cases (see
Supplementary Fig. 2) and provide a detailed description of EBOV
evolution during 2015. From these data we identified sources of
infection for some of the final EVD cases in Sierra Leone and in-
dicate potential routes of sexual and breast milk transmissions.
This was an unconventional use of new sequencing technol-
ogy under harsh conditions (high temperature, dust, high
humidity, unreliable power supplies, complicated reagent
transport, in a tent). Accordingly, special care was taken to en-
sure that the sequencing process was reproducible and consis-
tent with EBOV sequencing results obtained by other groups.
Furthermore, we provided quantitative data on the level of re-
sidual primer content from the amplicon sequencing method
and the potential level of sample cross contamination under
the sequencing conditions used (see Supplementary material).
Evolutionary analysis of the complete set of EBOV Makona
genomes revealed that at least nine viral lineages were circulat-
ing in Sierra Leone (Fig. 2). Eight of these lineages (A–H) were de-
rived from the SL3 variant that emerged in Sierra Leone in June
2014 (Park et al. 2015) and became the most prevalent lineage
(Tong et al. 2015). The remaining viruses were derived from a
separate introduction into Sierra Leone of the GUI-1 lineage
from Guinea (Simon-Loriere et al. 2015). By June 2015, reported
EVD cases were from infections by only three viral lineages A, E,
and F (Supplementary Fig. 3). The majority of these cases arose
from two separate outbreaks: one with lineage F viruses that oc-
curred primarily in the Port Loko and Kambia districts (80 ge-
nomes), and the other from lineage A viruses that were
identified primarily in the Magazine Wharf area of Freetown in
the Western Urban district (39 genomes). Both these outbreaks
persisted for over a month, with the phylogenetic analyses re-
vealing movement of the virus to surrounding districts. This vi-
rus movement was observed across the entire Sierra Leone
outbreak, with viruses from all lineages except B and C found in
more than one district (Supplementary Fig. 3).
The Ebola Outbreak Sequencing Support (EOSS) was estab-
lished in July 2015 as a coordinated effort from the Sierra Leone
Ministry of Health, WHO, CDC and the local sequencing facility
to rapidly sequence all new Sierra Leone EVD cases and rapidly
place them in phylogenetic context. EOSS processed 21 samples
from July-September 2015 (median 4 days, range 1–12 days,
Supplementary Fig. 4) and provided an additional level of infor-
mation to field workers tracing the source of the infection.
Three examples of the use of these sequence data follow.
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An EVD cluster occurred in late June 2015 in Mamusa, Port
Loko District. Case B, who was in the late stages of pregnancy,
had been exposed to EVD in another village (Kom Brakai) and
was under quarantine there. She fled quarantine and traveled
to the house of her aunt (case A) in Mamusa (Fig. 3a). Case B
went into labour, and died on 15 June during the birth of case
C. Cases B and C were subsequently found to be EBOV positive.
Consequently, all household contacts present at C’s birth were
placed in quarantine, including cases A, C (B’s newborn
daughter who died on 25 June), D (B’s sister), E (A’s 13-month
old daughter), and F (A’s sister). Cases A, E, and F were re-
leased from quarantine on 7 July after completing their obser-
vation period without apparent illness other than red
conjunctivae noted in A on 29 June, although no EBOV diag-
nostics were performed before release. Cases E and F subse-
quently developed symptoms of EVD on 10 July, 3 d after
completing quarantine (see timeline, Fig. 3a), prompting eval-
uation of A, who remained asymptomatic. Although a blood
sample from A was EBOV-negative on 17 July, two samples of
her breast milk were EBOV-positive on 13 and 17 July (Fig. 3a).
The full EBOV genome obtained from A’s breast milk (PL9192)
was found to phylogenetically cluster with genomes from E
(PL9150Rb) and F (PL9199Rb) (Fig. 3b). This cluster is strongly
supported and is distinct from genomes from the earlier cases
B, C, and D. We hypothesized three possible routes by which E
was infected:
Route 1: A, E, and F were infected while attending C’s birth by
direct contact with B or C.
Route 2: A was infected while attending C’s birth. A trans-
mitted the virus to E, through breastfeeding or direct contact;
the virus was subsequently transmitted onward to F during
quarantine due to close proximity of F with A or E.
Route 3: A, E, and F were infected by exposure to C or D dur-
ing the quarantine.
If Route 1 or 3 were correct, the viruses isolated from A, E,
and F would be more closely related to and cluster with viruses
isolated from cases B, C, and D.
However, the viral genome isolated from B and the two ge-
nomes from D bear distinct nucleotide changes (12,485 T->C and
8,182 A->G), that were not in the genomes of viruses obtained
from cases A, E, and F, with no evidence of mixed infections at
these genome sites (results not show), suggesting a separate trans-
mission chain. Based on these data, we therefore, concluded that
transmission scenarios Routes 1 and 3 were less likely.
Although A’s viral genome contains a unique mutation
(A8358G) not shared by any other virus, analysis of A’s viral
reads shows that this was a polymorphic position with 65% of
the reads having the G, and 35% containing the A. Therefore, as
cases A, E, and F have evidence for identical viruses, and they
all share a unique mutation (C1115A), they are likely to either
all share a common direct ancestor (likely B, C, or D given the
timings and locations) or one case gave rise to the others (e.g.
case A was infected by B/C/D and transmitted to E and F) and
the data best support Route 2.
It is important to note that given the practical difficulties of
obtaining multiple samples from EVD patients and that the pri-
mary priority of field workers at that time was to contain the epi-
demic, further sampling of community members and additional
body compartments and fluids was not performed, which could
have provided clarification of the transmission route. The two
EBOV-positive breast milk samples from A, and the fact that E
was actively breastfed by A during the quarantine period, support
the possibility of breast milk transmission. However, A and E also
had close contact other than breastfeeding, and the lack of an
earlier blood sample from A does not allow us to prove that trans-
mission occurred via breast milk. Similar complexities of drawing
conclusions about EBOV breast milk transmission have been re-
ported (Moreau et al. 2015; Nordenstedt et al. 2016).
In a second cluster, on 24 July 2015, EVD case G was identi-
fied in a village in Tonkolili district which had been EVD-free
for the previous 130 d. However, at that time, there were only
three locations in Sierra Leone with on-going EBOV transmis-
sion (Magazine Wharf in Freetown, Kambia and Port Loko) in
addition to cases in Guinea. Case G reported travel from
Figure 2. Maximum-likelihood tree showing the phylogenetic context of the viruses sequenced in this study. The 554 genomes generated here are shown as red circles,
while the nine comprising lineages are highlighted with colored boxes and labeled A–H for those derived from the SL3 lineage, or GUI-1 for viruses derived from the di-
vergent Guinean lineage. The tree was rooted on Gueckedou-C05 (GenBank accession no. KJ660348), with the scale bar indicating genetic distance in units of substitu-
tions/site. Specific genomes in the three transmission vignettes (see Fig. 3), MK8878, 19560_EMLK, and PL9192c are highlighted.
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Freetown to Tonkolili on 16 July 2015, providing a hypothesis
for EBOV appearance in Tonkolili. Phylogenetic analysis con-
firmed this hypothesis; the virus genome from G (MK8878) clus-
tered with recent infections from Magazine Wharf and not with
viruses from the other locations with active transmission at
the time (Fig. 4 and Supplementary Fig. 3). Furthermore, ge-
nomes from two subsequent EVD cases from Tonkolili, H
(MK10128; G’s brother), and J (MK10173; G’s aunt), both G’s care-
givers, were closely related to the G genome expanding the
transmission chain (Fig. 4). The combined data link case G to
known infections in Magazine Wharf and exclude the possibil-
ity that this Tonkolili cluster was a re-emergence of EBOV from
previous Tonkolili cases or from an unknown transmission
chain.
There is accumulating evidence of EBOV sexual transmission
(Deen et al. 2015; Christie et al. 2015; Mate et al. 2015; Blackley
et al. 2016; Sow et al. 2016; Uyeki et al. 2016). On 29 August 2015 in
the Kambia district, a post-mortem swab from case K tested posi-
tive for EBOV, some 50 d following the last confirmed case in this
district. The viral genome from case K (020380_EMLK) clustered
with a genome from case L from a blood sample collected on 7
July 2015 (19560R_EMLK, Fig. 5a). Case L was an EVD survivor, who
was released from quarantine on 18 July 2015 and subsequently
had sexual contact with K during August 2015. L provided a semen
sample on 7 September 2015 from which an EBOV genome was
obtained (19560_EMLK). The viral genome obtained from L’s se-
men was identical to the virus genome in L’s initial blood sample,
collected 2 months earlier during acute EVD (Fig. 5a). The cluster-
ing of genomes from case L with those from K, and from several
secondary contacts of K (cases N, O, P, and Q) indicates transmis-
sion among these cases in Kambia (Fig. 5a). In addition, the ab-
sence of nucleotide changes between the virus genomes of the
two L samples suggests that the virus was maintained in a low
replicating state within L. Consistent with this pattern, reduced
Figure 3. (a) Mamusa Cluster timeline. Key events in the Mamusa cluster examined in (b) are summarized. (b) Maximum-likelihood tree of the Mamusa cluster showing
the phylogenetic relationship between each case’s virus genome. The genome from the case A breast milk sample (PL9192, labeled in red, GenBank accession no.
KU296401) is highlighted in red. Additional cases in the cluster include the earlier case B (most probable index case of the cluster, GenBank accession no. KU296340);
case C (the 6 day-old newborn daughter of B, GenBank accession no. KU296618), and D (sister of B, includes two viruses sampled 3 d apart, GenBank accession nos.
KU296404 and KU296342). Contacts of A include cases E (13 month-old daughter of A, GenBank accession no. KU296522) and F (sister of A, GenBank accession no.
KU296371). Bootstrap support values greater than 50% are given below the respective node. The bar colors on the right indicate the place of sampling of each virus (leg-
end is shown on the left). All mutations within the case cluster are given above the relevant branch as the position in the original alignment followed by the nucleotide
change. The scale bar indicates the genetic distance in units of substitutions/site.
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virus evolutionary rate after virus re-emergence was also recently
reported (Blackley et al. 2016). Furthermore, at three positions in
the virus genome (3,993, 8,494 and 13,518), minority variants were
present in the K and M read sets that show a transition between
the majority nucleotide in L and the majority nucleotide in the vi-
ruses later in the putative transmission chain (Fig. 5b). Thus
mixed nucleotide variants at three positions in L’s semen virus
genome were consistent with L as the direct source of virus for K
and M.
An alternate transmission route might be contact of K with
unknown EVD cases in the community. However, such a hy-
pothesis would require that the virus in this unidentified con-
tact was as close, or more closely related to the viruses
sequenced from the known cases, which had only three nucleo-
tide differences between L and K. Alternately, transmission
from L to K could have occurred via non-sexual contact or with
other body fluids; however, given that L’s blood was negative
but L’s semen was genome positive, between these two possibil-
ities semen is the more likely source of K’s infection. There was
no report of sexual contact between L and M, so tentatively M
might have been infected from L’s bodily fluid or while taking
care of K. However, the phylogenetic analysis strongly supports
viral transmission between these cases (Fig. 5a), with sexual
transmission from L to K as the most likely component in the
transmission chain.
The local sequencing described here was rapid enough to be
epidemiologically useful; however, a comprehensive genome
database across the outbreak was essential to identify sources
of new infections. During the course of this project, the se-
quence data that were generated contributed more than a third
of the 1500 EBOV Makona genomes now available and represent
23.8% of the 2015 Sierra Leone cases (see Supplementary Fig. 2).
These data were made available to all groups involved in out-
break sequencing (Goodfellow et al. 2015a,b; Neher and Bedford
2015) and yielded a sufficiently comprehensive set of viral ge-
nomes to identify transmission chains in other countries and
across borders (Gardy et al. 2015).
In future epidemics, rapid and local sequencing of pathogens
at the onset and the end of the outbreak can support outbreak
investigation and control, but sequencing and data sharing dur-
ing peak transmission should also be maintained to provide
the genetic context for contact tracing and control of new cases.
With the increasing global risk of viral zoonosis, the success of
this project provides a strong incentive to establish and main-
tain local sequencing facilities throughout the world.
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Virus genomes reveal factors that spread 
and sustained the Ebola epidemic
A list of authors and their affiliations appears at the end of the paper
At least 28,646 cases and 11,323 deaths1 have been attributed to the 
Makona variant of Ebola virus (EBOV)2 in the two and a half years it 
circulated in West Africa. The epidemic is thought to have begun in 
December 2013 in Guinea, but was not detected and reported until 
March 2014 (ref. 3). Initial efforts to control the outbreak in Guinea 
were considered to be succeeding4, but in early 2014 the virus crossed 
international borders into the neighbouring countries Liberia (where 
the first cases were diagnosed in late March) and Sierra Leone (first 
documented case in late February5,6, first diagnosed cases in May7). 
EBOV genomes sequenced from three patients in Guinea early in the 
epidemic3 demonstrated that the progenitor of the Makona variant 
originated in Middle Africa and arrived in West Africa within the last 
15 years7,8. Rapid sequencing from the first reported cases in Sierra 
Leone confirmed that EBOV had crossed the border from Guinea 
and that these cases were not the result of an independent zoonotic 
introduction7. Subsequent studies have analysed the genetic makeup 
of the Makona variant, focusing on Guinea9,10,13, Sierra Leone14,15 or 
Liberia16,17, and have identified local viral lineages and transmission 
patterns within each country.
Although virus sequencing data have covered considerable fractions 
of the epidemic in each affected country, individual studies focused on 
either limited geographical areas or time periods, so that the regional 
level patterns and drivers of the epidemic across its entire duration 
have remained uncertain. Using 1,610 genome sequences collected 
throughout the epidemic, representing over 5% of recorded Ebola virus 
disease (EVD) cases (Extended Data Fig. 1), we reconstruct a detailed 
phylogenetic history of the movement of EBOV within and between 
the three most affected countries. Using a recently developed phylo-
geographic approach that integrates covariates of spatial spread18, we 
test which features of each region (administrative, economic, climatic, 
infrastructural or demographic factors) were important in shaping the 
spatial dynamics of EVD. We also examine the effectiveness of inter-
national border closures on controlling virus dissemination. Finally, 
we investigate why regions that immediately border the most affected 
countries did not develop protracted outbreaks similar to those that 
ravaged Sierra Leone, Guinea and Liberia.
Origin, ignition and trajectory of the epidemic
Molecular clock dating indicates that the most recent common ancestor 
of the epidemic existed between December 2013 and February 2014 
The 2013–2016 West African epidemic caused by the Ebola virus was of unprecedented magnitude, duration and impact. 
Here we reconstruct the dispersal, proliferation and decline of Ebola virus throughout the region by analysing 1,610 
Ebola virus genomes, which represent over 5% of the known cases. We test the association of geography, climate and 
demography with viral movement among administrative regions, inferring a classic ‘gravity’ model, with intense dispersal 
between larger and closer populations. Despite attenuation of international dispersal after border closures, cross-border 
transmission had already sown the seeds for an international epidemic, rendering these measures ineffective at curbing 
the epidemic. We address why the epidemic did not spread into neighbouring countries, showing that these countries 
were susceptible to substantial outbreaks but at lower risk of introductions. Finally, we reveal that this large epidemic was 
a heterogeneous and spatially dissociated collection of transmission clusters of varying size, duration and connectivity. 
These insights will help to inform interventions in future epidemics.
(mean, 22 Jan 2014; 95% credible interval (CI), 16 Dec 2013–20 
Feb 2014) and phylogeographic estimation assigns this ancestor to 
the Guéckédou prefecture, Nzérékoré region, Guinea, with high 
credibility (Fig. 1). In addition, we find that initial EBOV lineages 
that were derived from this common ancestor circulated among the 
Guéckédou prefecture and its neighbouring prefectures of Macenta and 
Kissidougou until late February 2014 (Fig. 1). These results support the 
epidemiological evidence that the West African epidemic began in late 
2013 in Guéckédou prefecture3.
The first EBOV introduction from Guinea into another country that 
resulted in sustained transmission is estimated to have occurred in 
early April 2014 (Fig. 1), when the virus spread to the Kailahun dis-
trict of Sierra Leone5,6. This lineage was first detected in Kailahun at 
the end of May 2014, from where it spread across the region (Figs 1, 2 
and Extended Data Fig. 2). From Kailahun, EBOV spread very rapidly 
in May 2014 into several counties of Liberia (Lofa, Montserrado and 
Margibi)17 and Guinea (Conakry, back into Guéckédou)9,13. The virus 
continued to spread westwards through Sierra Leone, and by July 2014 
EBOV was present in the capital city, Freetown.
By mid-September 2014, Liberia was reporting more than 500 
new EVD cases per week, mostly driven by a large outbreak in 
Montserrado county, which encompasses the capital city, Monrovia. 
Sierra Leone reported more than 700 new cases per week by mid- 
November, with large outbreaks in Port Loko, Western Urban 
(Freetown) and Western Rural districts (Freetown suburbs). 
December 2014 brought the first signs that efforts to control the 
epidemic in Sierra Leone were effective, as EVD incidence began to 
drop. By March 2015, the epidemic was largely under control in Liberia 
and eastern Guinea, although sustained transmission continued 
in the border area of western Guinea and western Sierra Leone. By the 
following month, prevalence had declined such that only a handful 
of lineages persisted10,14 (Fig. 2).
The last EBOV genome obtained from a conventionally acquired 
infection was collected and sequenced in October 2015 in Forécariah 
prefecture (Guinea)10. After this, only sporadic cases of EVD were 
detected: in Montserrado (Liberia) in November 2015, Tonkolili 
(Sierra Leone) in January and February 2016, and Nzérékoré 
(Guinea) in March 2016. All these sporadic cases probably resulted 
from transmission from EVD survivors with established, persistent 
infections11,12,14.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Factors associated with EBOV dispersal
To determine the factors that influenced the spread of EBOV among 
administrative regions at the district (Sierra Leone), prefecture 
(Guinea) and county (Liberia) levels, we used a phylogeographic gen-
eralized linear model (GLM)18. Of the 25 factors assessed (see Extended 
Data Table 1 for a full list and description), 5 were included in the 
model with categorical support (Table 1). In summary, EBOV tends to 
disperse between geographically close regions (great circle distance, 
Bayes factor (BF) support for inclusion: BF > 50). Half of all virus dis-
persals occurred between locations less than 72 km apart and only 5% 
involved movement over 232 km (Fig. 3a). Both origin and destina-
tion population sizes are very strongly (BF > 50) positively correlated 
with viral dissemination, with a stronger effect for origin population 
size. The positive effect of population sizes combined with the inverse 
effect of the geographic distance implies that the spread of the epidemic 
followed a classic gravity-model dynamic. Gravity models, widely used 
in economic and geographic studies and a natural choice for mod-
elling infectious disease transmission19–21, describe the movement of 
people between locations as a function of their population sizes and 
the distance that separates them. Here we use viral genomes to provide 
empirical evidence that such a process drove viral dissemination during 
the EVD epidemic.
In addition to geographical distance, we found a significant propen-
sity for virus dispersal to occur within each country, relative to inter-
national dispersal (nat./int. effect, BF > 50), suggesting that country 
borders acted to curb the geographic spread of EBOV. When interna-
tional dispersals do take place, they are more intense between admin-
istrative regions that are adjacent at an international border (IntBoSh, 
BF > 50).
We tested whether sharing of any of 17 vernacular languages explains 
virus spread, as common languages might reflect cultural links, includ-
ing between non-contiguous or international regions, but we found 
no evidence that such linguistic links were correlated with EBOV 
spread. A variety of other possible predictors of EBOV transmission, 
such as aspects of urbanization (economic output, population density, 
travelling times to large settlements) as well as climatic effects, were not 
significantly associated with virus dispersal. However, these factors may 
have contributed to the size and longevity of transmission chains after 
introduction to a region (see below).
Finally, to investigate the potential of ‘real-time’ viral genome 
sequencing, we considered the degree to which the findings could 
have been obtained at the height of the epidemic, had sequences been 
available shortly after the samples were taken (see Methods for details). 
For the factors associated with EBOV dispersal, the results were highly 
comparable to those for the full dataset whereby the same five factors 
were strongly supported and these had similar effect sizes (Extended 
Data Fig. 3).
Factors associated with local EBOV proliferation
The analysis above identified predominantly geographical and adminis-
trative factors that predict the degree of importation risk, that is, the like-
lihood that a viral lineage initiates at least one infection in a new region. 
However, the epidemiological consequences of each introduction— 
the size and duration of resulting transmission chains—may be 
affected by different factors. Therefore, we investigated which demo-
graphic, economic and climatic factors might predict cumulative case 
counts1 for each region (Bayesian GLM; see Methods) and found that 
these were associated with factors related to urbanization (Table 2): 
primarily population sizes (PopSize, BF = 29.6) and a significant 
inverse association with travel times to the nearest settlement with more 
than 50,000 inhabitants (TT50K, BF = 32.4). These results confirm 
the common perception that, in contrast to previous EVD outbreaks, 
widespread transmission within urban regions in West Africa was a 
major contributing factor to the scale of the epidemic of the Makona 
variant.
As the epidemic in West Africa progressed, there were fears that 
increased rainfall and humidity might prolong the environmental per-
sistence of EBOV particles, increasing the likelihood of transmission22. 
Although we found no evidence of an association between EBOV dis-
persal and any aspects of local climate, we find that regions with less 
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seasonal variation in temperature, and with more rainfall, tended to 
have larger EVD outbreaks (TempSS, BF > 50 and Precip, BF = 4.4, 
respectively).
The impact of international travel restrictions
Porous borders between Liberia, Sierra Leone and Guinea may have 
allowed the unimpeded EBOV spread during the 2013–2016 epi-
demic23–25. Our results indicate that international borders were associ-
ated with a decreased rate of transmission events compared to national 
borders (Extended Data Fig. 4), but that frequent international 
cross-border transmission events still occurred. These events were 
concentrated in the Guéckédou prefecture (Guinea), Kailahun district 
(Sierra Leone) and Lofa county (Liberia) during the early stages of 
the epidemic (Extended Data Fig. 5a), and between the Forécariah 
prefecture (Guinea) and Kambia district (Sierra Leone) at the later 
stage (Extended Data Fig. 5b). These later EBOV movements hin-
dered efforts to interrupt the final chains of transmission in late 2015, 
with EBOV from these chains moving back and forth across this 
border10,14,26. Sierra Leone announced border closures on 11 June 
2014, followed by Liberia on 27 July 2014, and Guinea on 9 August 
2014, but little information is available about what these border 
closures actually entailed. Although we show that the relative contribution 
of international spread to overall viral migration was lower after coun-
try borders were closed (mean nat./int. coefficient increasing from 
1.15 to 2.83 between August and September 2014; 80.0% posterior 
support; (Fig. 2b)), it is difficult to ascertain whether the border 
closures themselves were responsible for the apparent reduction in 
cross-border transmissions, as opposed to concomitant control efforts 
or public information campaigns. However, even if border closures 
reduced international traffic, particularly over longer distances and 
between larger population centres, by the time that Sierra Leone and 
Liberia had closed their borders, the epidemic had become firmly 
established in both countries.
Why did the epidemic not spread further?
A few EBOV exportations were documented from Guinea by road 
transport into Mali and Senegal27,28 and by air from Liberia to Nigeria 
and the USA29,30. However, apart from these limited exceptions, the 
West African Ebola virus epidemic did not spread into the neigh-
bouring regions of Côte d’Ivoire, Guinea-Bissau, Mali and Senegal. 
By extending our GLM (the supported predictors and their estimated 
coefficients) to include these regions we were able to address whether 
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arising from independent 
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a, EBOV lineages by country 
(Guinea, green; Sierra Leone, blue; 
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Table 1 | Summary of phylogenetic generalized linear model results
Predictor* Description Coefficient† 95% CI‡ Inclusion§ BF||
Nat./int. National dispersal 
relative to international
3.07 2.36, 3.77 1.0 >50
Distances Great circle distances 
between the locations’ 
population centroids¶
−0.77 −0.91, −0.63 1.0 >50
OrPop Population size at the 
location of origin
1.36 0.86, 1.84 1.0 >50
DestPop Population size at the 
destination location
0.74 0.43, 1.06 1.0 >50
IntBoSh Two locations share an 
international border
3.39 2.42, 4.33 1.0 >50
OrTempSS Index of temperature 
seasonality at origin
−0.47 −0.88, −0.11 0.1 3.79
*Predictors included in the model with Bayes factor >3. 
†Mean coefficient. 
‡95% highest posterior density credible interval (CI). 
§Probability that the predictor was included in the model. 
||BF, Bayes factor. 
¶Population centroids indicate the centre of a location weighted by population.
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these regions were spared EVD cases through good fortune, or because 
they were associated with an inherently lower risk of EBOV spread 
and transmission. We estimated the degree to which these, apparently 
EVD-free, regions had the potential to be exposed to viral introductions 
from affected regions (see Methods).
Overall, the contiguous regions in unaffected neighbouring coun-
tries were all predicted to have low numbers of EBOV introductions 
(Fig. 4a and Extended Data Fig. 6a) based on the phylogeographic 
history of the sampled cases. They were not, however, predicted to 
have particularly low levels of transmission if an outbreak had started 
(Fig. 4b and Extended Data Fig. 6b). Therefore, it is likely that some 
of these regions were at risk of becoming part of the EVD epidemic, 
but that their geographical distance from areas of active transmission 
and the attenuating effect of international borders prevented this from 
occurring. The Kati cercle in Mali and Tonkpi region in Côte d’Ivoire 
are to some extent exceptions to this general result, as these were more 
susceptible to EBOV introductions under the gravity model because of 
their large populations (1 million and 950,000, respectively) (Fig. 4a), 
and are predicted to have experienced many cases had EVD become 
established (Fig. 4b).
Metapopulation structure and dynamics of the epidemic
After the initial establishment of transmission in Sierra Leone and 
Liberia, Guinea experienced repeated reintroductions of viral lineages 
from disparate transmission chains from both countries (Fig. 2). Our 
analysis reveals that there were at least 21 (95% CI, 16–25) reintroduc-
tions into Guinea from April 2014 to February 2015. An early epidemic 
lineage was established around the Guinean capital, Conakry, and per-
sisted for the duration of the epidemic (GN-1 in Figs 1, 2). However, 
the continual reintroduction of EBOV into Guinea without a clear peak 
in transmission suggests that the virus may have been failing to main-
tain transmission elsewhere. There were also numerous introductions 
into Sierra Leone over a similar time period (median, 9; 95% CI, 6–12), 
but the resulting transmission chains constituted a very small propor-
tion of the country’s EVD cases, with the bulk of transmission resulting 
from one early introduction (Fig. 2a).
In all three countries, repeated introductions into administrative 
regions seems to have been a large factor in the longevity of the EVD 
epidemic (Extended Data Fig. 7). As such, regional case numbers 
were generally the result of multiple overlapping introduction events 
followed by within-region spread and occasional onward transmis-
sion to other regions. This suggests a metapopulation model in which 
the persistence of the epidemic was driven by introduction into novel 
contact networks rather than by mass-action transmission, such as 
susceptible-infectious-removed dynamics31,32. We found that, on 
average, EBOV migrates between administrative regions at a rate of 
Table 2 | Summary of generalized linear model results with case 
counts as the response variable
Predictor* Description Coefficient† 95% CI‡ Inclusion§ BF||
TempSS Temperature 
seasonality
−1.1 −1.6, −0.5 0.83 >50
TT50K Time to travel to a 
population centre of 
50,000 people
−0.9 −1.4, −0.4 0.62 32.4
PopSize Population size 0.9 0.3, 1.6 0.60 29.6
Precip Precipitation 0.8 0.2, 1.3 0.18 4.4
TT100K Time to travel to a 
population centre of 0.1 
million people
−0.8 −1.7, −0.1 0.16 3.8
*Predictors included in the model with Bayes factor >3. 
†Mean coefficient. 
‡95% highest posterior density credible interval (CI). 
§Probability that the predictor was included in the model. 
||BF, Bayes factor.
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Figure 3 | The metapopulation structure of the 
epidemic. a, Kernel density estimate of distances 
associated with inferred EBOV dispersal events: 
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estimate of the number of independent EBOV 
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0.85 events per lineage per year (95% CI, 0.72–0.97). Assuming a serial 
interval of 15.3 days33, this rate translates to a 3.6% chance (95% CI, 
3.0–4.1%) that over the course of a single infection, the transmission 
chain moved between regions. Given the key role that virus dispersal 
played in sustaining the epidemic, the detection and isolation of these 
relatively low proportions of mobile cases may have a disproportionate 
effect on the control of an EVD epidemic.
From our spatial phylogenetic model we conclude that many regions 
experienced numerous independent EBOV introductions (Fig. 3b). 
However, these introductions gave rise to clusters of cases that were 
generally small (a mean cluster size of 4.3 and only 5% larger than 17 in 
our sample; Fig. 3c) and of limited duration (a mean persistence time of 
41.3 days with only 5% greater than 181 days; Fig. 3d). Here, we define 
a cluster as a group of sequenced cases in a region that derive from a 
single introduction event and define persistence as the time between 
the introduction event and the last sampled case in the cluster. These 
definitions are conservative regarding sampling intensity, as we expect 
additional samples would have split clusters apart rather than join them. 
Furthermore, introductions that were not detected will be dispropor-
tionately smaller, and so the cluster size estimate will be biased upwards. 
Segregating these observations by country (Extended Data Fig. 8 (left)) 
shows that districts of Sierra Leone had more introductions and that 
Guinea generally had smaller clusters, but that persistence was similar 
between the three countries. A comparison between introductions that 
occurred before October 2014 and those that occurred after this date 
shows that the number of introductions per location was comparable, 
whereas those that occurred early generally resulted in larger and more 
persistent clusters (Extended Data Fig. 8 (right)).
Therefore, with 5.8% sampling, we arrive at a conservative estimate 
of approximately 75 regional cases per introduction event. Although 
larger population centres, in particular capital cities, generally expe-
rienced more introductions (Extended Data Fig. 9a), the cluster sizes 
are less strongly associated with population size (Extended Data 
Fig. 9b), further highlighting the role of virus movement into urban 
areas as major factor for the high caseloads in large population centres. 
Frequent cluster extinction, despite a small fraction of individuals being 
infected, suggests that individual outbreaks were constrained by the 
degree of connectedness among contact networks. Thus, it appears that 
the West African EVD epidemic was sustained by frequent introduc-
tions that resulted in numerous small local clusters of cases, some of 
which went on to further seed clusters in other locations.
Viral genomics as a tool for outbreak response
The 2013–2016 EVD epidemic in West Africa has unfortunately 
become a costly lesson in addressing an infectious disease outbreak 
in the absence of preparedness of both the exposed population and 
the international community. Our work demonstrates the value of 
pathogen genome sequencing in a public healthcare emergency and 
the value of timely pre-publication data sharing to identify the origins 
of imported disease case clusters, to track pathogen transmission as 
the epidemic progresses, and to follow up on individual cases as the 
epidemic subsides.
It is inevitable that as sequencing costs decrease, accuracy increases 
and sequencing instruments become more portable, real-time viral 
surveillance and molecular epidemiology will be routinely deployed 
on the front lines of infectious disease outbreaks10,14,16,34–36. Although 
we have shown here that the broad pattern of EBOV spatial movement 
was discernible from virus genomes derived from samples collected up 
until October 2014 only, there was a notable hiatus in sequencing at 
this time35 and the genomes in the present dataset from that time were 
sequenced retrospectively from archived material. The West African 
EVD epidemic has demonstrated that a steady sequencing pace34–36, 
local sequencing capacity10,14,16 and rapid dissemination of data7 are 
key requirements in generating actionable sequence data from an 
infectious disease outbreak. However, as viral genome sequencing is 
scaled up and approaches the timescale of viral evolution, the analysis 
techniques will increasingly represent the bottleneck for timely com-
munication of information for an outbreak response.
The analysis of the comprehensive EBOV genome set that was col-
lected during the 2013–2016 EVD epidemic, including the findings pre-
sented here and in other studies7,9,13–17,37,38, provides a framework for 
predicting the behaviour of future disease outbreaks caused by EBOV, 
other filoviruses and perhaps other human pathogens. However, many 
questions remain about the biology of EBOV. As sustained human-to-
human transmission waned, West Africa experienced several instances 
of recrudescent transmission, often in regions that had not seen cases 
for many months as a result of persistent sub-clinical infections11,12,39. 
Although, in hindsight, such sequelae were not entirely unexpected40, 
the magnitude of the 2013–2016 epidemic has put the region at ongo-
ing risk of sporadic EVD re-emergence. Similarly, the nature of the 
reservoir of EBOV, and its geographic distribution, remain as funda-
mental gaps in our knowledge. Resolving these questions is critical to 
predicting the risk of zoonotic transmission and therefore of future 
EVD outbreaks.
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METHODS
Sequence data. We compiled a dataset of 1,610 publicly available full EBOV 
genomes sampled between 17 March 2014 and 24 October 2015 (see https://github/
ebov/space-time/data/ for the full list and metadata). The number of sequences 
and the proportion of cases sequenced varies between countries; our dataset con-
tains 209 sequences from Liberia (3.8% of known and suspected cases), 982 from 
Sierra Leone (8.0%) and 368 from Guinea (9.2%) (Supplementary Table 1). Most 
(n = 1,100) genomes are of high quality, with ambiguous sites and gaps comprising 
less than 1% of the total alignment length, followed by sequences with between 1% 
and 2% of sites that comprised ambiguous bases or gaps (n = 266), 98 sequences 
with 2–5%, 120 sequences with 5–10% and 26 sequences with more than 10% 
of sites that are ambiguous or are gaps. Sequences known to be associated with 
sexual transmission or latent infections were excluded, as these viruses often exhibit 
anomalous molecular clock signals11,12. Sequences were aligned using MAFFT41 
and edited manually. The alignment was partitioned into coding regions and 
non-coding intergenic regions with a final alignment length of 18,992 nucleotides 
(available from https://github/ebov/space-time/data/).
Masking putative ADAR-edited sites. As noticed in previous studies15,38, some 
EBOV isolates contain clusters of T-to-C mutations within relatively short stretches 
of the genome. Interferon-inducible adenosine deaminases acting on RNA (ADAR) 
are known to induce adenosine to inosine hypermutations in double-stranded 
RNA43. ADARs have been suggested to act on RNAs from numerous groups of 
viruses42. When negative-sense single-stranded RNA virus genomes are edited 
by ADARs, A-to-G hypermutations seem to preferentially occur on the negative 
strand, which results in U/T-to-C mutations on the positive strand44–46. Multiple 
T-to-C mutations are introduced simultaneously by ADAR-mediated RNA editing 
which would interfere with molecular clock estimates and, by extension, the tree 
topology. We therefore designated that four or more T-to-C mutations within 300 
nucleotides of each other as a putative hypermutation tract, whenever there is 
evidence that all T-to-C mutations within such stretches were introduced at the 
same time, that is, every T-to-C mutation in a stretch occurred on a single branch. 
We detected a total of 15 hypermutation patterns with up to 13 T-to-C mutations 
within 35 to 145 nucleotides. Of these patterns, 11 are unique to a single genome 
and 4 are shared across multiple isolates, suggesting that occasionally viruses that 
survive hypermutation are transmitted47. Putative tracts of T-to-C hypermutation 
almost exclusively occur within non-coding intergenic regions, where their effects 
on viral fitness are presumably minimal. In each case, we mask out these sites as 
ambiguous nucleotides, but leave the first T-to-C mutation unmasked to provide 
phylogenetic information on the relatedness of these sequences.
Phylogenetic inference. Molecular evolution was modelled according to a 
HKY+Γ4 substitution model (refs 48, 49) independently across four partitions 
(codon positions 1, 2, 3 and non-coding intergenic regions). Site-specific rates 
were scaled by relative rates in the four partitions. Evolutionary rates were allowed 
to vary across the tree according to a relaxed molecular clock that draws branch- 
specific rates from a log-normal distribution50. A non-parametric coalescent 
‘Skygrid’ model was used to act as a prior density on trees51. The overall evolu-
tionary rate was given an uninformative continuous-time Markov chain (CTMC) 
reference prior52, while the rate multipliers for each partition were given an unin-
formative uniform prior over their bounds. All other priors used to infer the phy-
logenetic tree were left at their default values. BEAST XML files are available from 
https://github/ebov/space-time/data/. We ran an additional analysis with a subset 
of data (787 sequences collected up to November 2014—the peak of case numbers 
in Sierra Leone) to test the robustness of inference if they had been performed 
mid-epidemic.
Geographic history reconstruction. The level of administrative regions within 
each country was chosen so that population sizes between regions are compa-
rable. For each country the appropriate administrative regions were: prefecture 
for Guinea (administrative subdivision level 2), county for Liberia (level 1) and 
district for Sierra Leone (level 2). We refer to them as regions (63 in total, but 
only 56 are recorded to have had EVD cases) and each sequence, where available, 
was assigned the region where the patient was recorded to have been infected as 
a discrete trait. When the region within a country was unknown (n = 223), we 
inferred the sequence location as a latent variable with equal prior probability over 
all available regions within that country. Most of the sequences with unknown 
regional origins were from Sierra Leone (n = 151), followed by Liberia (n = 69) and 
Guinea (n = 3). In the absence of any geographic information (n = 2) we inferred 
both the country and the region of a sequence.
We used an asymmetric CTMC53,55 matrix to infer instantaneous transitions 
between regions. For 56 regions with recorded EVD cases, a total of 3,080 inde-
pendent transition rates would be challenging to infer from one realization of the 
process, even when reduced to a sparse migration matrix using stochastic search 
variable selection53.
Therefore, to infer the spatial phylogenetic diffusion history between the K = 56 
locations, we adopt a sparse GLM formulation of CTMC diffusion18. This model 
parameterizes the instantaneous movement rate Λij from location i to location j as 
a log-linear function of P potential predictors Xij = (xij1, …, xijP)′ with unknown 
coefficients β  = (β1, …, βP)′ and diagonal matrix δ with entries (δ1, …, δp). These 
latter unknown indicators δp ∈ {0,1} determine the inclusion in or exclusion from 
the model of a single predictor. We generalize this formulation here to include 
two-way random effects that allow for location origin- and destination-specific 
variability. Our two-way random effects GLM becomes
′ δβΛ ε ε= + +Xlog( ) (1)ij ij i j
where εk is distributed as normal(0, σ2) for k = 1, ..., K, and σ2 is distributed as 
inverse-Γ(0.001, 0.001), and where ε = (ε1, …, εK) are the location-specific effects. 
These random effects account for unexplained variability in the diffusion process 
that may otherwise lead to spurious inclusion of predictors.
We follow ref. 18 by specifying that a priori all βp are independent and normally 
distributed with mean 0 and a relatively large variance of 4 and by assigning inde-
pendent Bernoulli prior probability distributions on δp.
Let q be the inclusion probability and w be the probability of no predictors being 
included. Then, using the distribution function of a binomial random variable 
q = 1 − w1/P, where P is the number of predictors, as before. We use a small success 
probability on each predictor’s inclusion that reflects a 50% prior probability (w) 
on no predictors being included.
In our main analysis, we consider 25 individual predictors that can be classi-
fied as geographic, administrative, demographic, cultural and climatic covariates 
of spatial spread (Extended Data Table 1). Where measures are region-specific 
(rather than pairwise region measures), we specify both an origin and destina-
tion predictor. We also tested for sampling bias by including an additional origin 
and destination predictor based on the residuals for the regression of sample size 
against case count (Extended Data Fig. 1b), but these predictors did not receive 
any support (data not shown).
To draw posterior inference, we follow ref. 18 by integrating β and δ, and further 
employ a random-walk Metropolis transition kernel on ε and sample σ2 directly 
from its full conditional distribution using Gibbs sampling.
To obtain a joint posterior estimate from this joint genetic and phylogeographic 
model, an MCMC chain was run in BEAST 1.8.4 (ref. 54) for 100 million states, 
sampling every 10,000 states. The first 1,000 samples in each chain were removed 
as burnin, and the remaining 9,000 samples used to estimate a maximum clade 
credibility tree and to estimate posterior densities for individual parameters. 
A second independent run of 100 million states was performed to check conver-
gence of the first.
To consider the feasibility of ‘real-time’ inference from virus genome data from 
the height of the EVD epidemic we took only those sequences derived from sam-
ples taken up until the end of October 2014 (n = 787). We undertook the same joint 
phylogenetic and spatial GLM analysis as for the full dataset including the same set 
of 25 predictors. We ran this analysis for 200 million states, sampling every 20,000 
states and removing the first 10% of samples.
To obtain realizations of the phylogenetic CTMC process, including both tran-
sitions (Markov jumps) between states and waiting times (Markov rewards) within 
states, we used posterior inference of the complete Markov jump history through 
time18,56. In addition to transitions ‘within’ the phylogeny, we also estimate the 
expected number of transitions ‘from’ origin location i in the phylogeographic tree 
to arbitrary ‘destination’ location j as follows:
ζ τ μΛ π= /c (2)ij i ij i
where τi is the waiting time (or Markov reward) in ‘origin’ state i throughout the 
phylogeny, μ is the overall rate scalar of the location transition process, πi is the 
equilibrium frequency of ‘origin’ state i, and c is the normalizing constant applied 
to the CTMC rate matrices in BEAST. To obtain the expected number of transitions 
to a particular destination location from any phylogeographic location (integrat-
ing over all possible locations across the phylogeny), we sum over all 56 origin 
locations included in the analysis. We note that the destination location can also 
be a location that was not included in the analysis because we only need to con-
sider destination j in the instantaneous movement rates Λij; since the log of these 
rates are parameterized as a log-linear function of the predictors, we can obtain 
these rates through the coefficient estimates from the analysis and the predictors 
extended to include these additional locations. Specifically, we use this to predict 
introductions in regions in Guinea, for which no cases were reported (n = 7) and 
for regions in neighbouring countries along the borders with Guinea or Liberia 
that remained disease free (n = 18). To obtain such estimates under different pre-
dictors or predictor combinations, we perform a specific analysis under the GLM 
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model including only the relevant predictors or predictor combinations without 
the two-way random effects. For computational expedience, we performed these 
analyses, as well as the time-inhomogeneous analyses below, by conditioning on 
a set of 1,000 trees from the posterior distribution of the main phylogenetic anal-
ysis18. We summarize mean posterior estimates for the transition expectations 
based on the samples obtained by our MCMC analysis; we also note that the value 
of c is sample-specific.
Time-dependent spatial diffusion. To consider time-inhomogeneity in the spatial 
diffusion process, we start by borrowing epoch modelling concepts from ref. 57. 
The epoch GLM parameterizes the instantaneous movement rate Λijt from state 
i to state j within epoch t as a log-linear function of P epoch-specific predictors 
Xijt = (xijt1, …, xijtP)′ with constant-through-time, unknown coefficients β. We gen-
eralize this model to incorporate a time-varying contribution of the predictors 
through time-varying coefficients β(t) using a series of change-point processes. 
Specifically, the time-varying epoch GLM models
Λ β
β φ β φ β
= ′
= − +
X
I
t
t t t
log ( )
( ) ( ( )) ( ( ))
(3)ijt ijt
B A
where βB = (βB1, …, βBP)′ are the unknown coefficients before the change-points, 
βA = (βA1, …, βAP)′ are the unknown coefficients after the change-points, diagonal 
matrix ϕ(t) has entries ...> >t t(1 ( ), , 1 ( ))t t t tP1 , ⋅ t1 ( )( )  is the indicator function and 
T = (t1, …, tP) are the unknown change-point times. In this general form, the 
contribution of predictor p before its change-point time tp is βBp and its contribu-
tion after is βAp for P = 1, …, P. Fixing tp to be less than the time of the first epoch 
or greater than the time of the last epoch results in a time-invariant coefficient for 
that predictor.
Similar to the constant-through-time GLM, we specify a priori that all βBp and 
βAp are independent and normally distributed with mean 0 and a relatively large 
variance of 4. Under the prior, each tp is equally probable to lie before any epoch.
We used random-walk Metropolis transition kernels on βB, βA and T.
In a first epoch GLM analysis, we keep the five predictors that are convincingly 
supported by the time-homogeneous analysis included in the model and estimate 
an independent change-point tp for their associated effect sizes: distance, 
nat./int. effect, shared international border and origin and destination population 
size change-points. To quantify the evidence in favour of each change-point, we 
calculate Bayes factor support on the basis of the prior and posterior odds that tp 
is less than the time of the first epoch or greater than the time of the last epoch. 
Because we find only very strong support for a change-point in the nat./int. effect, 
we subsequently estimate the effect sizes before and after its associated change-
point, keeping the remaining four predictors homogeneous through time.
Within-location generalized linear models. EVD case numbers are reported by 
the WHO for every country division (region) at the appropriate administrative 
level, split by epidemiological week. For every region and for each epidemiological 
week four numbers are reported: new cases in the patient and situation report 
databases as well as whether the new cases are confirmed or probable. At the height 
of the epidemic many cases went unconfirmed, even though they were likely to 
have been genuine EVD. As such, we treat probable EVD cases in WHO reports 
as confirmed and combine them with laboratory-confirmed EVD case numbers. 
Following this we take the higher combined case number of situation report and 
patient databases. The latest situation report in our data goes up to the epidemio-
logical week spanning 8 to 14 February 2016, with all case numbers being down-
loaded on 22 February 2016. There are apparent discrepancies between cumulative 
case numbers reported for each country over the entire epidemic and case numbers 
reported per administrative division over time, such that our estimate for the final 
size of the epidemic, based on case numbers over time reported by the WHO, is 
on the order of 22,000 confirmed and suspected cases of EVD compared to the 
official estimate of around 28,000 cases across the entire epidemic. This likely arose 
because case numbers are easier to track at the country level, but become more 
difficult to narrow down to administrative subdivision level, especially over time 
(only 86% of the genome sequences had a known location of infection).
We studied the association between disease case counts using generalized linear 
models in a very similar fashion to the framework presented above. A list of the 
location-level predictors we used for these analyses can be found in Extended Data 
Table 1. We also employed stochastic search variable selection as described above, 
in order to compute Bayes factors (BFs) for each predictor. In keeping with the 
genetic GLM analyses, we also set the prior inclusion probabilities such that there 
was a 50% probability of no predictors being included.
λ
λ α β δ β δ
∼ −
=
+
= + + ... +
Y p r
p r
r
x x
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( )
log( )
i i
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i i P P iP1 1 1
where r is the over-dispersion parameter, δi are the indicators as before. Prior 
distributions on model parameters for these analyses were the same as those used 
for the genetic analyses whenever possible. We then use this model to predict how 
many cases the locations which reported zero EVD cases would have gathered, that 
is, the potential size of the epidemic in each location.
Computational details. To fit the models described above we took advantage of the 
routines already built in BEAST (https://github.com/beast-dev/beast-mcmc) but in 
a non-phylogenetic setting. Once again, posterior distributions for the parameters 
were explored using MCMC. We ran each chain for 50 million iterations and dis-
carded at least 10% of the samples as burn-in. Convergence was checked by visual 
inspection of the chains and checking that all parameters had effective sample sizes 
greater than 200. We ran multiple chains to ensure that results were consistent. 
To make predictions, we used 50,000 Monte Carlo samples from the posterior 
distribution of coefficients and the overdispersion parameter (r) to simulate case 
counts for all locations with zero recorded EVD cases.
Data availability. All collated data, genetic sequence alignments, phylogenetic 
trees, analysis scripts and analysis output are available at https://github.com/
ebov/space-time and http://dx.doi.org/10.7488/ds/1711. Individual virus genetic 
sequences are published in earlier works and are available from NCBI GenBank 
(see https://github.com/ebov/space-time for a list of accession numbers and 
references).
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a)
b)
Extended Data Figure 1 | Distribution and correlation of EVD cases and 
EBOV sequences. a, Administrative regions within Guinea (green), Sierra 
Leone (blue) and Liberia (red); shading is proportional to the cumulative 
number of known and suspected EVD cases in each region. Darkest 
shades represent 784 cases for Guinea (Macenta prefecture); 3,219 cases 
for Sierra Leone (Western Area urban district); and 2,925 cases for Liberia 
(Montserrado county); hatching indicate regions without reported EVD 
cases. Circle diameters are proportional to the number of EBOV genomes 
available from that region over the entire EVD epidemic with the largest 
circle representing 152 sequences. Crosses mark regions for which no 
sequences are available. Circles and crosses are positioned at population 
centroids within each region. b, A plot of number of EBOV genomes 
sampled against the known and suspected cumulative EVD case numbers. 
Regions in Guinea are denoted in green, Sierra Leone in blue and Liberia 
in red. Spearman correlation coefficient: 0.93.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 2 | Dispersal of virus lineages over time. 
Virus dispersal between administrative regions estimated using the GLM 
phylogeography model (see Methods). The arcs are between population 
centroids of each region, show directionality from the thin end to the thick 
end and are coloured in a scale denoting time from December 2013 in 
blue to October 2015 in yellow. Countries are coloured with Liberia in red, 
Guinea in green and Sierra Leone in blue.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 3 | Inference of GLM predictors in a ‘real-time’ 
context. For the dataset constructed from EBOV genome sequences 
derived from samples taken up until October 2014 (blue), the same 
5 spatial EBOV movement predictors were given categorical support 
(inclusion probabilities = 1.0) as for the full dataset (red). Likewise, the 
coefficients for these predictors are consistent in their sign and magnitude.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 4 | The effect of borders on EBOV migration 
rates between regions. Posterior densities for the migration rates between 
locations that share a geographical border and those that do not share 
borders for international migrations and national migrations. Where 
two regions share a border (right y axis), national migrations are only 
marginally more frequent than international migrations showing that 
both types of borders are porous to short local movement. Where the two 
regions are not adjacent (left y axis), international migrations are much 
rarer than national migrations.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 5 | Summarized international migration history 
of the epidemic. a, b, All viral movement events between countries 
(Guinea, green; Sierra Leone, blue; Liberia, red) are shown split by 
whether they are between regions that are geographically distant (a) or 
regions that share the international border (b). Curved lines indicate 
median (intermediate colour intensity), and 95% highest posterior density 
intervals (lightest and darkest colour intensities) for the number of 
migrations that are inferred to have taken place between countries.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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a)
b)
Extended Data Figure 6 | Comparison of predicted and observed 
numbers of introductions and case numbers. a, b, Left, scatter plots show 
inferred introduction numbers (a) or observed case numbers (b), coloured 
by region as in Extended Data Fig. 1. Administrative regions that did 
not report any cases are indicated with empty circles on the scatter plot. 
Right, administrative regions on the map are coloured by the residuals (as 
observed/predicted) of the scatter plot. Regions are coloured grey where 
0.5 < observed/predicted < 2.0 and transition into red or blue colours for 
overestimation or underestimation, respectively.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 7 | Region-specific introductions, cluster sizes 
and persistence. Each row summarizes independent introductions and 
the sizes (as numbers of sequences) of resulting outbreak clusters. Clusters 
are coloured by their inferred region of origin (colours are the same as 
in Extended Data Fig. 1). The horizontal lines represent the persistence 
of each cluster from the time of introduction to the last sampled case 
(individual tips have persistence 0). The areas of the circles in the middle 
of the lines are proportional to the number of sequenced cases in the 
cluster. The areas of the circles next to the labels on the left represent the 
population sizes of each administrative region. Vertical lines within each 
cell indicate the dates of declared border closures by each of the three 
countries: 11 June 2014 in Sierra Leone (blue), 27 July 2014 in Liberia (red) 
and 09 August 2014 in Guinea (green).
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 8 | Kernel density estimates for inferred 
epidemiological statistics. From top to bottom, distance travelled 
(distance between population centroids, in kilometres); number of 
introductions that each location experienced; cluster size (number of 
sequences collected in a location as a result of a single introduction); 
cluster persistence (days from the common ancestor of a cluster to its 
last descendent, single tips have persistence of 0. Left, analysis for Sierra 
Leone (blue), Liberia (red) and Guinea (green). Right, analysis for before 
October 2014 (grey) and after October 2014 (orange). Points with vertical 
lines connected to the x axis indicate the 50% and 95% quantiles of the 
parameter density estimates. Within Sierra Leone, Liberia and Guinea, 
50% of all migrations occurred over distances of around 100 km and 
persisted for around 25 days. Exceptions were for Sierra Leone, which 
experienced more introductions per location (around 12) than Guinea 
and Liberia (around 4); and Guinea, where migrations tended to occur 
over larger distances owing to the size of the country and whose cluster 
sizes following introductions tended to be lower (3 sequences versus 
Liberia and Sierra Leone, which had 5 sequences each). Between the first 
(grey) and second (orange) years of the epidemic there were considerable 
reductions in cluster persistence, cluster sizes and distances travelled by 
viruses, whereas dispersal intensity remained largely the same.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 9 | Relationship between cluster size, 
introductions or persistence and population size. a, The mean number 
of introductions into each location against (log) population sizes. 
The Western Area (in Sierra Leone) received the most introductions, 
whereas Conakry and Montserrado were closer to the average. The 
association between population size and the number of introductions 
was not very strong (R2 = 0.28, Pearson correlation = 0.54, Spearman 
correlation = 0.57). b, The mean cluster size for each location plotted 
against (log) population sizes. The association is weaker than for a 
(R2 = 0.11, Pearson correlation = 0.35, Spearman correlation = 0.57). 
c, The mean persistence times (per cluster, in days) against population 
sizes. A similarly weak association is observed as in b (R2 = 0.12, Pearson 
correlation = 0.37, Spearman correlation = 0.36). All computations were 
based on a sample of 10,000 trees from the posterior distribution.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Table 1 | Predictors included in the time-homogenous GLM
Predictor type Abbreviation Predictor description
Geographic Distances Great circle distances between the locations' population centroids, log-transformed, 
standardized 
Administrative Nat/Int Two locations are in the same country verses in different countries 
Administrative Nat/Int The relative preference of transitioning between locations in the same country over 
transitioning between locations in two different countries 
Administrative IntBoSh The relative preference of transitioning between location pairs that are in different 
countries and share a border 
Administrative NatBoSh The relative preference of transitioning between location pairs that are in the same 
country and share a border 
Administrative LibGinAsym Between Liberia-Guinea asymmetry 
Administrative LibSLeAsym Between Liberia-Sierra Leone asymmetry 
Administrative GinSLeAsym Between Guinea-Sierra Leone asymmetry 
Demographic OrPop Origin population size, log-transformed, standardized 
Demographic DestPop Destination population size, log-transformed, standardized 
Demographic OrPopDens Origin population density, log-transformed, standardized 
Demographic DestPopDens Destination population density, log-transformed, standardized 
Demographic OrTT100k Estimated mean travel time in minutes to reach the nearest major settlement of at least 
100,000 people at origin, log-transformed, standardized 
Demographic DestTT100k estimated mean travel time in minutes to reach the nearest major settlement of at least 
100,000 people at destination, log-transformed, standardized 
Demographic OrGrEcon Origin Gridded economic output, log-transformed, standardized 
Demographic DestGrEcon Destination Gridded economic output, log-transformed, standardized 
Cultural IntLangShared The relative preference of transitioning between location pairs that are in different 
countries and share at least one of 17 vernacular languages 
Cultural NatLangShared The relative preference of transitioning between location pairs that are in the same 
country and share at least one of 17 vernacular languages
Climatic OrTemp Temperature annual mean at origin, log-transformed, standardized 
Climatic DestTemp Temperature annual mean at destination, log-transformed, standardized 
Climatic OrTempSS Index of temperature seasonality at origin, log-transformed, standardized 
Climatic DestTempSS Index of temperature seasonality at destination, log-transformed, standardized 
Climatic OrPrecip Precipitation annual mean at origin, log-transformed, standardized 
Climatic DestPrecip Precipitation annual mean at destination, log-transformed, standardized 
Climatic OrPrecipSS Index of precipitation seasonality at origin, log-transformed, standardized 
Climatic DestPrecipSS Index of precipitation seasonality at destination, log-transformed, standardized 
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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ABSTRACT The Norovirus genus contains important human pathogens, but the role
of host pathways in norovirus replication is largely unknown. Murine noroviruses
provide the opportunity to study norovirus replication in cell culture and in small
animals. The human norovirus nonstructural protein NS1/2 interacts with the host
protein VAMP-associated protein A (VAPA), but the significance of the NS1/2-VAPA
interaction is unexplored. Here we report decreased murine norovirus replication in
VAPA- and VAPB-deficient cells. We characterized the role of VAPA in detail. VAPA
was required for the efficiency of a step(s) in the viral replication cycle after entry of
viral RNA into the cytoplasm but before the synthesis of viral minus-sense RNA. The
interaction of VAPA with viral NS1/2 proteins is conserved between murine and hu-
man noroviruses. Murine norovirus NS1/2 directly bound the major sperm protein
(MSP) domain of VAPA through its NS1 domain. Mutations within NS1 that disrupted
interaction with VAPA inhibited viral replication. Structural analysis revealed that the
viral NS1 domain contains a mimic of the phenylalanine–phenylalanine-acidic-tract
(FFAT) motif that enables host proteins to bind to the VAPA MSP domain. The
NS1/2-FFAT mimic region interacted with the VAPA-MSP domain in a manner similar
to that seen with bona fide host FFAT motifs. Amino acids in the FFAT mimic region
of the NS1 domain that are important for viral replication are highly conserved
across murine norovirus strains. Thus, VAPA interaction with a norovirus protein that
functionally mimics host FFAT motifs is important for murine norovirus replication.
IMPORTANCE Human noroviruses are a leading cause of gastroenteritis worldwide,
but host factors involved in norovirus replication are incompletely understood. Mu-
rine noroviruses have been studied to define mechanisms of norovirus replication.
Here we defined the importance of the interaction between the hitherto poorly
studied NS1/2 norovirus protein and the VAPA host protein. The NS1/2-VAPA inter-
action is conserved between murine and human noroviruses and was important for
early steps in murine norovirus replication. Using structure-function analysis, we
found that NS1/2 contains a short sequence that molecularly mimics the FFAT motif
that is found in multiple host proteins that bind VAPA. This represents to our knowl-
edge the first example of functionally important mimicry of a host FFAT motif by a
microbial protein.
KEYWORDS noroviruses, plus-strand RNA virus, protein structure-function, reverse
genetic analysis, viral replication, virus-host interactions
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Noroviruses (NoVs) are nonenveloped positive-sense single-stranded RNA virusesthat primarily infect the gastrointestinal tract. They are a leading cause of gastro-
enteritis worldwide (1–3). Noroviruses are divided into genogroups GI to GVI. Among
those genogroups, GI, GII, and GIV viruses cause human disease and GV encompasses
more recently discovered rodent NoVs, including murine norovirus (MNoV) (4). As
MNoVs replicate robustly in mice and cells and can be studied via mutagenesis of
infectious molecular clones, they serve as a powerful model for molecular studies of
norovirus replication, tropism, and pathogenesis (5, 6).
The norovirus genome encodes nine known proteins: seven nonstructural (NS)
proteins derived by proteolysis of the open reading frame (ORF) 1 polyprotein (7) and
two structural proteins, VP1 and VP2, derived from ORFs 2 and 3, respectively (6). MNoV
encodes virulence protein VF1 from ORF 4, which overlaps ORF 2 and has not been
found in human noroviruses (8). The N-terminal protein in the norovirus polyprotein,
NS1/2, comprises three domains: NS1, NS2, and a putative transmembrane domain (9).
The MNoV NS1 domain in isolation has a structured region preceded by an unstruc-
tured domain (9, 10). A single aspartic acid-to-glutamic acid difference within NS1
confers an altered conformation within the NS1 structured domain (10) and is associ-
ated with enteric tropism and the capacity of MNoV to persistently infect and be shed
from the mouse intestine (11). Ectopically expressed NS1/2 from GI human norovirus
(NS1/2GI) disrupts the Golgi apparatus and vesicular trafficking (12, 13) and is reported
to interact with the host protein VAMP-associated protein A (VAPA) (12). The role of
VAPA interactions with NS1/2 during viral replication has not been defined.
VAPA is a type II endoplasmic reticulum (ER)-resident protein that is conserved in
eukaryotes (14). VAPB is structurally related to VAPA (15). VAPA comprises a major
sperm protein (MSP) domain, a coiled-coil domain (CCD), and a transmembrane do-
main. Initially found to bind to proteins within the SNARE superfamily of vesicle
trafficking proteins (16–18), VAPA also binds a variety of client interacting proteins (14).
Importantly, through its cytosolic MSP domain, VAPA interacts with client proteins
primarily involved in lipid trafficking (14, 19–23). These client proteins interact with the
VAPA-MSP domain via a phenylalanine–phenylalanine-acidic-tract (FFAT) linear motif
(22, 24–27).
VAPA performs important functions during infection as both microbes and antimi-
crobial host molecules target VAPA and its client proteins. VAPA and VAPB enhance the
replication of hepatitis C virus (28, 29), rhinoviruses (30), tombusvirus (31, 32), and the
intracellular bacteria Chlamydia trachomatis (33, 34). Some of these microbes encode
molecules that interact with VAPA and VAPB and/or their client proteins, including
hepatitis C virus proteins NS5a and NS5b (28, 29), tombusvirus p33 (31, 32), and
C. trachomatis IncD (33, 34). Several observations support the idea that VAPA and VAPA
client proteins assist in organization of membranous structures critical for virus repli-
cation (35, 36), possibly by manipulating the lipid composition of these membranes
(30–32). Furthermore, VAPA binds to proteins regulated by interferon, interferon-
induced transmembrane protein 3 (37), and viperin (38, 39), suggesting that VAPA may
be involved in antiviral responses.
Here we found that VAPA enhances MNoV replication and defined the molecular
basis of NS1/2-VAPA interactions. Disruption of VAPA in permissive cells delayed MNoV
replication due to effects occurring after viral entry but prior to synthesis of viral
minus-sense RNA. VAPB was also important for MNoV replication and bound MNoV
NS1/2. The interaction between NS1/2 and VAPA was conserved between human
norovirus and MNoV NS1/2 proteins. The NS1 domain of MNoV NS1/2 interacted with
the MSP domain of VAPA. This interaction occurred independently of other cellular or
viral proteins and mapped to a short region in the NS1 domain sharing features of the
FFAT motif found in host proteins that also interact with the VAPA MSP domain. NS1
engaged VAPA MSP domain residues crucial for interaction with FFAT motifs found in
VAPA client proteins. Mutagenesis of conserved amino acids in NS1 to abrogate VAPA
interaction impaired recovery of infectious MNoV after transfection of permissive cells
with plasmids encoding the viral genome. These data indicate that NS1/2-VAPA binding
McCune et al. ®
July/August 2017 Volume 8 Issue 4 e00668-17 mbio.asm.org 2
is critical for efficient MNoV replication and that this occurs through viral mimicry of the
host FFAT motif by amino acids in the NS1 domain of the nonstructural NS1/2 protein.
RESULTS
Murine norovirus replication is diminished in VAPA-deficient cells. To test the
hypothesis that MNoV replication involves VAPA, we genetically engineered RAW 264.7
cells deficient in VAPA expression (here Vapa/) using clustered regularly interspaced
short palindromic repeats (CRISPR)-Cas9. In two single-cell cloned Vapa/ cell lines,
3A11 and 1E6, frameshifts in the first 37 nucleotides (see Fig. S1A in the supplemental
material) of coding sequence resulted in loss of VAPA protein expression (Fig. 1A).
Vapa/ cells infected with MNoV strain CW3 had 2.2-fold-fewer (1E6) or 4.0-fold-fewer
(3A11) NS1/2-positive cells by flow cytometry at 18 h postinfection (hpi) than wild-type
(WT) cells (Fig. 1B and C). We observed lower levels of replication of MNoV strains CW3
and CR6 in both Vapa/ cell lines (Fig. 1D; Fig. S1B). Reconstituting VAPA production
in Vapa/ cells via lentivirus transduction (Fig. 1E) increased the percentage of cells
FIG 1 Murine norovirus replication in Vapa/ cells is diminished. (A) VAPA Western blot of Vapa/ cell
lines. (B) Representative infection frequency of MNoV-CW3 in Vapa/ cells, measured by FACS analysis of
intracellular NS1/2 (18 h postinfection; MOI of 5.0). (C) Same as panel B. Data represent results of combined
experiments (repeated-measure two-way ANOVA, Dunnett posttest; n  3). (D) MNoV strain CW3 growth
in Vapa/ and Vapa/ cell lines (MOI, 0.05 [left] or 5.0 [right] PFU/cell). Data represent results of
repeated-measure one-way ANOVA and the Dunnett posttest (n  6). (E) Western blot of Vapa/ or
Vapa/ cell lines lentivirally transduced with FLAG-GFP or FLAG-Vapa. (F) Infection frequency in Vapa- or
GFP-transduced cells determined as described for panel B (two-way ANOVA, Sidak posttest; n 9). (G) CW3
growth in Vapa- or GFP-transduced cells. Data represent results of repeated-measure two-way ANOVA and
the Dunnett posttest (n  5). For G the asterisks refer to a comparison to the time-matched / GFP
control.
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expressing NS1/2 at 18 h postinfection by 2.7-fold (3A11) or 4.1-fold (1E6) compared to
transduction with green fluorescent protein (GFP) (Fig. 1F). Expression of VAPA, but not
GFP, rescued viral replication in Vapa/ cells (Fig. 1G). Because VAPA deficiency
incompletely blocked MNoV replication, we considered the possibility that VAPB might
compensate for VAPA function. We found that VAPB was also important for MNoV
replication (Fig. S1C). We were unable to efficiently isolate cell lines containing out-of-
frame mutations in both VAPA and VAPB to directly test the possibility that these two
proteins might compensate for each other (not shown). Furthermore, we were unable
to test the role of VAPA in mice as mutation of Vapa led to embryonic lethality (Fig. S1D
to F). We conclude that MNoV infectivity was enhanced by VAPA expression and chose to
examine the mechanism responsible in more detail for VAPA.
VAPA is important for an early postentry step in norovirus replication. To
investigate the role of VAPA in MNoV replication, we analyzed nonstructural protein
expression by assessing NS1/2 protein levels in infected cells by Western blotting.
Infected Vapa/ cells expressed lower levels of NS1/2 protein at 4 and 6 hpi (Fig. 2A),
with the difference diminishing later in infection. This supports the notion of a role for
VAPA in early events of MNoV replication. Because VAPA is associated with efficient
entry of an enveloped virus (37) as well as with the function of endosomes (19, 37, 40),
FIG 2 Murine norovirus replication in RAW 264.7-Vapa/ cells is impaired early in the viral life cycle. (A)
Western blot of NS1/2 in Vapa/ and Vapa/ (3A11) cell lines (MOI of 5). (Right panel) Combined
densitometry data from multiple experiments performed on film exposures for each time point within the
linear range of assay (n  2 to 4) (unpaired t test, means compared to Ho  100). (B) NS1/2 Western blot
after electroporation of viral RNA (vRNA) into Vapa/ and Vapa/ 3A11 cells (representative, n  3 to 5).
(Middle panel) Vapa/ and Vapa/ cells were transfected equivalently with pMAX-GFP. (Right panel)
Combined densitometry data determined as described for panel A (n  3 to 5). (C) Viral-strand-specific
quantitative PCR for negative strand (left) and positive strand (right) over time in infected Vapa/ and
Vapa/ 3A11 cells (MOI of 5; n  3; two-way ANOVA).
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through which MNoV likely passes to establish infection (41–43), we tested whether
impaired viral entry in Vapa/ cells accounted for decreased NS1/2 production and
viral replication. We reasoned that transfection of viral RNA would bypass any effect of
VAPA on viral entry and uncoating. After electroporating purified viral RNA into cells,
we continued to detect decreased NS1/2 levels in Vapa/ cells (Fig. 2B), despite
observing no difference in transfectability as measured by plasmid-driven GFP expres-
sion (Fig. 2B, middle panel). These data indicate that VAPA plays a role in viral protein
expression downstream of viral entry.
After the viral RNA accesses the cytoplasm, NS1/2 protein can be produced either by
translation of virion-derived plus-sense viral RNA or by transcription of plus-sense viral RNA
from newly synthesized minus-sense RNA. Using strand-specific reverse transcription-
quantitative PCR (RT-PCR) (44), we observed delayed accumulation of both negative-
sense and positive-sense MNoV RNA in the Vapa/ 3A11 (Fig. 2C) and 1E6 (Fig. S2) cell
lines, indicating that production of NS1/2 is impaired prior to synthesis of new viral
minus-sense RNA. Collectively, these observations support the notion of a role for VAPA
downstream of viral RNA delivery into the cytosol but upstream of minus-sense viral
RNA synthesis.
NS1/2 interaction with VAPA is conserved among norovirus strains. Prior work
showed that VAPA interacts with GI human norovirus NS1/2 protein (NS1/2GI) (12). To
test if VAPA interaction with NS1/2 is conserved across genogroups and species
boundaries, we engineered MNoV to express a FLAG tag in NS1/2 (nucleotide 383) and
also studied a previously described virus with a FLAG tag in NS4 (nucleotide 2600)
(Fig. S3A) (45). We selected NS4 for this experiment as it is known to bind NS1/2 (45).
Both MNoV-NS1/2FLAG and MNoV-NS4FLAG replicated similarly to wild-type virus
(Fig. S3B). FLAG-tagged viral proteins of appropriate molecular mass were expressed
during infection (Fig. 3A, top left). As expected, virus-derived FLAG-NS1/2 and FLAG-
NS4 localized with NS7, a marker for the viral replication complex (Fig. S3C) (46). Having
validated the use of FLAG-tagged viruses to study replication, we infected the BV2
microglial cell line with MNoV-NS1/2FLAG and MNoV-NS4FLAG. Both FLAG-NS1/2 and
FLAG-NS4 coprecipitated with VAPA but not NS7 or GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) (Fig. 3A, bottom). Thus, NS1/2, either independently or
together with NS4, interacts with VAPA (45).
To test for direct NS1/2-VAPA interaction independently of the presence of other
viral proteins, we assessed NS1/2 interaction with VAPA by mammalian 2-hybrid (M2H)
analysis. In this assay, interaction between a “bait” protein and a “prey” protein
generates a luciferase signal. As previously reported (12, 23, 47), we detected VAPA
interaction with itself, the host protein oxysterol-binding protein 1 (OSBP), and human
norovirus NS1/2GI, validating use of M2H analysis as an approach to assess VAPA
interactions (Fig. 3B). NS1/2MNoV from either MNoV strain CW3 or MNoV strain CR6
interacted with VAPA (Fig. 3B). Of interest, NS1/2 also interacted with VAPB (Fig. 3B).
NS1/2 interacts with FFAT-binding residues in VAPA MSP domain. Many VAPA
protein-protein interactions occur between the VAPA MSP domain and host cell
proteins containing FFAT motifs. Structure-function analyses of FFAT-VAPA interactions
support a model in which FFAT motifs from VAPA client proteins rest within a groove
present on the surface of the VAPA-MSP domain (24–26). Within this groove, VAPA
residues K50, K52, K94, M96, and K125 are critical for interaction with FFAT motifs. To
test if these residues also engage NS1/2, we introduced the following mutations into
VAPA: K50E/K52E, K94A/M96A, and K125E/R127E (Fig. 4A). Each of these mutation pairs
decreased VAPA interaction with NS1/2 (Fig. 4A) as measured by M2H analysis. To test
if NS1/2 interacts with sets of positively charged residues elsewhere in VAPA, we
mutated additional sites in VAPA selected to have the sequence (H/R/K)X(H/R/K).
Mutations K161E/H163E, H195E/R197E, and R202E/R204E had no effect on the NS1/2-
VAPA interaction (Fig. 4A). We conclude that the NS1/2 interaction specifically required
positively charged residues within the VAPA MSP domain.
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In work presented below, we found that the NS1 domain of NS1/2 is required for
NS1/2-VAPA interactions. To map the physical interactions between NS1 and the
VAPA-MSP domain, we used nuclear magnetic resonance (NMR) to analyze the chem-
ical shift perturbations of the 15N-labeled VAPA-MSP domain (M8–M132 of VAPA)
titrated with increasing amounts of unlabeled NS1 (S28–R114 of NS1/2). This analysis
revealed interactions between NS1/2 and four groups of residues on VAPA (Fig. 4B;
K52–T54, C60–N64, K92–V97, and D123–L126). These groups of residues all mapped to
the FFAT binding groove on a positively charged surface of the MSP domain. Further-
more, the VAPA residues that bind NS1/2 coincide with the FFAT-motif interaction
surface on the MSP domain (24, 25). Using the same experimental approach, we did not
observe any interactions of NS1 with the isolated coiled-coil domain (P133–S226 of
VAPA; data not shown).
We independently verified the role of the VAPA residues identified above in NS1/2-
VAPA interactions using M2H analysis (Fig. 4A). To this end, we replaced selected amino
acids in the VAPA MSP domain with either glutamate or alanine and tested for the
FIG 3 NS1/2 interactions with VAPA are conserved between norovirus strains and occur during infection.
(A) BV2 cells were infected with NS1/2-FLAG or NS4-FLAG MNV for 8 h (MOI of 10 TCID50/cell). FLAG
pulldown was performed on lysates, and immunoblotting was performed with the specified antibodies.
M, molecular marker. (B) M2H interaction of NS1/2GI, NS1/2MNoV (CR6 and CW3), OSBP, and VAPA with
VAPA or VAPB (bottom) (one-way ANOVA, Dunnett posttest; fold change data are shown on the right;
n  3). fluc, firefly luciferase; Rluc, Renilla luciferase.
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interaction of these mutant molecules with NS1/2. No interaction was detected with
glutamate or alanine substitutions at positions V51, K52, T54, K94, and K125 (Fig. 4C and
D). No interaction occurred after mutation of R62 to glutamate, but an interaction was
present with alanine at this site (Fig. 4C). At positions K50, T53, V61, N64, M96, and R127,
however, we observed interaction after replacing those residues with either glutamate or
FIG 4 NS1/2 binds FFAT-interacting residues in MSP domain of VAPA. (A) M2H interaction of NS1/2MNoV
with VAPA mutants. (B) Chemical shift perturbations of amide resonances upon unlabeled-NS1CW3 titration
into 15N-labeled VAPA MSP. The horizontal broken line represents the threshold. (C) M2H analysis of
additional single-residue mutant VAPA. Designations of residues interacting with FFAT are underlined
(one-way ANOVA, Dunnett posttest; fold change data are shown at the top; n  3). (D) Murine VAPA MSP
domain (PDB 2CRI). Pink highlighting indicates residues that disrupted the NS1/2-VAPA interaction in M2H
analysis when mutated; mutations in cyan residues did not disrupt interaction. (E) Multiple alignment of
VAPA and VAPB MSP domains from human (Hs) and mouse (Mm). Residues indicated with a black character
differ from consensus data. Red asterisks mark residues necessary for interaction in M2H analysis, and
triangles mark residues that shifted in NMR during NS1/2 titration.
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alanine (Fig. 4C and D). Notably, the residues within the VAPA-MSP domain that are
necessary for interaction with NS1 are conserved in VAPB (Fig. 4E).
Residues 47 to 54 of murine norovirus NS1 are necessary for interaction with
VAPA. While the NS2 domain is well conserved within the norovirus genus, NS1 is not
(Fig. 5A). Accordingly, we predicted that the conserved NS2 domain contributed to the
NS1/2 interaction with VAPA. Surprisingly, the MNoV NS1 domain containing residues
1 to 131 was sufficient to interact with VAPA whereas the NS2 domain did not interact
(Fig. 5B). To define the specific NS1 residues interacting with VAPA-MSP, we analyzed
the chemical shift perturbations of the NMR spectra of 15N-labeled NS1 (S28–R114 of
NS1/2) with increasing amounts of unlabeled VAPA (M8–S226 of VAPA). The largest
perturbations in NS1 from both the CR6 and CW3 strains of MNoV were observed for
a core of interacting residues centered on Y47–Q53 (YMTPPEQ) (Fig. 6A and Fig. S4A).
A longer sequence, encompassing residues I45 to A61, showed consistent but smaller
perturbations (Fig. 6A and Fig. S4A). There are no observable amides in prolines; hence,
no data were available for P50, P51, and P57.
To test the importance of this core of interacting residues, we carried out experi-
ments with three mutant forms of NS1, namely, NS1-CR6M48G, CW3T49G, and CW3E52K.
The heteronuclear single-quantum coherence (HSQC) spectra obtained for the mutants
were similar, indicating that these mutations did not destabilize tertiary structures (data
not shown). NS1-CW3T49G and CW3E52K mutations decreased binding to VAPA to
undetectable levels, while NS1-CR6M48G interacted with VAPA (Fig. 6A and Fig. S4B).
Within the NS1 domain, the VAPA interacting residues are predominantly within the
segment K26–P57, which shows a highly dynamic conformation in isolated NS1 (10).
The last few interacting residues of the core residues of NS1 that interact with VAPA are
in the structured domain of NS1 (G58–R114) (10).
Murine norovirus NS1 contains a mimic of host FFAT domains. The FFAT motif
is responsible for interactions of host proteins with the MSP domain of VAPA. We
identified residues 40 to 54 as the domain of NS1 which interacts with the MSP domain
of VAPA. Thus, we compared this region of NS1 with FFAT motifs. Generally, FFAT motifs
contain a core bulky aromatic residue flanked by acidic residues (22, 27). Correspond-
ingly, residues 40 to 54 of NS1/2 contain a bulky aromatic (Y47) flanked by acidic
residues E40, E42, D43, E44, E52, and E54 (Fig. 6B). Interestingly, this sequence is
conserved across MNoV strains (Fig. 6B and Fig. S4C), though positions 45, 46, and 48
are variable. The strong conservation of certain amino acids in this region suggested
that this motif has functional importance.
FIG 5 A poorly conserved NS1 domain within NS1/2MNoV interacts with VAPA. (A) Alignment of NS1/2
from representative strains from each norovirus genogroup. %ID, percent identity. (B) M2H analysis of
full-length or domain truncations of NS1/2MNoV (CR6) with VAPA (one-way ANOVA and Dunnett posttest;
fold change data are shown at the top; n  3).
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To test which residues within this domain contribute to interaction with VAPA, we
introduced single-residue mutations and assessed their effect by M2H analysis. For
positions in the N-terminal acidic segment, mutations E40A, E40K, E42A, E42K, D43A,
D43K, E44A, and E44K blocked NS1/2-VAPA interactions, while S41G maintained a
detectable interaction (Fig. 6C). Within the FFAT-like core segment, Y47A, Y47G, T49A,
and T49G ablated NS1/2 interactions with VAPA. Residues at positions 45, 46, and 48 are
variable across MNoV strains (Fig. 6B and Fig. S4C). To test the function of amino acids
in these positions, we introduced variants observed in other MNoV strains, including V45A,
V45I, N46C, N46D, M48A, and M48L, as well as variants not observed in MNoV isolates,
including V45G, N46G, M48D, M48I, and M48G. Mutations at these positions did not disrupt
interactions, suggesting that the interaction is preserved among variable sequences in
these positions across strains (Fig. 6C). For C-terminal acidic residues, E52K mutation
disrupted the interaction, but E54K maintained the interaction. Additionally, mutations
outside this region, including H69L, D121G, and D131G, did not prevent interaction
(Fig. 6C).
In summary, the S40-E54 region of NS1 mimics the host FFAT motif and serves as the
basis for interaction with the VAPA MSP domain based on the following findings: (i) the
order and chemical nature of the amino acids mimic those of the FFAT motif (acidic,
bulky aromatic, and then acidic); (ii) each of those acidic or bulky aromatic amino acids
is necessary for binding VAPA; (iii) this NS1 region interacts with the same region of
VAPA which binds to FFAT motifs in host proteins; and (iv) these critical amino acids are
conserved across norovirus strains.
NS1/2-VAPA interactions are required for recovery of murine norovirus from
infectious clones. We used an infectious molecular clone of MNoV to introduce
FIG 6 The N-terminal segment of NS1-MNoV interacts with VAPA. (A) Chemical shift perturbations of
amide resonances upon titration of unlabeled VAPA into 15N-labeled NS1-CR6 and CR6M48G. The
horizontal broken line represents the threshold. Purple residues are indicated as described for panel B.
(B) Sequence logo of FFAT-like amino acid sequence of NS1/2 derived from BLAST alignment (Fig. S4C).
The font size for each amino acid is proportional to percent conservation at each position. Residues
exhibiting greater variability across MNoV strains are highlighted with arrows (colored purple here). (C)
M2H interaction with NS1/2 substitutions (NS1/2, bait, VAPA, prey). Residues 69, 121, and 131 are not
predicted to interact with VAPA. Purple residues are indicated as described for panel B (one-way ANOVA,
Dunnett posttest; fold change data are shown at the top; n  3).
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mutations and to determine the importance of the NS1/2-VAPA interaction and the
specific amino acids in the NS1/2 FFAT-like domain required for MNoV growth. Muta-
tions were introduced in a plasmid encoding the CR6 viral genome, and recovery of
infectious virus was assessed after transfection of the plasmid into permissive cells. We
noticed three patterns of recovery of infectious virus in these experiments (Fig. 7A): (i)
some NS1/2 mutations had no discernible effect on virus recovery (V45G, V45A, V45I,
N46D, M48A, M48L, H69L, D121G, and D131G); (ii) some NS1/2 mutations resulted in
variable recovery (S41G, N46G, M48I, M48D, and E54K); (iii) some NS1/2 mutations
completely eliminated virus recovery (E40A, E40K, E42A, E42K, D43A, D43K, E44A, E44K,
Y47G, Y47A, M48G, T49G, T49A, and E52K). We saw similar patterns of virus recovery
after insertion of mutations into NS1/2 in the CW3 genome, with the following
exceptions: NS1/2 mutations S41G, N46C, M48I, M48D, and E54K resulted in consistent
recovery of virus; E40A and D43A mutations resulted in variable virus recovery; I45G
mutation completely prevented virus recovery (Fig. S5).
Importantly, this mutational analysis of the NS1 domains of two strains of MNoV
revealed a strong correlation between mutations that perturbed VAPA interaction
(Fig. 7B, top panel) and those which diminished recovery of virus (Fig. 7B, bottom two
panels). Side chains for residues that were critical for recovery of virus primarily mapped
to a sequence showing highly dynamic behavior in free NS1 and a few N-terminal
residues of the NS1 structured domain (10) (Fig. 7C). The specificity of the relationship
between side chain and function within this region is strikingly revealed by comparing
the role of the tyrosine at position 47, which was important for virus recovery, and the
FIG 7 NS1/2 interaction with VAPA enhances recovery of murine norovirus from infectious clones. (A)
Recovery titers of mutants of MNoV strain pCR6. Data represent passage 1 titers (n  7 to 20). (B)
Summary of interaction of NS1/2 mutants with VAPA in M2H analysis, and recovery of virus from
infectious clones for CW3 and CR6 NS1/2 mutants. (C) Molecular surface-and-ribbon diagram of solution
structure of NS1-MNoV (PDB 2MCD [10]) with viable (black) and nonviable (red) mutants.
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immediately adjacent methionine at position 48, where multiple amino acid substitu-
tions were tolerated.
DISCUSSION
In this report, we define the importance of the VAPA host protein and its interaction
with viral nonstructural protein NS1/2 in replication of MNoV. We confirmed the
previously identified interaction between a human norovirus NS1/2 protein and VAPA
(12) and found that this interaction is shared with the NS1/2 proteins of two MNoV
strains. Using a variety of approaches, including analysis of the interaction of the
proteins in vitro and in cells, we delineated the structural basis for the interaction
between VAPA and NS1/2 and used these data to test for the importance of specific
amino acids in NS1/2 for viral replication and for the interaction between VAPA and
NS1/2. These studies support the concept that VAPA is a proviral host protein for MNoV
infection and that interaction between NS1/2 and VAPA is important for viral replica-
tion. Remarkably, the MNoV NS1 domains appear to mimic host VAPA-binding proteins
through the conservation of a region that mimics host FFAT domains present in VAPA
MSP domain-interacting proteins.
Norovirus mimicry of host FFAT motifs. Mimicry of host molecules and motifs is
a pervasive evolutionary theme enabling microbes to hijack host processes (48). While
efforts have been made to predict mimicry on a large scale (49), detecting structural
and/or functional domain mimics requires validation through detailed studies of indi-
vidual microbial molecules. Other microbial proteins involved in targeting VAPA mim-
icry via a FFAT motif have not been reported. It will be interesting to determine
whether FFAT domain mimicry is a common strategy for microbial proteins that target
VAPA. If so, small molecules that target this interaction surface may have antiviral or
antimicrobial properties for multiple microbes that similarly bind VAPA. In this regard,
it is important that FFAT motifs tolerate variation at many positions (22, 27), are
relatively short, and are unstructured in solution (24), potentially enabling viruses or
other organisms to evolve strategies to target VAPA. It is interesting that much of the
region of MNoV NS1/2 that contains the FFAT mimic is unstructured in the purified NS1
domain (10). It seems possible that the interaction of these domains with the MSP
domain of VAPA is somehow enhanced by the unstructured nature of this region.
The greatest similarity of the MNoV NS1/2 sequences to host FFAT motifs was
identified in the N-terminal and C-terminal portions of the motif. The core sequence
was less similar, notably lacking a phenylalanine followed by D/E and instead encoding
a tyrosine without a flanking acidic residue. The third position of host FFAT motifs (the
second of the two F residues, which define the motif in host proteins) tolerates a wide
range of residue substitutions without loss of function. Similarly, both NMR experi-
ments and M2H experiments performed with the NS1 M48G mutant have shown
consistent tolerance of variability at this site. Nonetheless, at the structural level, the
mode of binding mode of NS1/2 to VAPA showed remarkable similarity to the binding
of host FFAT motifs to VAPA, for example, by interaction with specific VAPA amino acids
in the MSP domain. It is therefore interesting that the core portions of host and
norovirus FFAT motifs differ in some regards, suggesting that there may be specific
properties of the interaction that are unique to the viral FFAT motif. Future examination
of the molecular basis of the interaction between human norovirus NS1/2 and VAPA
and of the conservation of relevant amino acids across norovirus genogroups and
strains will be useful and interesting.
Role of VAPA in norovirus replication. Importantly, while we studied VAPA in
detail, we also found that the related VAPB protein plays a role in MNoV replication and
binds NS1/2. It seems possible that these two proteins play similar roles in NoV
replication. For VAPA, it is clear that the stages of viral replication after entry and before
minus-sense viral RNA synthesis are affected by VAPA. Nevertheless, our work did not
reveal the mechanism by which VAPA participates in the viral life cycle. We have
considered two possibilities (not mutually exclusive) for the function of the NS1/2-VAPA
interaction at this early stage of viral replication. First, the NS1/2-VAPA interaction could
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localize NS1/2 to the ER in order to initiate formation of the membranous viral
replication compartment. Notably, the advantage afforded by direct interactions of viral
proteins with VAPA and VAPB proteins has been reported for hepatitis C virus (28, 29),
which also required rearrangements of intracellular membranes to create a replication
complex. MNoV NS1/2 is associated with the ER when expressed independently of
other viral proteins (46, 50), and VAPA is an ER-resident protein, suggesting the
possibility of a role for VAPA in NS1/2 localization. It is notable that the NS1 domain that
contains the FFAT motif mimic would be the first portion of the polyprotein synthesized
from viral plus-sense RNA and might therefore contribute to coordination of initial
steps of viral replication at the ER prior to synthesis and processing of the rest of the
viral polyprotein.
Second, it is also conceivable that the interaction of NS1/2 with VAPA alters lipid
metabolism through competition for the interactions between VAPA and VAPA client
proteins that also have FFAT domains. In this regard, it is not known whether any of the
specific processes carried out by VAPA client proteins are important for enhancing or
inhibiting norovirus replication. The methods required to address this issue are likely to
be complex, since VAPA interacts with multiple client proteins such as OSBP and
ceramide transfer protein (CERT) and is involved in a range of processes in the cell,
including nonvesicular lipid transfer (20, 23, 51) and lipid metabolism (51, 52), and is
present at membrane contact sites (53–57). Nevertheless, the conservation of a struc-
tural motif related to the FFAT motifs found in proteins that interact with the MSP
domain of VAPA indicates the value of dissecting the possible role of VAPA-dependent
functions in the viral life cycle and the impact of NS1/2 function on VAPA-dependent
proteins.
MATERIALS AND METHODS
Cells and media. 293T, BV2, and RAW 264.7 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal calf serum (FBS), 1% penicillin/streptomycin (Pen/Strep), 2 mM
L-glutamine, and 10 mM HEPES. All transfections were performed with TransIT-LT1 (Mirus) unless
otherwise noted. The Genome Engineering and iPSC Center (St. Louis, MO) engineered Vapa/ RAW
264.7 cell lines 1E6 and 3A11. Briefly, guide RNAs (5= GGCGAAGCACGAGCAGATCCTGG 3= and 5= GATC
TGCTCGTGCTTCGCCATGG 3=) targeting Vapa were electroporated into RAW 264.7 cells transiently
expressing Cas9. Cells were clonally selected and verified for disruption of the endogenous locus via the
Cel-1 nuclease assay and were then subjected to deep sequencing to identify frameshift mutations.
Molecular cloning. NS1/2 from strain MNoV CR6 and CW3 infectious clones (11) and GI (NC_001959),
as well as VAPA (NM_013933), were cloned into Gateway vector pDONR221 (Life Technologies, Inc.) and
subcloned using Gateway destination vectors, including a modified phage-FLAG-hemagglutinin (HA)-
attR1-ccdB-attR2-internal ribosome entry site (IRES)-PuroR lentiviral construct. Cloning of mutant MNoV
plasmids (58) was done by site-directed mutagenesis using Q5/KLD mix or Phusion (New England
Biolabs) as described in reference 59. The MNoV-NS1/2FLAG infectious clone was generated similarly to
MNoV-NS4FLAG (45), with FLAG tag nucleotide sequence inserted after nucleotide 383.
Virus reagents and procedures. Stocks were generated as described previously (11). Briefly,
infectious clones were transfected into 293T cells to produce infectious virus, which was passaged twice
on RAW 264.7 cells. Clarified supernatant was subjected to ultracentrifugation, resuspended in
phosphate-buffered saline (PBS), and quantitated by plaque assay. The recovery of infectious FLAG-
tagged MNoV was described previously (60). Briefly, infectious clones were transfected in BSRT7 cells
infected with fowlpox virus expressing T7 RNA polymerase. BV2 cells were inoculated with the recovered
viruses, frozen/thawed upon appearance of cytopathic effects, centrifuged to remove cellular debris, and
quantitated by 50% tissue culture infective dose (TCID50) analysis. The stability of FLAG tag insertions at
passage 3 was verified by RT-PCR and sequencing of the viruses at relevant genomic locations and by
immunoblotting against FLAG tags using infected lysates (data not shown). MNoV infectious clones with
novel mutations were transfected in 293T cells as described above and passaged once on RAW 264.7
cells, and virus concentrations were assessed using plaque assay. For virus growth analysis, MNoV was
inoculated at indicated multiplicities of infection (MOI) into cells in suspension for 30 min on ice and was
subsequently washed three times with complete media and harvested at indicated times postinfection.
Quantitation of norovirus by plaque assay was performed as described previously (11) except using
adherent RAW 264.7 cells. TCID50 data were determined on BV2 cells as described previously (61). For
viral RNA electroporations, RNA was isolated from norovirus stocks with TRIzol (Thermo Fisher) and
transfected by the use of an Amaxa Mouse Macrophage Nucleofector kit (Lonza). Lentivirus was prepared
as described previously (62), except transfections were performed with TransIT LT1 (Mirus), and cells were
maintained in media with puromycin (5 g/ml) 48 h after transducing.
Flow cytometry. Cells were infected as described above. At indicated times, supernatant was
collected for determinations of viral titers and cells were prepared for fluorescence-activated cell sorter
(FACS) analysis as described in reference 62, except using primary antibody anti-NS1/2 rabbit sera (V.
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Ward) (1:2,500), and data were acquired on an LSR II or FACSCalibur (BD Biosciences) flow cytometer.
Analyses were performed using FlowJo (Treestar, OR).
Confocal microscopy. BV2 cells were seeded on glass coverslips and infected at an MOI of 1
TCID50/cell. At 12 hpi, cells were fixed with 4% paraformaldehyde (PFA)–PBS, quenched with 0.1 M
glycine–PBS, and permeabilized with 0.2% Triton X-100–PBS. After blocking was performed (using PBS
plus 0.1% Tween 20 [PBST] with 1% bovine serum albumin [BSA]–1% normal goat serum [Sigma-
Aldrich]), cells were stained with mouse monoclonal anti-FLAG M2 antibodies (Sigma-Aldrich) and rabbit
polyclonal anti-NS7 antibodies (1:1,000) at room temperature for 1 h, triply washed (PBST), and then
stained with goat anti-mouse IgG Alexa Fluor 488 and goat anti-rabbit IgG Alexa Fluor 546 (1:1,000) at
room temperature for 1 h. Coverslips were triply washed and then mounted with Mowiol medium
containing DAPI (4=,6-diamidino-2-phenylindole) stain. The confocal images were taken using a Zeiss 510
Meta laser confocal microscope.
Immunoprecipitation. For anti-FLAG immunoprecipitation, BV2 cells were infected at an MOI of 10
TCID50/cell and were harvested 8 hpi. Cells were triply washed with cold PBS before lysis was performed
with a mixture containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 2 mM MgCl2, 1% Triton
X-100, 1% (vol/vol) protease inhibitor cocktail (Promega), and 0.1% Benzonase (Sigma-Aldrich). The
lysates were incubated on ice for 30 min before being spun down for 10 min at 15,000 rpm at 4°C. The
supernatants were collected, and the protein concentrations were determined by bicinchoninic acid
(BCA) assay (Thermo Fisher). The anti-FLAG M2 affinity agarose gel (Sigma-Aldrich) was prewashed twice
with TBS buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl). A 2-mg volume of total protein in 1 ml lysis
buffer was loaded onto 40 l anti-FLAG agarose and incubated 4°C overnight with rotation. After
removal of unbound protein by centrifugation at 5,000  g for 30 s at 4°C and three more washes with
TBS buffer, the bound proteins were eluted by addition of 50 l of 2 SDS-PAGE sample buffer and
heating at 95°C for 3 min.
Western blotting. Laemmeli buffer was added to samples and then boiled for 10 to 15 min. Protein
was resolved on 10% SDS-PAGE Tris-glycine gels. Protein was transferred semidry to polyvinylidene
difluoride (PVDF) membranes, blocked with 5% milk–Tris-buffered saline with Tween 20 (TBST), and then
incubated with antibody overnight at 4°C. Membranes were triply washed with TBST and then incubated
for an hour with horseradish peroxidase (HRP)-conjugated secondary antibody. Membranes were triply
washed and incubated with ECL or ECL2 reagent (Pierce), and then signal was detected on film (MidSci).
For densitometry, NS1/2 band density was calculated using ImageJ, normalized to GAPDH band density,
and then reported as a ratio to the WT from each respective time point. We used the following
antibodies: polyclonal rabbit NS1/2 antisera, a kind gift from Vernon Ward; anti-VAPA clone K-15
(sc-48698; Santa Cruz Biotechnology), anti-FLAG (M2; Sigma-Aldrich), and anti-HA (H9658; Sigma-Aldrich)
(conjugated to HRP using a Lightning-Link HRP antibody labeling kit [701-0000; Innova Bioscience]);
GAPDH-HRP (G9295-25UL; Sigma-Aldrich); anti-actin (A5316; Sigma-Aldrich); and anti-rabbit HRP (111-
035-003), anti-goat HRP (705-035-003), and anti-mouse HRP (115-035-146) (Jackson ImmunoResearch,
Inc.).
Strand-specific qPCR. Cells were infected as described above. At each time point postinfection, cells
were lysed and total cellular RNA was extracted using a GenElute mammalian total RNA Miniprep kit
(Sigma-Aldrich). Quantities of genomic positive/negative RNAs were determined using strand-specific
real-time quantitative PCR (RT-qPCR) according to the method described in reference 44 with the
following changes: 100-ng total RNA was used in each RT reaction, and 5 l of cDNA was used for
genomic negative qPCR. The mean of log10 genome equivalents (gEq) per nanogram of total RNA of
mock-infected cells was used as the limit of detection (LOD). The results were obtained using a ViiA7
real-time PCR system.
Assessment of VAPB in murine norovirus replication. BV2 cells were transduced with lentivirus
expressing Cas9 and blasticidin resistance and were maintained in 4 g/ml blasticidin. Blasticidin-
selected cells were then transduced with lentivirus expressing puromycin resistance and either with no
single-guide RNA (sgRNA) (empty) or with sgRNA directed against CD300lf, Vapa, or Vapb. Cells were
maintained in 4 g/ml puromycin. Cells were infected at an MOI of 0.1 without washing and were
incubated at 37°C for 18 h. Cells were fixed and prepared for FACS analysis as described above. Each
point represents an independent MNoV infection; cells were derived from 3 independent transductions
of sgRNA-expressing lentivirus. For percent nonhomologous end joining (%NHEJ) estimates, DNA was
isolated from cells using QiaAMP (Qiagen), melted and annealed on a thermocycler, treated with T7
endonuclease at 37°C for 1 h, and resolved on 2% agarose gel. Fragment densities were quantified using
ImageJ, and percent cleavage was calculated using the following formula: %NHEJ  100 * [1  (parental
fraction)1/2], where parental fraction  (band intensity parental band)/(band intensity parental band 
band intensity lower fragments).
Mammalian 2-hybrid assays. Checkmate vectors (Promega) pACT (prey) and pBIND (bait) were
converted to Gateway destination vectors, and genes were subcloned using Gateway LR reactions (Life
Technology). Subsequent M2H analysis was performed as described in reference 63. In brief, 7.5 fmol bait
and prey plasmids were transfected with 100 ng pG5 plasmid into subconfluent 293T cells. At 48 to 51 h
posttransfection, cells were lysed and luminescence was measured by the use of a dual-luciferase
reporter assay (Promega) using an Opticomp II (MGM Instruments) luminometer. All data shown
represent n  3 and were analyzed by one-way analysis of variance (ANOVA) and the Tukey posttest,
comparing the greater of the bait-only value and prey-only value to the value corresponding to the
combination of the bait data plus the prey data. Fold change was calculated from the value representing
the average of the combination of the bait data plus the prey data/the greater of the bait data and the
prey data.
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Vapa mutant mouse. The Washington University Animal Studies Committee approved all mouse
studies performed here. Mice were bred and housed per university guidelines. Day 0.5 B6/J inbred
embryos underwent pronuclear microinjection with gRNA and Cas9-mRNA, and then embryos were
implanted in surrogate mothers as described previously (64). Mutations in live-born pups were identified
by isolation of tail DNA, PCR amplification of the Vapa targeted locus, and Sanger sequencing. Genotypes
were verified by TOPO-TA (Life Sciences) cloning of the amplicons and Sanger sequencing. Genotyping
was performed as follows. For mutant line 1, primers were designed to amplify the Vapa locus
(F-CTGCTGAGCGGACAGGCTG, R-CGCAAGATGGCGGCGGAG) (WT, 500 bp; deletion, 440 bp). For mutant
line 2, genotyping to detect single-base-pair insertion was designed as described in reference 65. In brief,
primers designed to detect specifically the WT (F-GGCCCCGTCCTAGAGCTCCG, R-ATATGATAGTAACTAT
CCAGGATCTGCTCGTGCTACGC) amplified a 180-bp product. Primers detecting the mutant (F-GGCCCCG
TCCTAGAGCTCCG, R-AAAAACCAGGATCTGCTCGTGCTTAGG) amplified a 159-bp product. Genotyping was
verified by Sanger sequencing.
Protein preparation for NMR experiments. Natural-abundance protein and the 15N-labeled
N-terminally His6-tagged 28–114 domain of MNoV NS1/2 protein were purified as described previously
(10). Three fragments of natural-abundance protein and 15N-labeled N-terminally His6-tagged murine
VAPA protein were purified from Escherichia coli expression plasmids as follows. (i) The VAPA MSP
domain (8–132) gave excellent NMR spectra. (ii) The MSP domain with linker and coiled-coil domain
(8–226) gave excellent NMR spectra and formed stable dimers in solution confirmed by size exclusion
chromatography and diffusion NMR experiments. (iii) A VAPA fragment (133–226) showed a dimeric size
in solution and NMR spectra indicative of contributions from -helical and disordered segments. Protein
samples were concentrated and dialyzed extensively against 10 mM KH2PO4–20 mM KCl (pH 7.0). Final
concentrations of NS1/2 28–114 (280  13,940 M1 cm1) and VAPA (280  8,250 M1 cm1) were
0.4 mM and 1.6 mM, respectively, as determined spectrophotometrically. All samples contained reducing
reagent (1 mM dTCEP [deuterated tris(2-carboxyethyl)phosphine]—5% D2O) for the lock signal and
0.5 mM DSS for chemical shift reference.
Chemical shift perturbation experiments. After 24 h of dialysis against the same buffer solution,
protein samples were mixed by stepwise addition of VAPA solution. Each addition was followed by NMR
experiments, carried out at 25°C on a Bruker 600-MHz instrument equipped with a cryoprobe. First, for
each 15N-labeled NS1/2 protein construct, 15N-1H HSQC spectrum was recorded for an NS1/2 protein
only. Following that step, 5 to 6 spectra were recorded after each addition of natural-abundance VAPA,
typically at 0.5-fold to 10.0-fold excess over the NS1/2 concentration present. NMR data were processed
(Topspin 3.2; Bruker), and the chemical shift perturbations were analyzed using NMRFAM-SPARKY (66).
The chemical shift assignments for NS1/2 (BMRB entries 19439 and 19444) and closely related human
VAPA (BMRB entry 7025) are available in the Biological Magnetic Resonance Data Bank (BMRB). The
specific values of chemical shifts for the buffer conditions and protein constructs used here were verified
by acquisition of a standard suite of triple resonance experiments performed on 13C/15N-labeled samples.
Chemical shift perturbations on 15N-labeled VAPA were analyzed in analogous fashion, except that the
initial concentrations of VAPA and NS1/2 were 0.1 mM and 2.2 mM, respectively, with stepwise addition
of NS1/2. Figures show combined differences of 1H and 15N chemical shifts observed between zero and
the highest concentration of unlabeled protein used. The combined differences in units (in parts per
million) were calculated as   1
2
H2	 N5 2	
 and are referred to as chemical shift
perturbations. The threshold for perturbations interpreted as specific protein-protein interactions was set
at 4 standard deviations above the mean perturbation, excluding the highest perturbations for each
data set.
Statistics and software. All statistics were calculated using GraphPad Prism (ns, P 0.05; *, P
 0.05;
**, P
 0.01; ***, P
 0.001; ****, P
 0.0001; all error bars signify standard errors of the means). Sequence
alignments and analysis were performed in Geneious 9.1 (67). Molecular graphics were produced using
UCSF Chimera (68).
Accession number(s). The chemical shift assignments for NS1/2 (BMRB entries 19439 and 19444)
and closely related human VAPA (BMRB entry 7025) are available in the BMRB database.
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